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Abstract 
Human embryonic stem cells (hESCs) are undifferentiated cells arising from the 
inner cell mass of the blastocyst, which are able to self-renew or differentiate in 
vitro into specialised cell types. These pluripotent cells are a powerful tool to study 
human embryonic development and have great potential in the field of 
regenerative medicine. 
Human ESC pluripotency is governed by an intrinsic transcriptional network 
composed of the three well-known transcription factors OCT4, SOX2 and NANOG, 
whereas the role of extrinsic cell/microenvironment interactions in the 
maintenance of hESC stemness has been neglected to some extent. The aim of this 
work was to develop a systems biology approach oriented on these extrinsic factors 
and their links with the transcriptional network, in order to uncover some of the 
fundamental mechanisms underlying the stemness state.  
The thesis is divided into two complementary approaches: a top-down in silico 
study and a bottom-up in vitro study. The top-down in silico approach consists of a 
meta-analysis of hESC transcriptional data, leading to the construction of a hESC 
transcriptome. These mRNA data served as proxy for proteins in a protein-protein 
interaction database to build a hESC interactome. This interactome (or protein-
protein interaction network) was structurally defined to identify the likely cell 
surface and extracellular proteins regulating hESC stemness by revealing the 
’module organiser’ or hub proteins and the ’module connector’ or bottleneck 
proteins, along with the extracellular/transcriptional links. 
The bottom-up in vitro approach was the study of five of the previously identified 
cell surface/extracellular proteins in hESC fate decision. These candidates, together 
with OCT4, were stably knocked down using short hairpin (sh)RNAs and lentiviruses. 
The optimisation of the shRNA lentivirus production led to the development of a 
method for the direct quantification of these lentiviral particles. The effects of 
shRNA-mediated knockdown on hESC phenotype were investigated by assessing cell 
morphology and by determining the expression levels of the following groups of 
mRNAs: candidate stemness mRNAs, pluripotency mRNAs, as well as 
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trophectoderm, endoderm, mesoderm and ectoderm mRNAs. We found that the 
candidates could modulate each other’s expression and appeared to regulate hESC 
commitment into different lineages. Furthermore, the expression levels of some of 
the candidates were regulated by OCT4.  
Taken together, these results suggest that by using the novel in silico approach 
developed during this project, it is possible to identify new stemness factors that 
could potentially have a role in either maintaining hESC self-renewal or in regulating 
lineage specification. 
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Chapter 1 – Introduction 
Introduction 
 
1.1. Human embryonic stem cells among the stem cell world  
Stem cells are undifferentiated cells arising from embryos, foetuses or adult tissues. 
Unlike terminally differentiated cells, which are nullipotent, stem cells are able to 
self-renew or differentiate into one or several specialised cell types depending on 
the presence or absence of specific stimuli.  
1.1.1. From unipotency to totipotency 
Figure 1 illustrates the different types of human stem cells. 
 
Figure 1 | Human stem cell origins 
Origins of totipotent, pluripotent, multipotent and unipotent human stem cells are schematised. 
Only a few examples of unipotent and nultipotent cells are given (ECCs: embryonal carcinoma cells; 
EGCs: embryonic germ cells; ESCs: embryonic stem cells; HSCs: hematopoietic stem cells; ICM: inner 
cell mass; iPSCs: induced pluripotent stem cells; SCNT: somatic cell nuclear transfer). 
Unipotent cells are present in adult tissues and can engender only a single cell type, 
like skin stem cells that give rise to keratinocytes [1]. 
Chapter 1 – Introduction 
 
3 
 
Multipotent cells play a role in the homeostasis and/or repair of foetal and adult 
tissues, where they generate different cell types already committed into a lineage 
[2-4]. Multipotent cells can be found in multiple different organs throughout the 
body, including the gut [2, 5] and the muscles [3, 6]. A well-characterised example 
of a multipotent cell is the hematopoietic stem cell (HSC), which resides in the bone 
marrow and differentiates into the different types of blood cells [7].  
Pluripotent cells are cells that can differentiate into all the body's tissues, but are 
not capable of giving rise to some extra-embryonic tissues. These cells can naturally 
be found in the inner cell mass (ICM) of blastocysts [8] (embryonic stem cells), in 
the epiblast (epiblast stem cells) or pluripotency can be acquired (induced 
pluripotent stem cells, section 1.1.2.1).  
The notion of cancer stem cells (CSCs) dates from the 1950s. CSCs possess features 
of multipotency [9] or pluripotency [10, 11], therefore, like normal stem cells, are 
capable of self-renewal and differentiating into tumor cells. Recently, they have 
been identified in several solid tumors, e.g. brain [12], prostate [13] and colon [14], 
as well as in leukaemia [15]. They could play a direct role in the development of 
cancer [16, 17]. 
Totipotent cells are the only cells capable of forming a whole embryo. They do not 
self-renew, but differentiate towards the trophoblast and the blastocyst ICM. They 
constitute the embryo, zygote and blastomeres, up to the eight cell stage (morula 
stage) [18].  
1.1.2. Pluripotency in detail 
1.1.2.1. The timeline 
The story of the pluripotency began in 1964 with the isolation of embryonal 
carcinoma cells (ECCs, Figure 1) from mouse testicle tumors [10, 11], and later from 
humans [19]. These cells can generate teratomas containing a wide range of cell 
types, as well as gametes following transplantation into mouse blastocysts [11]. 
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The first line of embryonic stem cells (ESCs, Figure 1) was isolated in 1981 from the 
ICM of a mouse blastocyst [20, 21]. The first human line of ESCs (hESCs) was 
established 17 years later, from the ICM of supernumerary embryos obtained after 
in vitro fertilisation [8]. In June 2014, there were 691 hESC lines around the world 
listed in the European Human Embryonic Stem Cell Registry website ([a], founded 
by the European Commission). ESCs have also been derived from embryos of other 
animals, such as hamsters [22] or monkeys [23, 24], with more or less success.  
In 1992, mouse embryonic germ cells (EGCs, Figure 1) were derived directly from 
primordial germ cells (PGCs) [25]. EGCs were also isolated from humans, but they 
have a limited in vitro self-renewal and can only be maintained for short periods 
[26]. 
Finally, epiblast stem cells (epiSCs) were obtained in 2007 from the mouse epiblast 
(or primitive ectoderm) of early postimplantation embryos [27, 28].  
Pluripotency can also be imposed on the nuclei of somatic cells, using one of the 
three following techniques (Figure 1). The first one is called somatic cell nuclear 
transfer and consists of transplanting the nucleus of a somatic cell into an 
enucleated oocyte: factors within the oocyte cytoplasm reprogram the somatic cell 
nucleus that becomes pluripotent [29-32]. The second technique is cell fusion, 
where a somatic cell is fused with a pluripotent cell: the somatic cell nucleus is 
reprogrammed by factors within the pluripotent cell cytoplasm [33]. The third 
technique, the most recent, involves the reprogramming of somatic cells by forced 
expression of three or four key transcription factors and generates reprogrammed 
cells named induced pluripotent stem cells (iPSCs). The first mouse (m)iPSCs were 
generated in 2006 [34], followed by human (h)iPSCs in 2007 [35]. This novel 
technique was rewarded by a Nobel Prize in 2012 to Shinya Yamanaka (and to Sir 
John B. Gurdon for his work on somatic cell nuclear transfer) [b]. Different types of 
mouse and human somatic cells have now been reprogrammed, including 
mesenchymal stem cells [36], neural stem cells [37], fibroblasts [35, 36], 
hepatocytes and gastric epithelial cells [38]. In June 2014, there were 52 hiPSC lines 
listed in the European Human Embryonic Stem Cell Registry website [a]. 
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1.1.2.2. Pluripotency assays 
Three assays are commonly used to ascertain the pluripotency of a cell lineage 
(Figure 2). The first in vivo test consists of forming teratomas, which are benign 
tumors containing different types of tissues, by injection of stem cells into an 
immunodeficient mouse [39] (Figure 2A). However, the utility of this practice, which 
uses a subtantial number of mice, is sometimes questionned [40]. An alternative is 
the in vitro formation of embryoid bodies (EBs), structures composed of cells 
representing the three germ layers [39, 40] (Figure 2A). The second in vivo test 
observes, after injection of stem cells into a mouse blastocyst and transfer to a 
surrogate, the formation of chimeric embryos (organisms composed of cells with 
different genetic origins): the generation of germ line cells is a key feature of ESCs 
[41] (Figure 2B). Obviously, this test cannot be used with hESCs. The last tests are 
performed in vitro to verify the cell differentiation potential to form the three germ 
layers, either spontaneouly or by changing the culture conditions [40] (Figure 2C). 
 
Figure 2 | Pluripotency assays 
(A) In vivo formation of teratomas or in vitro formation of embryoid bodies (EBs), (B) in vivo 
formation of chimeras and (C) in vitro differentiation. 
1.1.3. Human ESC: interests & issues  
Human ESCs have great potential for both fundamental research and medicine, but 
their use also raises ethical issues in both fields. 
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1.1.3.1. Interests in fundamental research & ethical issues 
ESCs represent an amazing tool for understanding human embryonic development 
and the differentiation mechanisms taking place at that time [42]. They allow the 
generation of genetically modified mouse strains and/or hESC lines that help to 
study the function of targeted genes during development, either by knockouts, 
where both copies of a target gene are rendered non-functional [43, 44], or by 
knockins where a coding sequence is inserted into a specific locus [44, 45]. These 
strains and cells lines provide models for human disease too [46, 47]. 
ESCs are also a good model to study the influence and toxicity of pharmacological 
molecules on embryonic development, and, therefore, could potentially be used to 
identify teratogens [48]. Since the advent of iPSC technology, huge efforts are being 
made to generate hiPSC lines from patients with particular diseases [49, 50] that 
can serve as a model to understand the mechanisms of disease development [51] 
and discover new drugs [52]. 
Because of their origin, hESCs are at the core of the stem cell debate. Two main 
issues appear: the embryo status and embryo/oocyte donation. For scientists and 
religious leaders, life is a continuum [53-55]. However, it is possible to distinguish 
three different statuses: 1) embryos do not have a personal status, 2) embryos have 
a pre-personal status, but are not humans and 3) embryos are humans. This last 
point is the official point of view of the Catholic Church, which is against hESC 
research, as are Greek and Coptic Orthodox Churches, Conservative Protestants and 
Taoists, whereas Muslims, Jews, Hindus and Buddhists support generally the field 
[56]. A consensus can be found about embryo status, which is more pragmatic than 
philosophical: embryos are less human than foetuses than babies [55]. These 
different points of view about embryo status can pose the problem of public 
financing of hESC research [57]. 
The development and validation of safety procedures implies the utilisation of a 
certain number of embryos, which poses the embryo/oocyte donation or payment 
dilemma, the latter being particularly relevant when access to medicine is 
dependent on the ability to pay. The US National Academies of Science (NAS) 
advocates for donation [58]. Patients with infertility treatment may also be under 
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pressures from their physicians who want to supply embryos to their colleagues 
working on hESC research. That is why some guidelines are careful about the time 
that patients need to take a decision [59], like the Canadian Stem Cell Oversight 
Committee (SCOC) [c] and the Human Fertilisation and Embryology Authority 
(HFEA) [d] in United Kingdom.  
Despite their definition and properties, older hESC lines have been found to develop 
problems such as an increase of karyotypic changes and abnormalities [60, 61] or 
mitochondrial dysfunctions [62], which may arise due to adaptation to culture or 
simply to length of time cultured ex vivo. They can be ‘contaminated’ by feeder cells 
and/or animal-derived culture conditions [63]. That stretches the need to derive 
new ‘healthy’ cell lines, as it is necessary to understand intra- and extra-cellular 
mechanisms, which control self-renewal, proliferation and differentiation 
processes, before being able to use stem cells in therapy. 
1.1.3.2. Interests in medicine & issues relating to stem cell therapies 
Stem cells can be used to discover new drugs [49, 64, 65], but they represent above 
all a powerful instrument for developing regenerative medicine and tissue 
engineering strategies for the repair/replacement of defective tissues or organs, 
because of age, disease, damage or congenital defects [66-70]. Due to the fact that 
populations of most societies are ageing, the prevalence of chronic diseases is 
increasing, leading to a greater demand for organ transplantation [71]. The use of 
stem cells as a new treatment could side-step this issue [69, 72].  
Adult stem cells have already been employed in cell therapy since 1968 with the 
use of HSCs for bone marrow transplant [73]. Although adult stem cells have a 
tumorigenic potential lower than hESCs, their low proliferation and differentiation 
potential can make them less attractive. Human ESC therapies open the way to 
treat organ failures [69], degenerative diseases like Parkinson's disease [74] or 
specific type of blindness [75], and tissue injuries such as spinal cord transection 
[76-78]. 
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The first authorisation to start a human clinical trial using hESC-derived cells was 
allocated by the Food and Drug Administration (FDA) to the American company 
Geron Corporation in January 2009 to treat spinal cord injury [e]. This trial was 
stopped by the company in November 2011 [f], but has now received new funding 
to start again [g]. A second FDA authorisation has been delivered in 2010 to 
Advanced Cell Technology Company to treat Stargardt’s macular dystrophy, an 
incurable macular degeneration disease, using hESC-derived retinal cells [h]. In the 
UK, Coffey’s group should begin very soon a trial with hESC-derived retinal pigment 
epithelial cells to treat age-related macular degeneration [i, j]. 
Nevertheless, substantial issues have to be solved to develop this new field:  
i) the difficulty in obtaining a high quantity of pure mature cells capable of 
repairing damaged organs [79]; 
ii) the genetic and epigenetic instability induced by culture [80]; 
iii) the possible formation of teratomas and teratocarcinomas after injection of 
undifferentiated hESCs [81-85]; 
iv) immunological incompatibility [81, 82, 86, 87]; 
v) the risk of migration to non-target organs [81, 82]; 
vi) the risk of heterogeneous differentiation or mal-differentiation [81, 82]. 
The iPSC technology has the advantage of allowing the generation of patient-
specific hESC-like cells [88], while avoiding the destruction ex utero of human 
embryos. It, therefore, avoids ethical and immunological problems engendered by 
the utilisation of hESCs. Consequently, hiPSCs could be better candidates than 
hESCs for the development of new tissue-regenerative therapies. The medical 
potential of these cells has already been proven in animal models for diseases like 
Parkinson [89] and in liver regeneration [90, 91]. However, it is necessary to develop 
reliable, reproducible, accessible and safe reprogramming protocols to use hiPSCs in 
medicine. Retroviruses [35] and lentiviruses [92] have been initially utilised to 
generate hiPSCs. Because of the integration of the viral DNA into the receiver cell, 
there is a risk of proto-oncogene dysregulation leading to carcinogenesis. More 
recently, new protocols have been elaborated to avoid this issue by using non-
integrating viruses such as adenoviruses [93] and sendaï viruses [94], or by direct 
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delivery of the reprogramming proteins into the cells [95]. However, some 
problems persist and others arise: 
i) the use of oncogene (such as c-MYC) to reprogram somatic cells [96]; 
ii) genetic and epigenetic instability [97];  
iii) the risk of heterogeneous reprogramming [98];  
iv) the risk of migrating to non-target organs;  
v) the risk of tumour formation [83, 84, 99]. 
Furthermore, there are ethical concerns appearing with the use of hESCs and 
hiPSCs. Indian, Russian and Chinese clinics, among others, already offer 
transplantations of embryonic and foetal stem cells although safety and efficiency 
of these transplantations are not known [100, 101]. Moreover, studies report 
tumour development linked with stem cell treatments: a patient with lupus 
nephritis (a disease of the immune system with inflammation of the kidney) treated 
by direct renal injection of stem cells developed haematuria (presence of blood in 
the urine) and masses at the injection sites [102]; a boy with ataxia telangiectasia 
(rare genetic neurodegenerative disease) treated by brain injections of foetal neural 
stem cells developed a brain tumour four years after his treatment [103]. Both 
pathologies were certainly derived from stem cells. To avoid such issues, the 
European Science Foundation (ESF) makes recommendations in the driving of 
clinical trials [k] and the EU Tissues and Cells Directive (EUTDC) regulates the quality 
of all cells utilised for human therapies along with their Good Manufacturing 
Practice-based production [l] [104]. 
1.2. The systems biology field 
A challenge of biology in the context of physiology and medicine is to understand 
how living organisms function. This goal cannot be addressed by looking at 
molecules one by one and requires considering them as a system. The mechanisms 
involved in pluripotency, self-renewal and differentiation of hESCs are complex, 
multi-level and non-linear, and are determined by the intrinsic cell potential, cell-
cell interactions and cell-microenvironment interactions. These processes require 
the coordinated and regulated expression of thousands of genes and proteins [105, 
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106]. Thus, the use of systems biology approaches could help to understand better 
the stemness state. 
1.2.1. Definition 
The notion of systems biology refers to a multidisciplinary approach using 
experimental, computational and mathematical tools to model complex systems in 
order to understand how functions or processes, such as cell differentiation, arise 
from the system dynamics [107, 108].  
Even if the systems biology field appears to be relatively new, the original concept 
dates from the middle of the 20th century, when the Austrian biologist Karl Ludwig 
Von Bertalanffy contributed to develop the General System Theory applicable in a 
wide range of science, including biology [109, 110]. Mihajlo Mesarovic, a Serbian 
professor of Systems Engineering and Mathematics, is also well recognised as a 
pioneer in the field of systems theory with its publication in 1968 [111].  
Systems biology analyses aim to quantify and predict the behaviour of the studied 
system as a whole, by summarising knowledge about the molecular parts of the 
system (coming from wet experiments) under a mathematical/computational 
model (giving rise to dry experiments) that serves as a complement for the 
biologist’s reasoning [112].  
Systems biology approaches have been successfully applied on unicellular 
organisms like bacteria [113-115] and yeasts [116-119], but remain challenging and 
more complicated to achieve with mammals.  
Assembling information to solve systems architectures and predict their functional 
properties can be led by two different strategies: top-down and bottom-up (Figure 
3). 
1.2.2. Top-down and bottom-up approaches 
Top-down approaches consist of analysing large-scale datasets coming from ’omics’ 
experiments such as microarrays, yeast-two-hybrid experiments, etc., (see section 
2.1.2 for more information on ’omics’ experiments using hESCs) to build networks. 
These networks (metabolic, transcriptional, protein-protein interaction networks, 
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and so on, section 2.1.1 for the definition of a network) are used to gain insight into 
more complex systems that typically constitute cells, tissues, organs or organisms 
(Figure 3) [120-122].  
 
Figure 3 | Systems biology: top-down and bottom-up approaches 
Combination of low throughput experiments, high throughput experiments and mathematical 
modelling constitutes both top-down and bottom-up systems biology approaches. 
Bottom-up approaches, on the other hand, start with quantitative data of single 
molecules or events such as cell-cell contact, to piece together mathematical 
models in order to predict outcomes by computational simulations (Figure 3, 
section 4.1.2) [123-125]. 
1.3. The approach 
The ESC core transcriptional network is composed of the three well-known 
transcription factors OCT4 [126-129], SOX2 [130, 131] and NANOG [129, 132, 133]. 
Though it has been studied by both top-down [126, 133-135] and bottom-up [128-
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130] approaches, cell/cell and cell/microenvironment interactions have been 
neglected to an extent. Although hESCs have been cultured for years, relatively little 
is known about the extrinsic factors regulating their stemness (section 4.1.1.1). A 
systems biology approach focusing on these extracellular factors (membrane and 
secreted proteins such as growth factors and matrix proteins) should help to 
capture novel clues to better understand the stemness state (Figure 4). 
 
Figure 4 | Systems biology study of hESCs 
Part 1: the top-down in silico approach to identify potential extracellular proteins involved in hESC 
stemness by transcriptomic and interactomic analyses. Part 2: the bottom-up in vitro approach to 
study the role of previously identified proteins in hESC stemness maintenance by stable knockdown. 
1.3.1. In silico investigations: a top-down approach 
The first part of the thesis aimed to use an in silico approach to establish a hESC 
transcriptome and interactome (section 2 and Figure 4). The hESC transcriptome 
was built by a meta-analysis of microarray datasets and annotated using Gene 
Ontology database. The combination of mRNA data as proxy for protein data and 
the utilisation of the STRING database led to the construction of a hESC protein-
protein interaction network or interactome. This network was structurally defined 
to highlight the extracellular proteins potentially regulating hESC stemness. 
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1.3.2. In vitro investigations: a bottom-up approach 
The second part of the thesis was the in vitro study of five of the previously 
identified extracellular proteins in the maintenance of hESC pluripotency. A RNA 
interference approach using short hairpin (sh)RNA and lentiviruses was applied for 
that purpose.  
The optimisation of the shRNA lentivirus production led to the development of a 
method for the absolute quantification of shRNA lentiviral particles (section 3). The 
knockdown effects of the targeted proteins on hESC pluripotency were assessed by 
relative quantification of the expression of candidate proteins, pluripotency 
markers, endoderm markers, mesoderm markers, ectoderm markers and 
trophectoderm markers, at the mRNA level by RT-qPCR and at the protein level by 
immunofluorescence and Western blotting (section 4 and Figure 4). 
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Chapter 2 – In silico study: a hESC transcriptome and interactome  
In silico study: a hESC 
transcriptome and interactome 
 
This chapter starts by an overview of the biological top-down based knowledge on 
hESCs, both at the wet level with the high-throughput analytical techniques and at 
the dry level with the development of biological networks. It is followed by the 
presentation of the in silico study, published in PeerJ (section 2.2), where 
transcriptomic data were combined with data obtained from a protein-protein 
interaction database to construct a hESC interactome and hypothesise on the likely 
key stemness actors. 
2.1. Top-down knowledge 
Top-down approaches have been developed to produce and analyse large-scale 
datasets with the aim of better understanding cells as a whole. A very large amount 
of raw data has been generated by these high-throughput techniques (often called 
‘omics’), and they provide data for the generation of biological networks. 
2.1.1. Dry laboratory side: networks 
Cells require thousands of biochemical processes to produce and transform 
components (such as glucose into pyruvate), respond to environmental stimuli and 
transmit information. The establishment of networks helps to gain a more global 
view of cellular biochemistry and physiology. 
2.1.1.1. Basic network features: topological parameters, motifs and modules 
A network can be described as a static graphical representation of a dynamic 
system developed from the graph theory and characterised by statistical properties 
[136, 137]. It is composed of nodes representing molecules and links (edges for 
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undirected networks or arrows for directed networks) representing interactions 
between molecules.  
The average degree 〈k〉, path length 〈l〉 and clustering coefficient 〈C〉 are intrinsic 
topological parameters depending on the network size (the number of nodes N and 
of links L) whereas degree P(k) and clustering C(k) distribution functions are 
independent of N and L and, therefore, give the network’s generic features and 
permit the classification of the network (Figure 5) [136-138] (section 2.1.1.2). 
 
Figure 5 | Graph illustration and formulae of the five main topological parameters 
All graphs and formulae are based on undirected networks. (A) Neighbours of the node i are nodes 
linked to it by edges. The node degree is its neighbour number ki. (B) The distance lij  between two 
nodes i and j is the minimum number of edges linking them (in green). (C) The diameter D is the 
maximum distance that can exist between any two nodes in a network. (D) The clustering coefficient 
ci measures the percentage of existing edges ri among the neighbourhood of the node i. (E) The 
betweenness bl of the node l represents the fraction of shortest paths between all pairs of nodes 
going through the node l [138]. 
Motifs are elementary graph units appearing significantly more often in a given 
network than in a random network. Networks can be classified according to the 
characteristic motifs they contain (Figure 6) [139]. 
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Figure 6 | Examples of network motifs 
Upper side: undirected network; Lower side: directed network. In directed networks, this feed-
forward loop triangle motif was characteristic in both neural and transcription-regulatory networks 
whereas this four-node feedback loop motif was present in electronic circuits [139]. 
Many real networks are modular, which means they can be partitioned into 
modules (or clusters) permitting the visualisation of complex systems, and helping 
to understand network structure and function. Each module is a group of highly 
linked nodes working together to perform a (relatively) distinct and identifiable 
task: signalling pathways can constitute modules. Detection of modules can lead, 
for instance, to the prediction of protein function [140-143]. 
2.1.1.2. Network models: random, scale-free and hierarchical  
One model of random graphs is the Erdös-Rényi model (Figure 7A), where the node 
degree k follows a Poisson distribution, meaning that most nodes have 
approximately the same number of links (k ≈ 〈k〉), and, therefore hubs, which are 
highly connected nodes are absent [144]. The Erdös-Rényi graph has no inherent 
modularity (so C(k) is independent of k), and has small average path length 〈l〉 and 
clustering coefficient 〈C〉. Another popular random graph is the Watts and Strogatz 
model, which has also a small 〈l〉 , but a high 〈C〉, and exhibits the small-world 
property (〈l〉 is proportional to the logarithm of the network size, 〈l〉~logN), where 
each node can reach another through a small number of nodes [136, 145, 146]. 
The scale-free model (Figure 7B) has been introduced by Barabási and Albert [147]. 
Its degree distribution follows a power-law P(k)~ k−γ. Therefore, there is no 
typical number of connections per node, involving the presence of hubs. As for the 
Watts and Strogatz network, the Barabási and Albert model has no inherent 
modularity and exhibits the small-world property architecture [136, 147, 148]. 
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The hierarchical network (Figure 7C) has been generated by an iterative manner to 
assume the coexistence of modularity, local clustering and scale-free topology. The 
main feature of this kind of network is its clustering coefficient, which follows a 
power law C(k)~k−1 [136, 149, 150]. 
 
Figure 7 | Network models 
(A) A random graph has a degree distribution P(k) exhibiting a Poisson distribution and a clustering 
coefficient distribution C(k) independent of the degree k. (B) A scale-free graph has P(k) following a 
power-law P(k)~ k−γ and C(k) independent of the degree k. (C) A hierarchical graph has P(k) and 
C(k) following power laws P(k)~ k−γwith γ = 1 +
𝑙𝑛4
𝑙𝑛3
= 2.26 and C(k)~k−1 respectively [136]. 
Several bioinformatics tools have been developed to visualise and analyse 
networks. Among them, Cytoscape [151] [m] is widely used.  
2.1.2. Wet laboratory side: the high-throughput experiments 
High throughput techniques have been increasingly implemented to produce 
different types of ‘omics’ data, from genomes to interactomes, allowing the 
construction of networks. These techniques have been widely tested in bacteria 
[152-155] and yeast [156-158], and are rapidly spreading among the mammalian 
cell community. 
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2.1.2.1. Transcriptome, proteome, metabolome, glycome and lipidome 
A transcriptome is the complex set of all RNA molecules transcribed in a cell, 
including mRNAs, tRNAs, rRNAs, microRNAs and other non-coding RNAs [159]. It is 
generally reduced to the mRNAs, transcripts coming from protein-coding genes 
[160, 161]. It is estimated that the human genome contains between 20,000 and 
25,000 genes, so comprising less than 2% of the entire genome [159]. Nonetheless, 
a transcriptome, even reduced to the mRNA sub-set, is still highly complex with 
probably more than 180,000 mRNAs due to alternative splicing [162-164]. 
In a multicellular organism, almost all the cells contain the same genome and, 
therefore, the same set of genes. However, expressed genes differ among cells due 
to physical (cell/cell contact) [165], biochemical (molecule availability) [165, 166], 
spatial (tissue type) [164] and developmental (different time points) differences 
that confer specific cell properties and behaviours such as stemness [167, 168]. 
Most transcriptomic data are generated with microarrays, which are also widely 
utilised in the stem cell field (Table 1), and are accessible through publications or 
through public databases such as Gene Expression Omnibus (GEO) from National 
Center for Biotechnology Information (NCBI) [169] [n] or ArrayExpress from 
European Bioinformatics Institute (EBI) [170] [o]. 
Although the transcriptome is a very important set of molecules, the proteome is 
arguably more crucial, because it is the set of molecules, namely the proteins, that 
carry out most biochemical processes, including the generation of secondary gene 
products (e.g. lipids, polysaccharides) [196-198]. Though the human proteome is 
generated from 20,000 to 25,000 genes, the actual number of proteins is much 
greater due to mRNA alternative splicing [164], alternative initiation of translation 
(e.g. fibroblast growth factor (FGF) 2 [199]) and post-translational modifications 
[200, 201]. The human proteome map contained 30,057 identified proteins from 
17,294 identified genes in August 2014 [202] [p], but this is a gross underestimate. 
As an example there are at least 30 different glycoforms of the two immunoglobin 
loop isoforms of FGF receptor-1, and this receptor has many splice variants and 
phosphorylation states [203, 204]. Proteome and phosphoproteome studies use 
mass spectrometry, which have just started to spread into the hESC field (Table 1). 
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In order to characterise better transcriptomes and proteomes, mRNAs and proteins 
have been classified into sub-sets through different projects such as the Gene 
Ontology (GO) Consortium [205] [q] where GO terms are biological process, 
molecular function and cellular component. 
 Study focus Cell type(s) Technique References 
Tr
an
sc
ri
p
to
m
ic
s 
mRNA expression profile hESC Microarrays [171] 
Identify similarities and differences in pathways 
required to maintain stemness 
hESC/mESC 
Microarrays [172] 
Microarrays [173-175] 
hESC/mESC/epiSC Microarrays [28] 
Identify pathways required to maintain stemness 
and/or trigger differentiation 
hESC/ 
Differentiated cells 
Microarrays [176] 
hESC/oocyte Microarrays [177] 
hESC/EB Microarrays [178, 179] 
Identify miRNAs and mRNAs involved in 
stemness maintenance 
hESC/EB/Differentiated 
cell 
Microarrays [180] 
Oxygen concentration effects on mRNA 
expression profile 
hESC Microarrays [181] 
Identify the transcriptional regulatory network 
associated with OCT4 
hESC Microarrays [126] 
P
ro
te
o
m
ic
s 
Quantitative proteome comparison hESC/hECC 
LC-MS/MS 
[182] 
iTRAQ 
Qualitative plasma membrane proteome 
comparison 
hESC/hECC LC-MS/MS [183] 
Qualitative extracellular proteome to identify 
proteins involved in stemness maintenance 
hESC LC-MS/MS [184] 
Qualitative phosphoproteome hESC LC-MS/MS [185] 
Quantitative plasma membrane proteome 
comparison to identify proteins involved in 
stemness maintenance 
hESC 
LC-MS/MS 
[186] 
SILAC 
Quantitative proteome and phosphoproteome 
to identify proteins involved in stemness 
maintenance 
hESC 
LC-MS/MS 
[187] 
SILAC 
M
et
ab
o
-
lo
m
ic
s 
Metabolome comparison 
hESC/hESC-derived neural 
precursor 
LC-MS [188] 
Metabolome to study developmental toxicity hESC LC-MS [48] 
Metabolome comparison to study the role of 
oxidation in ESC differentiation 
hESC/mESC/ 
Differentiated cell 
LC-MS [189] 
In
te
ra
ct
om
ic
s 
Links between transposable elements and the 
core transcriptional network 
hESC/mESC ChIP-seq [190] 
Identify similarities and differences in pathways 
required to maintain stemness 
hESC/mESC/epiSC ChIP-on-chip [28] 
Identification of NANOG, SOX2 and OCT4 targets hESC ChIP-on-chip [191] 
Identify the transcriptional regulatory network 
associated with OCT4 
hESC/EB/ 
Differentiated cell 
ChIP-on-chip / 
ChIP-PET 
[126] 
Y2H cDNA libraries mESC Y2H [192] 
Identify SOX2 endogenous interactions HeLa IP/MS [193] 
Identify endogenous protein complexes Glioblastoma cell IP/MS [194] 
G
ly
co
-
m
ic
s 
Determine the N-glycome 
hESC/ 
Differentiated cell 
MS [195] 
Table 1 | hESCs and high-throughput experiments 
Non-exhaustive list of high-throughput techniques used to study hESCs. Unfortunately, Y2H and 
IP/MS have not currently been applied directly to hESCs. 
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Another important group of molecules are the metabolites forming the 
metabolome. Metabolic networks, presenting both protein and metabolite 
information, focus on the mass flow and the energy required in chemical pathways 
that generate essential components such as amino acids, sugars, and lipids [206] [r]. 
This field is emerging within the stem cell area (Table 1). The glycome regroups 
glycans, highly abundant and structurally diverse carbohydrates that are conjugated 
to proteins and lipids, and play functional roles in cell processes [207, 208]. The 
hESC glycome starts to be studied (Table 1), whereas the hESC lipidome formed by 
lipids [209, 210] has not been investigated yet. 
2.1.2.2. Interactome 
Although proteins are the key components of biological processes, to achieve their 
biological function, they work in complexes with other proteins, nucleic acids, 
polysaccharides, lipids and metabolites. All these molecular interactions form the 
interactome [211]. 
High-throughput techniques such as chromatin immunoprecipitation (ChIP)-on-
chip, ChIP-PET (paired-end tag) and ChIP-seq (sequencing) allow the study of 
DNA/protein interactions [191, 212] and the generation of transcriptional 
regulatory networks, which have already been implemented in the hESC field (Table 
1).  
However, the largest amount of interaction data currently available is between 
proteins. Therefore, the term 'interactome' usually refers to protein-protein 
interactions (PPI) only [213]. Two techniques recently scaled up are commonly used 
to detect PPI: the yeast two-hybrid (Y2H) to identify binary interactions [213], and 
co-immunoprecipitation-mass spectrometry (MS) to identify protein complexes 
[194]. To increase the PPI coverage, computational methods have also been 
developed [214]. 
The human PPI size is currently estimated to be about 650,000 interactions [215]. 
All these PPI data are stored in databases such as Search Tool for the Retrieval of 
Interacting Genes/Proteins (STRING) [216] [s]. PPI networks are scale-free networks 
formed by nodes representing proteins and by edges representing physical 
interactions [136, 217]. Understanding the meaning of these PPI in the context of a 
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particular cell, notably by the development of PPI networks, is one of main post-
genomic goals, since this relates directly to cell biochemistry, physiology and hence 
function [218-220].  
2.1.3. A top-down strategy 
A top-down systems biology approach has been chosen to find potential novel 
extracellular proteins regulating stemness, starting by the construction of a hESC 
transcriptome. 
Several transcriptomic studies have established transcriptomes of hESC specific cell 
lines [171-174, 176-179, 181]. Meta-studies have also been carried out. One of 
them used 38 published lists of expressed hESC mRNAs (not raw data) and mainly 
focused on upregulated genes in hESCs to find that 1,076 genes were 
overexpressed in at least three studies, but only OCT4 was found to be 
overexpressed in all studies [221]. That is a poor overlap. Another study 
demonstrated that reanalysing microarray raw data rather than using published 
data increases the overlap: when they compared published data from 3 different 
hESC studies, they found an overlap of 7 genes while when they reanalysed the raw 
data instead, they increased the overlap to 111 genes [222]. However, the number 
of analysed datasets and the final list of genes were still small.  
It was decided to go further and produce a meta-analysis of raw transcriptomic 
data from a large number of microarrays run on different hESC lines in different 
laboratories to identify a robust core hESC transcriptome. In parallel, 
transcriptomes of early differentiated cells were also built, allowing transcriptomic 
comparisons of hESC and hESC-derived cells and identification of likely key 
regulators of pluripotency.  
The following step was the construction of an in silico hESC interactome using the 
combination of the hESC transcriptome with the STRING PPI database. This 
interactome was structurally studied to reveal the ’module organiser’ or hub 
proteins along with the ’module connector’ or bottleneck proteins and identify the 
extracellular proteins likely involved in stemness maintenance.  
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2.2. Network based meta-analysis prediction of microenvironmental 
relays involved in stemness of human embryonic stem cells 
(Manuscript)  
Virginie Mournetas, Quentin M. Nunes, Patricia A. Murray, Christopher M. 
Sanderson, David G. Fernig 
Published as a preprint in PeerJ, June 2014 
(http://dx.doi.org/10.7287/peerj.preprints.415v2)  
Published as a reviewed paper in PeerJ, October 2014 
(https://peerj.com/articles/618/) 
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Supplemental data 
(Available online, https://peerj.com/articles/618/#supplemental-information) 
 
Table S1 | List of mRNAs forming hESC and hESC-derived transcriptomes 
Each mRNA is identified by the EntrezGene ID, the Official Gene Symbol and the full gene name. 
'Transcriptome' column: transcriptome(s) or sub-transcriptome containing the mRNAs (hESC: human 
embryonic stem cells; Endo: endothelial cell; F: fibroblast; Mix: mixture of hESC-derived cells). 
Colour code (see Legend sheet) indicates different transcriptome and sub-transcriptomes. GO term 
column: GO terms found during the GO extraction (CA: cell adhesion; CC: cell cycle; CCo: cell 
communication; CS: cytoskeleton organisation; J: cell junction; EC: extracellular part; HS: heparan 
sulfate binding proteins; TF: transcription factor related part). (Excel file) 
Table S2 | General network parameters 
ALL R is the randomised network from the ALL interactome while C+S R is the randomised network 
from the C+S interactome (C: common part; S: specific part; R: random). Power law of the degree 
distribution: P(k)~ αk−γ with R2, the polynomial regression coefficient (degree 2). 
Table S3 | GO/KEGG analyses 
GO Biological Processes term and KEGG pathway enrichments analysis of A) EC+TF interactomes, B) 
full lists of candidates and C-I) sub-sets of candidates (EC: extracellular part; TF: transcription factor 
related part). 
Table S4 | The complete list of candidates 
Each protein is identified by its corresponding EntrezGene ID, gene acronym and full gene name. 
'Transcriptome' column: transcriptome(s) or sub-transcriptome containing the corresponding mRNA 
(Endo: endothelial cell; F: fibroblast; Mix: mixture of hESC-derived cells). A colour code is applied to 
aid recognition of each transcriptome and sub-transcriptome (see the Legend sheet). GO term 
column: GO terms found during the GO term analysis (CA: cell adhesion; CC: cell cycle; CCo: cell 
communication; CS: cytoskeleton; J: cell junction; EC: extracellular part; HS: heparan sulfate binding 
proteins; TF: transcription factor related part). "Hubs" column: indicates the number of edges 
associated with each hub protein. 'S/C' and 'EC/TF' columns: indicates if a protein is in the 
specific/common interface or extracellular/transcription factor interface respectively. A) the longest 
ALL_EC+TF list of candidates, B) the random list, C) the ALL_EC list, D) the C+S_EC+TF list and E) the 
shortest C+S_EC list of candidate proteins, in which C = common part and S = specific part. (Excel file) 
Data S1 | The hESC putative interactomes 
The hESC EC+TF putative interactomes A) ALL and B) C+S (C: common part; S: specific part). 
(Cytoscape file) 
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2.3. Additional results: The hESC putative protein interactome and 
sub-putative protein interactome structures 
The hESC putative protein interactome was generated from a human interactome 
composed of 13,108 proteins and 143,179 interactions [223], by selecting the nodes 
only present in the hESC transcriptome and their attached edges. The resulting 
hESC putative protein interactome, termed ALL1, possessed 6,514 nodes (named N 
and representing proteins) and 46,954 edges (named L and representing physical 
interactions, Figure 8, Data S1A) is a static picture of the network governing 
pluripotency. It was called a putative protein interactome, because the mRNA 
expression data served as a proxy for protein expression data. Removing self-loops 
(ALL2, Figure 8, Data S1B) and the isolated nodes (ALL3, Figure 8, Data S1C) resulted 
in a network of 6,011 nodes and 45,075 edges with a decreased number of 
connected components (independent sub-networks) within the network (Table 2A). 
To discover meaningful nodes and/or edges for stemness in the whole hESC 
putative protein interactome, a sub-putative protein interactome composed of the 
specific mRNAs (S) expressed by the hESCs and the common mRNAs (C) shared by 
the hESCs and the hESC-derived cells was extracted. This sub-putative protein 
interactome was called hESC C+S putative protein interactome (or C+S1, Figure 8, 
Data S1D) and was composed of 2,090 nodes and 5,978 edges. Removal of self-
loops (C+S2, Figure 8, Data S1E) and the isolated nodes (C+S3, Figure 8, Data S1F), 
resulted in a network with 1,533 nodes and 5,347 edges (Table 2A). As previously 
for the transcriptome presented section 2.2, specific and common parts were kept 
together to highlight the hESC specificities among the whole PPI network. 
The ALL putative protein interactomes have an increased average degree (which is 
the number of edges per node) <k> and a reduced characteristic path length (which 
is the average shortest path length between two nodes) <l> compared to the C+S 
putative protein interactomes (Table 2A), indicating that the ALL putative protein 
interactomes were slightly more compact. The average clustering coefficient <C> 
indicating the network cohesiveness was closer to zero for all the randomised 
networks, which serve as control, in stark contrast to the real ALL and C+S putative 
protein interactomes (Table 2A). 8 | hESC transcriptomes and interactomes 
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Figure 8 | hESC transcriptomes and interactomes 
 C 
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This implied a significant stronger presence of hubs (highly connected nodes) in the 
latter real interactomes, as well as the presence of modules or clusters (group of 
highly interconnected nodes). The C+S putative protein interactomes presented a 
decreased <C> compared to the ALL putative protein interactome, until the isolated 
nodes were removed (Figure 9A, Table 2A). ALL and C+S interactomes exhibited the 
small-world property ( 〈C〉 ≫ 〈Crandom〉 and  
<𝑙>
<lrandom>
≥ 1), which means most 
pairs of nodes are linked by a small number of edges [136, 145, 146] (Table 2A). 
 
Figure 9 | hESC ALL and S+C putative protein interactomes, general network parameters 
(A) The average clustering coefficient 〈C〉 of real networks and their corresponding average 
randomised networks (mean±SEM; One sample t-test, n=5, ***p-value<0.001). (B) The node degree 
distribution P(k) and (C) the clustering coefficient distribution C(k) of ALL3, C+S3 and a 
corresponding randomised network (C: common part; S: specific part; R: random). 
All the real putative protein interactomes, as showed in previous PPI network 
studies, exhibited a scale-free structure [136, 217], where the degree distribution 
P(k) follows a power-law P(k)~ k−γ, involving the presence of hubs (Figure 9B and 
Table 3), and the clustering coefficient distribution C(k) is independent of k meaning 
there is no inherent presence of modules (Figure 9C). The randomised putative 
protein interactomes were also scale-free networks (Figure 9B,C). 
These results assess that the skimmed putative protein interactomes (ALL3 and 
C+S3) were similar to the non-skimmed putative protein interactomes (ALL1 and 
C+S1) and were suitable for further analysis.  
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 Table 2 | General network parameters 
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ALL1 ALL2/3 S+C1 S+C2/3 
ALL  
(P) 
ALL  
(D) 
ALL  
(D 0.7) 
S+C  
(P) 
S+C  
(D) 
S+C  
(D 0.7) 
γ -1.6 -1.6 -1.5 -1.5 -1.5 -1.4 -1.3 -1.5 -1.6 -1.5 
R2 0.886 0.884 0.896 0.893 0.859 0.859 0.841 0.784 0.887 0.914 
Table 3 | Power law of the degree distribution P(k) 
Power law of the degree distribution: P(k)~ αk−γ with R2, the polynomial regression coefficient 
(degree 2). 
As the aim is to learn more about the cell/cell and cell/matrix interactions, sub-
putative protein interactomes containing only the transcriptional and extracellular 
components were extracted together (EC+TF) from the ALL3 (ALL (P) with 1,000 
nodes and 4,239 edges, Figure 8) and from the C+S3 (C+S (P) with 314 nodes and 
672 edges, Figure 8). Similar sub-interactomes were established by means of the 
STRING database [216] using the lowest interaction confidence of 0.15 (ALL (D) with 
998 nodes and 5,601 edges and C+S (D) with 309 nodes and 709 edges, Figure 8) or 
a higher one of 0.7 (ALL (D 0.7) with 702 nodes and 3,201 edges and C+S (D 0.7) 
with 209 nodes and 371 edges, Figure 8 and Figure 10 for more information about 
the impact of edge confidence on the number of nodes and edges in each network). 
The use of STRING data (D), rather than publication [223] data (P), slightly 
decreased the number of nodes N, but increased the number of edges L by 32% for 
ALL and 6% for C+S. The application of a higher edge confidence (D 0.7) reduced 
both N (by 30%/32% for ALL/C+S) and L (by 43%/48% for ALL/C+S) leading to the 
fragmentation of the networks and, therefore, the augmentation of connected 
components (Table 2A). 
As previously, the C+S (P) sub-putative protein interactomes had a reduced average 
degree <k> compared to the ALL (P) sub-putative protein interactomes. 
Nevertheless, the use of STRING data improved the interconnectivity by increasing 
<k> in the ALL and C+S sub-putative protein interactomes (Table 2A). The 
characteristic path length <l> indicated that the C+S (P) sub-putative protein 
interactomes were slightly less compact than the ALL (P) sub-putative protein 
interactomes, but STRING data also increased it (Figure 11).   
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Figure 10 | EC+TF putative protein interactomes and edge confidences  
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Figure 11 | EC+TF sub-putative protein interactomes, general network parameters 
Six sub-putative protein interactomes are analysed: three containing all the EC+TF components (ALL) 
and three containing only the specific and common parts of the EC+TF sub-interactomes (C+S). The 
difference between each three similar interactomes is the data source (P: publication data or D: 
STRING data) and the interaction confidence (D: 0.15 and D 0.7: 0.7). (A) The average clustering 
coefficient 〈C〉 of real networks and their corresponding average randomised networks (mean±SEM; 
One sample t-test, n=5, ***p-value<0.001). (B) The node degree distribution P(k) and (C)(D) the 
clustering coefficient distribution C(k) (C: common part; S: specific part; R: random). 
The C+S sub-putative protein interactomes presented a decreased average 
clustering coefficient <C> compare to the ALL sub-putative protein interactomes, 
but they were significantly higher than for the randomised networks (Figure 9A). 
Nonetheless, the use of STRING data improved the cohesiveness even more by 
increasing the interaction confidence (Figure 11A and Figure 12 for more 
information the impact of edge confidence on the number of nodes and edges in 
each EC+TF sub-network).  
All the EC+TF putative protein interactomes exhibit the small-world property 
architecture [136, 145, 146](Table 2B). 
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Figure 12 | EC+TF putative protein interactomes and sub-sets 
Percentage of nodes/edges in the EC+TF putative protein interactomes in function of the sub-sets 
(ALL, C+S, C and S or HS, EC non HS, TF, EC, HS+TF, EC non HS+TF and EC+TF). The edge confidences 
(0.15, 0.7 and 0.9) are compared to the ALL (P) network. (A) Node % in the ALL, C+S, C and S sub-
sets; (B) Edge % in the ALL, C+S, C and S sub-sets; (C) Node % in the HS, EC non HS, TF, EC, HS+TF, EC 
non HS+TF and EC+TF sub-sets; (D) Edge % in the HS, EC non HS, TF, EC, HS+TF, EC non HS+TF and 
EC+TF sub-sets (C: common part; S: specific part; EC: extracellular part; TF: transcription factor 
related part; P: publication data; D: STRING data). 
As previously, all the EC+TF putative protein interactomes exhibited a scale-free 
structure, where P(k) followed a power-law P(k)~ k−γ (Figure 11B and Table 3) and 
C(k) was independent of k, even if there was a tendency to be hierarchical 
(C(k)~ k−β) compared to the random networks, meaning that modules are more 
inherent in this smaller networks than in the whole hESC network (Figure 11C, D). 
These results demonstrate that the EC+TF putative protein transcriptomes and 
especially the ones from STRING data were suitable for further analyses which were 
done in the PeerJ publication (section 2.2). 
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2.4. Discussion 
2.4.1. Further comments on the transcriptome and interactome 
The hESC transcriptome found here was large, but incomplete. As discussed in the 
PeerJ publication (section 2.2), the way the transcriptome was established certainly 
reduced the number of false positives, but also increased the number of false 
negatives, as illustrated by the absence of NANOG. Also, the use of EntrezGene IDs 
or Official Gene Symbols as identifiers did not permit discrimination of mRNA 
variants and later protein isoforms. Moreover, the microarray technique implies the 
selection of mRNAs through the probe set that does not cover the whole possible 
transcriptome. High-throughput next generation sequencing could be an alternative 
to generate more complete transcriptomes [224-226]. 
The hESC putative protein interactome, with its scale-free architecture, exhibited a 
high error (random mutations) tolerance thanks to redundancy, and a high attack 
vulnerability due to the presence of hubs [227]. The origin of the interaction data 
(the fixed human interactome from a publication [223] or the STRING database 
[216]) did not change the network architecture. The fixed human interactome 
allowed a whole picture of the hESC putative protein interactome to be assembled, 
which is impossible with the STRING database due to the restriction of node 
number. On the other hand, STRING data allowed the manipulation of edge 
confidences and the gain of edge knowledge, such as the experiment type and 
reference. 
2.4.2. Meta-analysis, going beyond 
The amount of ‘omics’ data is growing extremely fast, allowing more and more 
meta-analyses to gain a global vision of the stemness state. However, this torrent of 
raw data is coming from studies with specific foci, with differences in stem cell 
lines, culture medium, laboratory formulations and experimental techniques. This 
highlights the problem of data comparability and brings the need of standardisation 
to prevent and minimise systematic errors and estimate the rational error [228]. 
Common standards for storage, data representation and transfer are appearing in 
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several fields such as genomics with Gene Ontology (GO) [205], transcriptomics 
with Minimum Information About Microarray Experiment (MIAME) [229], and 
proteomics with Proteomics Experiment Data Repository (PEDRo) [230]. Definition 
of standards for biological models and signalling pathways as Systems Biology 
Markup Language (SBML) [231] and Cell Markup Language (CellML) [232] are also 
developed to integrate, correlate, visualise and present data stored in various 
databases.  
2.4.3. From a qualitative static model to a quantitative dynamic model 
Mechanisms involved in stemness are complex, multi-level and determined by the 
intrinsic cell potential, cell/cell and cell/matrix interactions. These mechanisms 
require the coordinated expression of hundreds of genes and proteins regulated by 
feedback loops, feed-forward loops and cross-talk between signalling pathways 
[105, 106, 233]. Modelling the cell system is limited by data availability and quality 
and thus, by experimental technologies. Improving these two parameters is critical 
to achieve better cell models. At the transcriptomic level, genes are highly and 
tightly regulated to trigger different responses in function of the context of 
expression [234]. Identification and quantification of all mRNAs and their variants 
are the next level of transcriptomic analysis, as well as identification and 
quantification of all proteins and their isoforms are the next level of proteomic 
analysis. Integration of information about protein activation, such as 
phosphorylation, has also to be considered. At the interactomic level, all molecule 
interactions have to be combined and characterised: when, where and why an 
interaction occurs, especially in vivo, are crucial questions.  
Each cell type has its own characteristic expression pattern and each cell within this 
cell type can also have a specific one [235, 236]. ESCs are especially known to be 
heterogeneous within the same culture, which is an intrinsic feature of stem cells 
and reflects the exposure to a variety of micro-environmental disturbances 
(described as stochastic effects) [105, 233, 237]. This important feature tends to be 
the least studied, because generally most analyses are performed at the cell 
population level, though this is about to change with the development of single-cell 
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analysis [238] (section 5.1). Moreover, current high throughput techniques give 
snapshots, and generating static networks from them is only the first step towards 
the construction of dynamic models [239]. Developing notions of attractors (cell 
stable stationary states), landscapes formed with valleys (attractors) and hills 
(barriers between attractors), and cell state transitions (Figure 13), is necessary to 
design integrative ‘omics’ studies where transcriptomics, proteomics and so on will 
be measured simultaneously and in a time-series manner to reach the dynamic 
level of system behaviour [105, 239-241]. 
 
Figure 13 | System theory illustration 
Attractors represent stable stationary states. Landscapes are formed with valleys (attractors) and 
hills (barriers between attractors). (A) A single attractor, small potential of fluctuations; (B) two 
reachable attractors and (C) two unreachable attractors. 
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Reverse genetics, the opposite of forward genetics, seeks to study the function of a 
gene by discovering the phenotype(s) arising from the disruption or modification of 
this gene or its product. Gene silencing, including RNA interference (RNAi), is a 
powerful reverse genetic tool that allows partial or complete suppression of a 
specific gene product. This approach can be used to find novel genes involved in the 
maintenance of stem cell pluripotency or differentiation processes. 
3.1. A short introduction to RNA interference approaches 
RNAi is a process that leads to the post-transcriptional knockdown of target genes. 
It is mediated by double-stranded short interfering RNAs that contain an anti-sense 
or ‘guide’ strand, complementary to the target mRNA and upon binding, decreases 
the target protein expression. This process was accidentally observed in 1990 
during an experiment with petunias [242]. The endogenous mechanism behind 
RNAi was then suggested in Caenorhabditis elegans [243], before being 
exogenously exploited in plants [244], Caenorhabditis elegans [245] (by Andrew Z. 
Fire and Craig C. Mello who jointly received the 2006 Nobel Prize in Physiology or 
Medicine [t] for their work on RNAi) and Drosophila melanogaster [246]. 
3.1.1. Endogenous mechanisms 
Three main types of small regulatory (and non-coding) RNAs have been described in 
eukaryotes: PIWI-interacting RNAs (piRNAs, not discussed here), microRNAs 
(miRNAs) and short interfering RNAs (siRNAs, reviewed in [247]). Long endogenous 
double-stranded (ds)RNA precursors (arising from different processes such as RNA 
virus replication or mobile genetic elements) and hairpin pre-miRNAs are cleaved in 
the cytoplasm by the endonuclease Dicer into double-stranded siRNAs and double-
stranded miRNAs, respectively. These siRNA and miRNA duplexes, which are 20-30 
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nucleotides in length, are transferred by Argonaute proteins to the RNA Induced 
Silencing Complex (RISC). RISC separates the two strands allowing the 
complementary strand to anneal to its target mRNA sequence [247] leading to the 
decreased synthesis of the corresponding protein by different processes: siRNA 
sequence is highly homologous to the targeted mRNA and triggers its degradation 
through cleavage, whereas miRNAs tend to contain mismatches (and, therefore, 
can target several mRNAs [248]) and regulate gene expression by inhibiting 
translation [249]. MicroRNA-mediated degradation of the target mRNA can also be 
triggered by deadenylation and decapping [250, 251]. 
3.1.2. RNA interference as a reverse genetic technique 
Attempts to use long dsRNA as RNAi inducer in mammalian cells turned out to be 
inefficient due to the interferon response [252, 253]. In contrast, exogenous siRNA 
or short hairpin (sh)RNA duplexes show relatively high specificities and efficiencies 
in triggering gene knockdown [254, 255].  
3.1.2.1. Delivery methods: transfection or transduction? 
The main challenge in RNAi approaches is to succeed in transferring negatively 
charged molecules (siRNAs or shRNAs) through the impermeable and negatively 
charged plasma membrane of the cell into the cytosol. Here, I present a non-
exhaustive list of methods commonly used to deliver RNAs into eukaryote cells 
(Figure 14). 
Lipofection, or liposome transfection, is a chemical transfection method where 
positively charged lipid subunits form liposomes that surround the small RNAs, 
neutralise their charges and help to overcome the electrostatic repulsion of the 
cell’s lipid bilayer (Figure 14A). These liposome-DNA/RNA aggregates fuse with the 
cell membrane, allowing the RNAs to cross this barrier into the cytosol [256, 257].  
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Figure 14 | Delivery methods of exogenous DNA/RNA for RNA interference approaches 
(A) Chemical transfections (lipofection and calcium phosphate-mediated transfection); (B) physical 
transfection by electroporation; (C) lentivirus production and transduction together with the 
description of the RNAi mechanism. 
Calcium phosphate-mediated transfection is another chemical transfection 
method that is commonly utilised. A calcium chloride solution (positively charged) 
containing the DNA of interest (negatively charged) combined to a 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-buffered saline solution 
forms a precipitate that cells can assimilate [258, 259] (Figure 14A). 
Chapter 3 – RNA interference and stem cells 
 
62 
 
Electroporation or electro-permeabilisation, is a physical transfection method 
where cells are exposed to short electrical pulses that briefly create holes in the 
plasma membrane allowing the DNA/RNA to enter [260] (Figure 14B). 
Transduction introduces foreign DNA into a cell via viral (adenoviral, retroviral or 
lentiviral) vectors. These vectors have to be first generated by a producer cell line 
through transfection of appropriate plasmids (Figure 14C). These vectors lack the 
ability of self-replication. Therefore, they do not ‘infect’, but rather ‘transduce’ the 
target cells. 
3.1.2.2. Transient, stable and inducible knockdown 
Table 4 gives some examples of hESC studies using RNAi approaches.  
Study target 
Technique 
Time of 
analysis 
References Type of 
knockdown 
Type of RNAi Delivery method 
OCT4 
Transient shRNA vector Electroporation 3, 4 and 7 days [128] 
Inducible shRNA vector Electroporation up to 7 days [261] 
Transient siRNA Lipofection 3 days [126] 
Transient siRNA Lipofection up to 5 days [262] 
Transient siRNA Lipofection up to 7 days [263] 
NANOG 
Stable shRNA vector Stable transfection up to 28 days [133] 
Transient siRNA Lipofection up to 6 days [264] 
OCT4/NANOG Stable 
shRNA 
retrovirus/ 
lentivirus 
Transduction up to 7 days [129] 
SOX2 Transient siRNA Lipofection 3 and 5 days [130] 
OCT4/NANOG/SOX2 
Transient siRNA Electroporation 4 days [265] 
Stable 
shRNA 
lentivirus 
Transduction up to 12 days [135] 
Table 4 | Exogenous RNA interference in hESCs 
Non-exhaustive list of RNAi approaches used to study the role of OCT4, SOX2 and NANOG in the 
maintenance of hESC stemness. 
Transient knockdowns can be achieved in vitro by transfection (chemical or 
physical) and/or by adenoviral vectors [266]. The assimilated siRNAs/shRNAs are 
available for expression but rarely integrate into the host genome and, therefore, 
do not replicate. Effects of the siRNAs/shRNAs on cells usually last for a few days, 
until they are degraded and/or diluted through cell division [267]. Transient 
knockdowns are applicable in vivo too [268]. 
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Stable knockdowns can also be achieved in vitro by transfection. To select stably 
transfected cells, a resistance gene has to be co-transfected with the 
siRNAs/shRNAs for selection. However, the rate of genome integration through 
transfection is relatively low [269]. The in vitro transduction of retroviral or 
lentiviral vectors is more efficient to achieve stable knockdown, as they integrate 
into the host genome [270, 271]. Similarly to stable transfection, the 
siRNAs/shRNAs are commonly co-transduced with a resistance gene, allowing cell 
selection. Remaining cells should permanently express the foreign DNA sequence. 
Stable knockdowns are possible in vivo too [272]. 
Inducible knockdowns can also be achieved, in vitro [261, 273] and in vivo [274, 
275], using the tetracycline-inducible expression system [276]. 
3.1.3. The approach 
A stable knockdown using a shRNA lentivirus approach has been chosen to study 
the potential role of previously identified candidate proteins (section 2) in the 
maintenance of hESC stemness. For this purpose, shRNA lentiviral particles were 
produced and an absolute quantification method was developed. 
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3.2. Absolute quantification of produced shRNA pseudotyped 
lentiviral particles by real-time PCR  (Manuscript) 
Virginie Mournetas, Sofia Melo Pereira, David G. Fernig, Patricia A. Murray 
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Abstract 
Gene silencing techniques, including RNA interference methodologies, are widely 
used in reverse genetics to study the role of specific genes in biological processes. 
Over recent years, RNA interference has become easier to implement thanks to 
‘The RNA Consortium’ (abbreviated TRC), which have developed libraries of short 
hairpin RNA (shRNA) sequences in pseudotyped lentiviruses capable of targeting 
most genes in the human and mouse genomes. However, a current problem with 
using the libraries is the lack of a simple method to titrate the produced lentiviral 
particles, making it difficult to optimise and standardise shRNA experiments. In the 
present study, we describe a quick, non-laborious and reliable method for the 
titration of TRC pseudotyped lentiviruses that is based on the detection and 
measurement of viral RNA using quantitative PCR. Our data demonstrate that 
purified linearized shRNA plasmids represent more suitable standards than circular 
or unpurified linearized plasmids. We also show that for precise absolute 
quantification, it is important to determine suitable plasmid and viral cDNA 
concentrations in order to find the linear range for quantification, as well as to 
reduce inhibition and primer dimer amplification. Primers utilised in this non-
functional titration can potentially be applied to functional titration of proviral DNA 
copies or transgene expression, overcoming the absence of fluorescent reporter 
gene in TRC plasmids. 
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Introduction 
Gene silencing is a powerful reverse genetic tool that is commonly used to discover 
novel genes underlying specific biological processes such as apoptosis [1,2] or cell 
differentiation [3]. Gene knockout techniques are still considered the gold-standard 
in loss-of-function experiments, and the International Knockout Mouse Consortium 
currently provides more than 1,700 mutant mouse strains and 17,400 mutant 
murine embryonic stem cell clones [4]. However, such repositories are still 
incomplete and no human version has been developed. Also, generating de novo 
knockout models remains laborious, expensive and time consuming [5]. Moreover, 
some issues limit the use of this technique. Embryonic lethality, affecting about a 
third of the knockouts generated, is the most prominent problem which prevents 
the study of the targeted gene, although it serves to identify genes involved in 
embryogenesis [6]. The phenotype arising from the knockout can also be 
attenuated through adaptation and/or compensation processes [7,8]. 
RNA interference (RNAi) is a widely adopted reverse genetic technique [9,10] that 
provides an alternative approach for inducing loss or reduction-of-function in 
mammalian cells [11]. Such reverse genetic techniques are quicker, easier and 
cheaper to implement than knockout models and also overcome the problems of 
embryonic lethality and adaptation [12]. The simplest RNAi approach is the 
transient transfection of short interference (si)RNA [13], which can be easily 
obtained from commercially available siRNA libraries. However, some cells are 
difficult to transfect [14] and transient transfection usually leads only to short-term 
knockdown and is unsuitable for long-term investigations. 
These problems with siRNA can be overcome by using a lentiviral system to 
introduce constructs encoding a small hairpin RNA (shRNA) that can mediate 
permanent knockdown of the target gene. Lentiviruses have very high transduction 
efficiencies [15], and can be used to genetically modify most types of cells, including 
those that are refractory to transfection [16], as well as dividing [17,18] and non-
dividing cells [19-23]. The elaboration of replication-defective lentiviral particles has 
provided safe conditions for their utilisation [24]. 
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The combination of this shRNA approach with lentiviral technology has been used 
with great effect by The RNAi Consortium (TRC), which has developed genome-
scale shRNA libraries against the human and mouse genomes [10]. 
Quantification of lentiviruses is an important step in developing robust and 
reproducible RNAi protocols and several methods have been elaborated to quantify 
viral titres. These methods can be divided into two types: functional titrations to 
determine the concentration of viral particles needed to infect a cell, and non-
functional titrations to determine the number of viral particles secreted by 
producer cells. 
In the context of functional titration, if a fluorescent reporter gene such as eGFP 
[17,25] or DsRed [18] is transduced alongside the sequence of interest, the 
functional titre can be determined by FACS analysis. However, this quantification 
method requires a fluorescent marker and cannot distinguish single from multiple 
proviral DNA integration sites within the host genome. An alternative approach is 
the estimation of the number of integrated proviral DNA copies per cell by 
quantitative (q)PCR [17,18,25]. Because proviral copies can be inserted into 
different chromatin regions, the transgene expression can vary [25]. Quantification 
of the expressed transgene by reverse transcription (RT)-qPCR avoids this drawback 
[25]. 
Functional titrations require transduction, which is time intensive, and efficiencies 
depend on both cell types and transgenes [25,26]. To determine the titre of a 
lentiviral particle batch for protocol optimisation and standardisation purposes, the 
non-functional approaches are more suitable. It has been demonstrated that 
manipulating the amount of any of the plasmids (transfer, packaging or envelope) 
needed for pseudotyped lentivirus production can affect the non-functional titre 
without altering the functional one [27]. These non-functional methods rely either 
on the measurement of expressed viral protein p24 or of viral RNA. The p24 antigen 
measurement by ELISA has some reliability issues, due to the presence of a variable 
amount of p24 originating from defective particles and non-particle-associated p24 
[17,28,29]. Alternatively, several groups have developed methods for measuring 
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viral RNA, either directly by qPCR [30] or indirectly by RT-qPCR [17,25,28,31-33]. 
Even if viral RNA-based titrations also measure defective particles to some extent 
[33], it has been shown that mainly full-length viral RNA transcripts are 
incorporated into pseudotyped lentiviruses [28]. However, none of the previously 
set-up primers were suitable for the titration of TRC shRNA pseudotyped 
lentiviruses as they were targeting sequences missing from TRC plasmids 
[17,25,28,31-33]. 
In this study, we have developed an RT-qPCR method for absolute titration of TRC 
shRNA pseudotyped lentiviral particles using TRC shRNA plasmids as standards. We 
demonstrate that the conformation of the plasmid as well as its purity (either 
circular, linearized or purified linearized) plays an important role in qPCR efficiency, 
and show that absolute quantification requires both plasmid and viral cDNAs to be 
within an appropriate concentration range. 
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Materials and methods 
shRNA plasmid amplification, purification and digestion 
E. coli containing the TRC shRNA plasmids [4,22] (Sigma-Aldrich Mission shRNA 
SHCLNG, Dorset UK, Table 1) were cultured overnight in a shaking incubator at 37°C 
in Terrific Broth medium (Sigma-Aldrich T0918, Dorset UK) with ampicillin (Sigma-
Aldrich A5354, Dorset UK, 100 µg/mL final concentration) for selection. Plasmids 
were purified using Qiagen plasmid maxi kit (12162, Manchester UK) and diluted in 
200 μL of water (GIBCO 10977-035, Paisley UK). Plasmid concentration and purity 
were measured using Nanodrop 2000 (Thermo Scientific, Hemel Hempstead UK). 
500 ng of each plasmid were digested with 1.5 units of EcoR1 (New England Biolabs 
R3101S, Herts UK, Fig. 1) for 1 h at 37°C (final volume of 25 µL). The enzyme was 
then inactivated for 20 min at 65°C and a 1% agarose gel was run with the 
HypperLadder I (Bioline BIO-33053, London UK) as molecular size marker to check 
digestion efficacy (Fig. 2 and Fig. S1B). The digested plasmids were then purified by 
phenol:chloroform extraction/ethanol precipitation and stored at -20°C. 
Pseudotyped lentiviral particle production 
Human embryonic kidney (HEK)-293TN cells (Cambridge Bioscience LV900A-1, 
Cambridge UK) were seeded at 40% confluence in 6 well-plates (40,000 cells/cm²) 
with 2 mL cell medium comprising DMEM, 2 mM L-glutamine and 10% (v/v) foetal 
bovine serum (FBS, GIBCO 10270-106, Paisley UK) for 6 h at 37°C in a humidified 
incubator with 5% (v/v) CO2. After changing the cell medium, cells were transiently 
co-transfected using the Sigma CAPHOS Calcium Phosphate Transfection Kit, where 
plasmids of the second-generation packaging system were added at a total of 2 
µg/well, at a ratio of 4:2:1 of TRC transfer vector [4,22] (Sigma-Aldrich Mission 
shRNA SHCLNG, Dorset UK, Table 1): Packaging vector psPAX2 (Addgene plasmid 
12260, Middlesex UK): Envelope vector pM2D.G (Addgene plasmid 12259, 
Middlesex UK). Cells were incubated at 37°C in a humidified incubator with 5% (v/v) 
CO2 for 16 h followed by an additional 48 h after medium change. Cell medium 
containing the secreted pseudotyped lentiviral particles was then cleared of cell 
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debris by low-speed centrifugation (500 xg for 10 min) and filtered using 0.45 μm 
filters. Cell medium aliquots were frozen in crushed dry ice and stored at -80°C. 
Medium from non-transfected HEK-293TN cells was used as a negative control for 
absolute quantification of the pseudotyped lentiviral particles. 
Viral RNA extraction, cDNA synthesis and real-time PCR 
Viral RNA was purified from the cell medium using Qiagen QIAamp viral RNA kit 
(52904, Manchester UK) and the concentration was measured using Nanodrop 
2000 (Thermo Scientific, Hemel Hempstead UK). Viral RNA (500 ng) was treated 
with 1 unit of RQ1 DNase (Promega M198A, Southampton UK) for 30 min and then 
reverse transcription (RT) was performed by adding 100 ng of DNA-free viral RNA 
with 200 units of SuperScript III enzyme (Invitrogen 18080-044, Paisley UK) in the 
presence of 200 ng of random hexamers (Qiagen 79236, Manchester UK) and 
10 mM of dNTPs (Invitrogen 10297, Paisley UK). The reaction was performed in 
three steps: 25°C for 5 min, 50°C for 60 min and 70°C for 15 min. The reaction was 
assumed to be 100% efficient. Viral RNA and cDNA were stored at -80°C. Real-time 
qPCR was performed on a Bio-Rad CFX Connect instrument. Amplification mixtures 
contained 5 μL of viral cDNA or digested plasmid, 10 µL of 2X SYBR Green JumpStart 
Taq ReadyMix (Sigma-Aldrich S4438, Dorset UK), 3 µL of water and 1 µL of each 
primer at 10 µM (designed with NCBI primer-BLAST online tool [34] and synthesised 
by Sigma-Aldrich, Forward=5’-GGGGATTTGGGGTTGCTCTG-3’, Reverse=5’-
TTCTCTGTCCCACTCCATCCA-3’, final concentration of 200 nM per reaction). The 
reaction started with an initial denaturation step for 3 min at 95°C, followed by 40 
cycles of two-step PCR (denaturation at 95°C for 10 s, annealing and elongation at 
60°C for 30 s) and ending with the construction of a dissociation curve (0.5°C 
temperature increase every 5 s, from 65°C to 95°C). A 2.5% agarose gel was run 
with the HypperLadder V (Bioline BIO-33057, London UK) as molecular size marker 
to verify qPCR product sizes. 
Lentiviral particle absolute quantification 
Plasmids were used as standard for absolute quantification. A range of different 
concentrations were run in triplicate, from 0.3 pg/reaction to 5 ng/reaction (12 
points tested). The concentrations yielding the best technical replicates in terms of 
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their similarity of signal and the absence of primer dimers (checked using the 
melting peak data) were used to generate standard curves. Serial dilutions of viral 
cDNA were also run in triplicate, from 0.6 to 7.5 ng/reaction (2X serial dilution, 5 
points tested). No reverse transcription (NRT) and no template controls (NTC) were 
performed to confirm absence of contamination. Raw qPCR data were extracted 
with Bio-Rad CFX Manager 3.1 software. 
To determine qPCR amplification efficiencies (E), standard curves were constructed. 
Cycle threshold (Ct) values of the standard dilutions were plotted against the 
logarithm of the number of plasmid molecules/μL (N) which was calculated as 
follows [35]: 
N (number of plasmid molecules/μL) 
=  
6.022 × 1023 (molecules/mole) × DNA concentration (g/μL)
plasmid length (base pairs)  × 660 daltons
 
Linear regression curves (C𝑡  =  [𝑠𝑙𝑜𝑝𝑒] × [𝑙𝑛(𝑁)] + b) were fitted to establish 
E =  10
−1
slope − 1 [36]. A slope of -3.32 is equivalent to an amplification efficiency E 
of 1 (or 100%). The same standard curves were used to establish the pseudotyped 
lentiviral particle absolute titre as following (each lentiviral particle carries two RNA 
copies implying a theoretical ratio of ½ [37]): 
viral cDNA molecules/μL = 𝑒
(
viral cDNA amplification Ct−b
slope
)
 
and 
number of lentiviral particules/μL of medium 
=  
viral cDNA molecules/μL
viral cDNA concentration (ng/μL)
× initial viral RNA concentration (ng/μL) ×
1
2
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Results and discussion 
The use of shRNA lentiviral approaches to knockdown gene expression typically 
requires the implementation of the RT-qPCR technique to quantify knockdown 
efficiencies. The present titration method does not demand further investments to 
determine absolute titres. In the described protocol, plasmid amplification and 
purification followed by pseudotyped lentiviral production took less than 5 days. 
From there, an additional 3 days were needed to determine absolute titres (Fig. 3). 
Standard optimisation 
In order to get a precise measurement of the absolute titre of pseudotyped 
lentiviral particles, standards had to be as reliable and efficient as possible. Three 
different standard states (different conformations and different purities) were 
tested: circular plasmids, plasmids linearized by EcoR1 digestion and purified 
linearized plasmids. According to our results, only the last state gave the most 
reliable and efficient standard with an amplification efficiency E of 84% (Fig. 4, Fig. 
S2 and Table S1A). For circular plasmids, E was 37%, suggesting that the circular 
shape had a negative effect on the PCR reaction. The PCR reaction was also 
inhibited when the linearized plasmid was non-purified (E = 38%), perhaps due to 
the presence of some compounds such as the buffer used when performing the 
digestion step. 
To ensure reproducibly, we encourage researchers to determine the standard 
stability during storage (over time and temperature), as it has been shown it can 
significantly affect quantification [38]. The workable concentration range is also an 
important parameter. On the one hand, very high template concentration can 
interfere with the qPCR reaction and decrease E; our data demonstrated that 
removing the two highest tested plasmid concentrations of 5 and 1 ng/μL improved 
E by 19% ± 8% (Fig. 5, Table 2, Fig. S1B, Fig. S3 and Table S1B). On the other hand, 
very low template concentrations (usually from 0.3 pg/μL in the present case) can 
more easily generate primer dimers, as seen by the qPCR product melting peaks 
(Fig. 5B) followed by gel electrophoresis (Fig. 5C, Fig. S1B and Table S1B) and, 
therefore, must be excluded from the analysis. 
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Reaction specificity 
BLAST 
The pair of primers used to amplify the 124 base pair sequence (Fig. 1) was tested 
for sequence complementarity against the following human and mouse databases: 
Refseq mRNA, genome, NCBI Chromosome Sequences, Transcript Reference 
Sequences and Nucleotide Collection. It appeared that they were highly specific to 
the HIV-1 integration site, as expected (Table S2E). Other predicted PCR products 
had a too high product length to be amplified by our qPCR reaction conditions 
(Table S2A-E and Table S3A-E). 
DNase treatment 
Because HEK-293TN cells were transiently transfected, transfer vector could 
contaminate the pseudotyped lentiviral particle supernatant. To avoid the 
amplification of contaminating plasmid DNA, viral RNA was DNase treated prior to 
RT. This step could be omitted if a stable producer cell line was used instead [39]. 
DNase treated viral RNA was used as qPCR non-RT (NRT) control to ensure no 
remaining contamination from plasmid DNA (Fig. 6A-C and Fig. S1B). 
Dissociation curve & Gel electrophoresis  
The qPCR product specificity was validated by comparing the qPCR product melting 
peak (Fig. 6B and Table S1C) and gel electrophoresis (Fig. 6C and Fig. S1B) of the 
viral cDNA templates with NRT/NTC controls (Fig. 7and Fig. S1B). 
To verify if the viral RNA was contaminated by RNAs from the producer cells, we 
performed a viral RNA extraction of non-transfected HEK-293TN cells. RNAs were 
detected by Nanodrop 2000 measurement, suggesting that exosomes/vesicles 
containing RNAs were secreted by the HEK-293TN cells [40]. However, none of the 
tested cDNA concentrations gave a specific amplification of our product of interest 
(Fig. 7 and Fig. S1B). 
Pseudotyped lentiviral particle absolute quantification 
As for the plasmids, our data demonstrate that it is very important to determine 
the workable concentration range suitable for viral cDNA amplification. Using low 
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viral cDNA concentrations resulted in the non-specific amplification of primer 
dimers (Fig. 6A-C, Fig. S1B and Table S1C), leading to an overestimation of the 
absolute number of pseudotyped lentiviral particles (Fig. 8A). Using high viral cDNA 
concentration led to PCR reaction inhibition and, therefore, to the underestimation 
of the absolute number of pseudotyped lentiviral particles (Fig. 8B). Because the 
suitable concentration range for titration was limited (usually between 1 and 
7.5 ng/reaction maximum), calculating the cDNA amplification efficiency was not 
relevant. 
For calculation purposes, the viral RNA conversion to viral cDNA was considered 
100% efficient, meaning that one molecule of viral RNA was generating one 
molecule of viral cDNA. However, inhibitors coming from viral RNA isolation can 
affect RT efficiency [41]. Therefore, we recommend performing technical replicates 
of the viral RNA extraction and cDNA conversion. To better estimate the absolute 
titre, more than one cDNA concentration was utilised to calculate the final 
quantification (Fig. 6D and Table S1C). 
From non-functional to functional titre 
Primers were designed in the part of the shRNA plasmid that is integrated into the 
host genome after transduction. Specifically, they are located right after the Rev 
response element sequence (Fig. 1). Consequently, they can be potentially used for 
functional titration of both integrated proviral DNA copies and expressed transgene 
before complete splicing, overcoming the fact that the shRNA plasmids do not 
contain a fluorescent reporter gene [4,22].  
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Conclusions 
A large number of studies have demonstrated that shRNA lentivirus-based 
approaches are able to give efficient and stable knockdown in various types of cells. 
The developed method presented here is a simple way to non-functionally quantify 
the absolute number of produced pseudotyped TRC shRNA lentiviral particles in a 
batch. It can be used prior to transduction for protocol standardisation and 
optimisation, such as finding the best producer cell line or investigating the optimal 
harvesting period. Because qPCR is highly sensitive, extra care must be given to 
both plasmid and cDNA workable concentration ranges, to limit problems of 
inhibition and primer dimer formation. The same primer pair can potentially be 
used for functional titration of both integrated proviral DNA copies and expressed 
transgene level in mouse and human cells. 
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Tables 
 
Gene 
target 
TRC Number Clone ID shRNA sequence 
Control 
(SHC002) 
  
CCGGCAACAAGATGAAGAGCACCAACTCGAG 
TTGGTGCTCTTCATCTTGTTGTTTTT 
CDH8 TRCN0000054223 NM_001796.2-1784s1c1 
CCGGGCCAAGTCATTCAAACTGTTACTCGAG 
TAACAGTTTGAATGACTTGGCTTTTTG 
NRP1 TRCN0000063524 NM_003873.2-369s1c1 
CCGGCGGACCCATACCAGAGAATTACTCGAG 
TAATTCTCTGGTATGGGTCCGTTTTTG 
POU5F1 
(OCT4) 
TRCN0000004879 NM_002701.1-998s1c1 
CCGGTCATTCACTAAGGAAGGAATTCTCGAG 
AATTCCTTCCTTAGTGAATGATTTTT 
PLXNB1 TRCN0000061535 NM_002673.3-6152s1c1 
CCGGCCCGATCAACAAACTTCTGTACTCGAG 
TACAGAAGTTTGTTGATCGGGTTTTTG 
SERPINE1 TRCN0000052272 NM_000602.1-546s1c1 
CCGGCATCATCAATGACTGGGTGAACTCGAG 
TTCACCCAGTCATTGATGATGTTTTTG 
Table 1 | shRNA plasmid references and sequences 
Description of key elements to identify the shRNA plasmids used in this work, such as the official 
gene symbol, the RNA Consortium (TRC) plasmid number, clone ID and detailed shRNA nucleotide 
sequence. Please note that these shRNAs were designed to target human genes. Nucleotides 
coloured in orange represent the beginning and the end of the insert, nucleotides coloured in green 
represent the loop sequence within the shRNA. 
  
 
 shControl shCDH8 shNRP1 shOCT4 shPLXNB1 shSERPINE1 Mean SEM 
A 0.63 0.79 0.75 0.64 0.70 0.75 0.71 0.06 
B 0.76 0.88 0.85 0.71 0.75 0.83 0.80 0.07 
C 0.78 0.99 0.91 0.99 0.82 0.92 0.90 0.09 
Table 2 | Standard efficiencies  
Calculated efficiencies of six different purified and linearized shRNA plasmids: A) with the both 
highest tested concentrations, B) without the highest concentration of 5 ng/reaction and C) without 
the both highest tested concentrations of 5 and 1 ng/reaction. 
 
Table S1 | qPCR amplification and melting temperature data 
Quantitative PCR amplification and melting temperature data of A) circular, linearized and purified 
linearized shOCT4 plasmid, B) purified linearized plasmid and C) viral cDNA of shCDH8, shNRP1, 
shOCT4, shPLXNB1 and shSERPINE1 (excel file). 
Table S2 | Primer Blast against human 
Primer Blast against the following human databases: A) Refseq mRNA, B) genome, C) NCBI 
Chromosome Sequences, D) Transcript Reference Sequences and E) Nucleotide Collection (excel 
file). 
Table S3 | Primer Blast against mouse 
Primer Blast against the following mouse databases: A) Refseq mRNA, B) genome, C) NCBI 
Chromosome Sequences, D) Transcript Reference Sequences and E) Nucleotide Collection (excel 
file).  
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Figures 
 
 
Figure 1 | Partial pLKO.1-puro plasmid sequence  
The 5,810 to 7,086 pLKO.1-puro plasmid sequence is represented and contains the following 
elements: qPCR primers (bold underline green), PCR product (green), EcoR1 site (bold underline 
red), loop and shRNA extremities (bold underline purple), shRNA (purple), rev response element 
(orange) and U6 promoter (blue). The qPCR product was predicted to have a size of 124 base pairs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 | Plasmid digestion 
1% agarose gels of circular and linearized shRNA plasmids: (A) shPLXNB1, (B) shOCT4, (C) shCDH8, 
(D) shNRP1, (E) shSERPINE1 and (F) shControl. 
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Figure 3 | From plasmid amplification to pseudotyped lentiviral particle quantification 
Main steps in the timeline of pseudotyped lentiviral particle production, starting with plasmid 
amplification and ending with pseudotyped lentiviral particle absolute quantification. 
 
 
 
 
 
 
Figure 4 | Effect of standard state on qPCR efficiencies 
Efficiency curves of circular (red), linearized (orange) and purified linearized (blue) shOCT4 plasmid. 
Linear regression curves are given with their correlation coefficient R
2
. The purified linearized 
plasmid gives a slope of -4.01 which is the closest to -3.32, the ideal slope resulting in an 
amplification efficiency of 100%.  
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Figure 5 | Dynamic range of the standard curve 
Examples of (A) amplification curves, (B) melting peaks and (C) agarose gel of qPCR products from 
the shSERPINE1 standard. The tested plasmid concentration range is represented: the highest in 
orange, the intermediate in green and the lowest in red. (D) Efficiency curves of purified linearized 
shSERPINE1 standard with the two highest plasmid concentrations (purple), without the highest 
concentration of 5 ng/reaction (green) or without the both highest tested concentrations of 5 and 1 
ng/reaction (blue). Linear regression curves are given with their correlation coefficient R2. The blue 
curve gives a slope of -3.52 which is the closest to -3.32, the ideal slope resulting in an amplification 
efficiency of 100%. 
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Figure 6 | shRNA pseudotyped lentiviral particle absolute quantification 
Examples of (A) amplification curves, (B) melting peaks and (C) agarose gel of qPCR products from 
the shPLXNB1 viral cDNA. The viral cDNA concentration in green was the highest tested and in 
orange the lowest. The NRT is represented in red. (D) Absolute quantification of shControl, shCDH8, 
shPLXNB1, shNRP1, shSERPINE1 and shOCT4 pseudotyped lentiviral particles in molecules/μL of 
supernatant (mean±SD). 
 
 
Figure 7 | cDNA amplification from non-transfected producer cells 
(A) Amplification curves, (B) melt peaks and (C) agarose gel of qPCR products from amplified cDNA 
of purified secreted RNA of HEK-293TN cells in orange, an example of amplified shOCT4 plasmid in 
green and NTC in red. 
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Figure 8 | Effect of the highest and lowest viral cDNA concentrations on pseudotyped lentiviral 
particle quantification 
Comparisons of shRNA lentiviral particle absolute quantification using intermediate and (A) the 
lowest or (B) the highest viral cDNA concentrations (pseudotyped lentiviral particles/uL of 
supernatant, mean±SD). 
 
 
Figure S1 | Original agarose gel pictures 
(A) Original shRNA plasmid in 1% agarose gels and (B) original qPCR product in 2.5% agarose gels (1: 
gel for figure 7; 2: gel for figure 6; 3: gel for figure 5). Gel pieces in green were not manipulated, and 
in orange the contrast was increased. 
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Figure S2 | Effect of standard state on qPCR efficiencies, a second example 
Efficiency curves of circular (red), linearized (orange) and purified linearized (blue) shControl 
plasmid. Linear regression curves are given with their correlation coefficient R2. The purified 
linearized plasmid gives a slope of -4.18, which is the closest to -3.32, the ideal slope resulting in an 
amplification efficiency of 100%. 
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Figure S3 | Effect of the highest standard concentrations on qPCR efficiencies 
Efficiency curves of purified linearized standards (A) shPLXNB1, (B) shOCT4, (C) shNRP1, (D) shCDH8 
and (E) shControl with the two highest plasmid concentrations (purple), without the highest 
concentration of 5 ng/reaction (green) without both highest tested concentrations of 5 and 
1 ng/reaction (blue). Linear regression curves are given with their correlation coefficient R2. The blue 
curves give a slope closer to -3.32, the ideal slope resulting in an amplification efficiency of 100%, 
compared to the purple and green ones. 
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3.3. Discussion 
3.3.1. The stable knockdown choice 
Knockdown versus knockout – Generating knockout cell lines is much more time 
consuming (three months, at least [277]) than generating knockdown cell lines (less 
than two weeks in our laboratory). Moreover, phenotypes arising from knockout 
can be altered by adaptation and/or compensation processes [278, 279]. Even if 
such problems can potentially occur with stable knockdown, the shorter time 
required to generate a knockdown cell line reduces the potential for adaptation and 
compensation and makes this approach much more attractive than knockout. 
Stable versus transient knockdown – The transient knockdown usually lasts for a 
few days in dividing cells or a few weeks in non-dividing cells [267]. The transient 
knockdown in ESCs, which is short [263, 267] because these cells have a high 
proliferation rate [280], might not be sufficient to trigger hESC differentiation. 
Consequently, a stable knockdown appears to be a better RNAi approach to study 
the role of specific proteins in the maintenance of hESC stemness. 
3.3.2. ‘Off-target’ and silencing issues 
The ‘off-target’ issue – The specific (‘on-target’) effect of siRNA or shRNA goes 
often with ‘off-target’ effects through three ways (reviewed here [281]):  
i) miRNA-like ‘off-target’ effects;  
ii) immune system stimulation; 
iii) saturation of the RNAi machinery.  
Briefly, miRNA-like ‘off-target’ effects are due to the complementarity of the 3’ 
UTRs of ‘off-target’ transcripts with the 5’ region of the sense or antisense siRNA, 
leading to silencing transcripts with limited sequence homology [282]. RNAi can 
also trigger immune system activation [283], which is dependent on the cell type 
and the RNAi sequence length [284, 285]. Finally, the RNAi machinery can be 
saturated and generate concentration dependent ‘off-target’ effects, from 
endogenous miRNA pathway inhibition [286] to animal death [287]. 
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Novel siRNA designs have been developed to decrease miRNA-like ‘off-target’ 
effects [288]. However, the best option is to use multiple siRNA sequences to target 
the mRNA of interest: as each siRNA sequence has a unique off-target pool, 
observing the same phenotype while utilising different siRNAs increases confidence 
that this phenotype is specifically induced by the target mRNA silencing. If a stable 
knockdown is implemented, it is also important to work out the shRNA lentivirus 
concentration to transduce target cells in order to get the ‘on-target’ silencing 
effect while avoiding the saturation of the RNAi machinery. Finally, the immune 
system response can be avoided or at least decreased by the use of RNAi sequences 
shorter than 20 base pairs [284, 289, 290]. 
The site of viral integration can also generate aberrant splicing events [291]. 
Silencing of the RNAi – Loss of long-term silencing while using lentiviral shRNA has 
been reported [284]. Unfortunately, the reasons underlying this loss have not been 
documented yet in the context of RNAi. However, silencing of retroviral vectors is a 
well-known feature of iPSCs, which depends on several factors such as the position 
of insertion into the host genome or histone modifications (reviewed here [292]). 
These facts emphasise the need to verify knockdown efficacy over time. 
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Human ESCs, transiently present in vivo during embryogenesis, can be derived in 
vitro [8] and be either maintained undifferentiated [293] or committed into a 
lineage under specific culture conditions [294].  
4.1. Bottom-up knowledge 
A large number of low/medium-throughput studies have been performed to 
characterise mRNAs and microRNAs (by Northern blotting [295, 296] or PCR [173, 
296]), proteins (by Western blotting [296], flow cytometry [297], 
immunocytochemistry [173], etc.), protein-protein interactions (by co-
immunoprecipitation [296]) and protein/DNA interactions (by chromatin 
immunoprecipitation [191]) involved in the maintenance of stemness.  
4.1.1. The wet side: culture conditions, molecules & pathways 
4.1.1.1. Self-renewal 
To maintain their self-renewal, hESCs were originally cultured on feeder cell layers 
of mouse embryonic fibroblasts (MEFs) in the presence of serum [8]. Although 
these conditions tend to be reliable and robust [298], many issues emerge with 
these culture conditions. Firstly, MEFs and serum have batch-to-batch variability, 
meaning that the reproducibility is impaired. Secondly, they contain animal 
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components, which are unsuitable for human therapeutic use due to risks of 
contamination with animal pathogens. Lastly, they are undefined, and, therefore, 
the study of extracellular matrix (ECM) molecules and growth factors in stemness is 
difficult. Consequently, serum- and feeder-free culture conditions have been 
developed [299-302] that allow the investigation of the roles of growth factors (e.g. 
fibroblast growth factor 2 (FGF2) [303] and activin A [304]), and extracellular matrix 
molecules (e.g. heparan sulfate [305]) in self-renewal and differentiation. These 
more defined culture conditions have to be carefully tested, as it has been noted 
they can increase the degree of spontaneous differentiation [306], induce karyotype 
abnormalities [301] or can be effective only with particular cell lines [293]. It has 
also been suggested that under particular conditions, some stem cells differentiate 
to generate feeder-like cells that produce factors responsible for promoting self-
renewal of the remaining ESC population [307]. Human ESCs can be sustainably 
cultured in a chemically defined medium containing activin A, FGF2 and 
neurotrophin 4 (NT4) [293], whereas mESCs depend on leukemia inhibitory factor 
(LIF) [308] and on bone morphogenetic protein 4 (BMP4) [309]. Mouse epiSCs 
require similar culture conditions to hESCs, but can also proliferate without FGF2 
[27]. 
Intrinsic factors: the core transcriptional network 
The core transcriptional network, common to human and mouse ESCs, consists of 
three transcription factors, OCT4, SOX2 and NANOG. Octamer-binding transcription 
factor 4 (OCT4), encoded by the gene Pou5f1 (for Pit-1, octamer, unc-86 class 5 
homeobox 1), is a POU family transcription factor, which is indispensable for ESC 
self-renewal [127, 135]; OCT4 knockdown induces differentiation in hESCs [135, 
262]. SOX2 is a sex determining region Y (SRY)-related transcription factor and a 
transcriptional partner of OCT4 [310]. Over-expression or repression of SOX2 in 
hESCs results in their differentiation into trophectoderm lineages [130, 265, 311, 
312]. NANOG is a NK2-family homeobox transcription factor indispensable for 
repressing hESC differentiation [135, 264]. The interactions between OCT4, SOX2 
and NANOG, and their genes are essential for the maintenance of hESC features. 
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They have many targets in common, a substantial number of which are 
transcription factors that are involved subsequently in embryo development [191].  
Other factors also appear to play a role in maintaining hESC pluripotency, including 
transposable elements [190], epigenetic regulators [313-316] and microRNAs [295, 
317-320]. 
Extrinsic factors: molecules and pathways  
The transforming growth factor (TGF)-β superfamily of ligands plays a major role in 
hESC stemness. They can signal through two major pathways: the SMA and mothers 
against decapentaplegic related protein (SMAD) 1-5, which transduce via activin 
receptor-like kinase (ALK)1, ALK2, ALK3 and ALK6 on behalf of BMP and growth 
differentiation factor (GDF); and the TGF-β/activin/nodal pathway with SMAD2/3 
activation via ALK4, ALK5 and ALK7. This second pathway is mainly associated with 
hESC stemness [321-324]. Moreover, activin A suppresses the BMP signal and 
induces the expression of proteins involved in pluripotency, such as OCT4, NANOG 
and FGF2 [304]. BMP signalling is also repressed by FGF2 [325, 326].  
Other pathways may be important for hESC stemness maintenance, such as those 
of mitogen-activated protein kinases (MAPK)/extracellular signal-regulated kinases 
(ERK), phosphoinositide 3-kinase (PI3K)/Akt, nuclear factor of kappa light 
polypeptide gene enhancer in beta-cells (NFκβ) [178, 327] and wingless-type MMTV 
integration site (WNT) family [304, 322, 328-332]. 
4.1.1.2. Differentiation 
Human ESCs cultured in suspension spontaneously form embryoid bodies (EBs, 
Figure 15) [333, 334]. EBs are spheroid three-dimensional (3D) multicellular 
aggregates that recapitulate several aspects of early embryogenesis and have been 
used as a first step in ESC differentiation protocols [335, 336] (Table 5). 
Differentiation can also be induced in two-dimensional (2D) cultures (Table 5). 
However, irrespective of whether hESCs are differentiated in 2D or 3D, these 
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processes usually generate a heterogeneous differentiated population, requiring 
subsequent purification steps to isolate the desired cell type [336, 337].  
 
Figure 15 | hESCs and EBs in culture 
(A) 2D culture of hESCs and (B) EBs in cell culture dishes. 
 
Lineage Achieved differentiation Differentiation type References 
M
es
o
d
er
m
 
Hematopoietic cells EBs [335, 338, 339] 
Mast cells EBs [340] 
Dendritic cells 
EBs [341] 
2D [342] 
Macrophages EBs [336] 
Mesenchymal precursors 2D [343] 
Vascular progenitors 
EBs [344] 
2D [345] 
Endothelial cells 
EBs [344] 
2D [345] 
Smooth muscle cells 
EBs [344, 346] 
2D [345-347] 
Cardiomyocytes EBs [348, 349] 
Osteogenic cells 
EBs/2D [350] 
EBs [351] 
Ec
to
d
e
rm
 
Neural precursors EBs [352] 
Astrocytes EBs [352] 
Dopamine neurons 2D [353, 354] 
Oligodendrocytes EBs [352] 
Glial cells EBs [352] 
Keratinocytes EBs [355] 
En
d
o
-
d
e
rm
 Endodermal cells 2D [356] 
Pancreatic cells 2D [357] 
Hepatocytes 2D [337, 358] 
Germ cells EBs [359] 
Table 5 | hESC differentiation 
Non-exhaustive list of protocols (either through EB formation or not) to differentiate hESCs into cells 
from the three germ layers and into germ cells (EB: embryoid body). 
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4.1.1.3. Reprogramming 
The four transcription factors OCT4, SOX2, Krüppel Like Factor 4 (KLF4) and c-MYC 
were used in the first reprogramming protocol of both mouse and human somatic 
cells to induced pluripotent stem cells (iPSCs) [34, 35]. Generation of hiPSCs can 
now also be achieved without c-MYC [360], without SOX2 [361], by using NANOG 
and LIN28 instead of KLF4 and c-MYC [92] or by using only OCT4 and SOX2 with 
valproic acid [362]. 
4.1.2. The dry side: mathematical modelling 
Mathematical models, as part of the systems biology field, have been developed to 
describe cells as dynamic systems through two main ways: the deterministic 
approach with ordinary differential equations (ODE) or partial differential equations 
(PDE), and the stochastic (or probabilistic) approach with master equations. The 
difference is that the deterministic approach does not include the ‘noise’ 
engendered by slow chemical reactions and/or by small numbers of molecules, and 
neglects random fluctuations. However, both synthesise molecular knowledge 
through the mathematical formalism and require detailed data about signalling 
pathways, molecular interactions and constants of dissociation. 
Other models such as the principal components analysis (PCA) and partial least 
square (PLS) regressions have been applied. They do not require a priori knowledge, 
but use large-scale data and allow the reduction of the number of data space 
dimensions by grouping together the quantities which covary to yield a dataset of 
components.  
All these approaches are explained in more detail in a review [106] and Table 6 
presents some mathematical models used to study hESCs. 
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Cell type(s) Modelling type Focus References 
mESC/hESC Deterministic 
Role of the SOX2/OCT4/NANOG 
regulation in ESC fate 
[124] 
hESC Deterministic Role of PI3K/Akt pathway in stemness [363] 
Differentiated hESC Deterministic Integrating hESC-cardiomyocyte data [364] 
hESC Stochastic 
Role of NANOG partitioning in hESC 
heterogeneity 
[365] 
hESC Stochastic Understanding endoderm specification [366] 
Differentiating hESC Regression (PLS) 
Understanding the impact of used 
endoderm differentiation pathway on 
pancreatic maturation 
[367] 
mESC/hESC/miPSC/hiPSC Regression (PCA) Studying microRNA profile [368] 
Table 6 | Modelling in hESCs 
Non-exhaustive list of mathematical approaches used to study hESCs (PCA: Principal Components 
Analysis; PLS: Partial Least Square). 
4.1.3. A bottom-up strategy 
4.1.3.1. Method of study 
Five of the previously identified putative stemness proteins were selected, and their 
role in hESC self-renewal and differentiation to specific lineages (i.e. 
trophectoderm, endoderm, mesoderm and ectoderm) was investigated by stably 
knocking down their expression levels using a short hairpin (sh)RNA/lentiviral 
approach. The selected candidates were cadherin 8 (CDH8), cerberus 1 (CER1), 
neuropilin 1 (NRP1), plexin B1 (PLXNB1) and serpin peptidase inhibitor clade E1 
(SERPINE1).  
Pseudotyped lentiviral particles containing shRNA were produced against each 
target mRNA. In addition, a shRNA control, targeting no mRNA, served as a negative 
control, and shRNAs against OCT4 served as positive controls. The targeted mRNA 
knockdowns and their effects on hESCs were assessed by relative quantification of 
the expression of the candidates, as well as on markers of pluripotency, 
trophectoderm, endoderm, mesoderm and ectoderm, at the mRNA level by RT-
qPCR and at the protein level by immunofluorescence and/or Western blotting. 
4.1.3.2. The candidates 
Within the 92 candidate proteins identified as potentially being involved in the 
maintenance of hESC stemness by the in silico study (section 2), proteins already 
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known to have a role in human or mouse ESCs were removed together with 
proteins which have a central role in the cell machinery such as cell cycle proteins. 
Among the remaining proteins, the candidates were chosen to reflect different 
parts of the hESC transcriptome/interactome: some were commonly expressed by 
hESCs and early differentiated cells while others were specific to hESCs; some were 
binding heparan sulfate proteins while others not; some were hubs while others 
were bottlenecks; and some linked the common and specific subsets of transcripts 
while others were linking the extracellular with the transcriptional part (Table 7). 
Official 
Gene 
Symbol 
Name Transcriptome GO term S/C EC/TF Hub Bottleneck 
CDH8 cadherin 8, type 2 SPECIFIC CA/HS X X     
CER1 
cerberus 1, cysteine knot 
superfamily, homolog 
(Xenopus laevis) 
SPECIFIC 
CCo/EC 
non-HS 
X X     
NRP1 neuropilin 1 COMMON CCo/HS       4022.8 
PLXNB1 plexin B1 SPECIFIC 
CS/CCo/EC 
non-HS 
X       
SERPINE1 
serpin peptidase inhibitor, 
clade E (nexin, plasminogen 
activator inhibitor type 1), 
member 1 
COMMON CCo/HS   X 24 10022.8 
Table 7 | The candidates selected from the in silico study 
‘Transcriptome’ column: specific mRNA expressed only by hESCs, or common mRNA expressed by 
both hESCs and early differentiated cells. ‘GO term’ column: GO terms found during the GO 
extraction (CA: cell adhesion; CCo: cell communication; CS: cytoskeleton organisation; EC: 
extracellular part; HS: heparan sulfate binding proteins; TF: transcription factor related part). ‘Hubs’ 
column: node degree in the hESC interactome. ‘Bottlenecks’ column: node betweenness in the hESC 
interactome. The ‘S/C’ column indicates if the protein is in the specific/common interface and the 
‘TF/EC’ column indicates if the protein is in the EC/TF interface. 
Cadherin 8 - Cadherin 1 (CDH1), also known as epithelial cadherin (E-cadherin), is a 
well characterised type I classical cadherin [369] involved in cell-cell adhesion and 
plays a role in cancer suppression [370]. It has been demonstrated that CDH1, 
combined with laminin, can sustain hESC growth [371]. This cadherin is found in the 
hESC transcriptome, but is not part of the specific sub-set of mRNAs only expressed 
in hESCs (section 2.2). 
The only classical cadherin found in the specific sub-set of mRNAs is cadherin 8 
(CDH8, section 2.2). This protein is part of the common/specific and 
extracellular/transcriptional interfaces, and binds heparan sulfate (Table 7). CDH8 is 
a type II classical cadherin involved in calcium-dependent cell-cell adhesion [369]. 
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This transmembrane protein is expressed in the brain, where it participates in 
synaptic adhesion [372], and axon guidance and outgrowth [373]. It is also 
expressed in foetal kidney and renal cell carcinoma [374]. 
Cerberus 1 (CER1), also known as DAND4, is a cytokine member of the cysteine knot 
superfamily. This secreted protein is a BMP antagonist involved in head formation in 
vertebrates [375]. BMP signalling is known to be repressed by activin A [304] and 
FGF2 [326] in hESCs, helping to maintain self-renewal. Other BMP antagonists have 
been found in the hESC transcriptome (such as gremlin 1 and follistatin), but CER1 is 
the only one belonging to the sub-set of mRNAs only expressed by hESCs and is part 
of both the common/specific and the extracellular/transcriptional interfaces (Table 
7, section 2.2).  
Moreover, CER1 is also an antagonist of nodal and WNT signals [376, 377], both 
these signals being known to be involved in the maintenance of hESC self-renewal 
[322, 324, 332]. CER1 can be used as a marker for definitive endoderm 
differentiation [378]. CER1 expression is also promoted during neuro-ectodermal 
differentiation [379]. However, CER1 overexpression in hESCs did not induce their 
differentiation [380]. 
Taken together, these results suggest a crucial role of CER1 in promoting hESC self-
renewal and/or differentiation towards endodermal or ectodermal lineages. 
However, the direct involvement of CER1 in hESC maintenance has yet to be shown. 
Neuropilin 1 (NRP1), also known as CD304, binds heparan sulfate and was found in 
the common sub-set of mRNAs expressed by hESCs and early hESC-derived cells 
together with neuropilin 2 (section 2.2). However, unlike NRP2, NRP1 is also a 
bottleneck protein (Table 7). It is a co-receptor/agonist for vascular endothelial 
growth factor (VEGF) [381, 382] and a receptor for semaphorin III [383] involved in 
cell guidance in vascular [384] and neural [385] systems during embryogenesis. Both 
these systems emerge from the same pool of hESCs expressing NRP1 [386]. The role 
of NRP1 in the vascular system is also extended to the tumour environment where 
this transmembrane protein is commonly overexpressed [387, 388]. It has been 
demonstrated that VEGF signalling induces endothelial differentiation [389] and is 
involved in hematopoietic differentiation of hESCs [390].  
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NRP1 may have a complex role, because it has been found to be a pure agonist of 
VEGF receptor-2 [382] and it also interacts and regulates the activity of FGF2 [391], 
a key hESC growth factor, as well as a range of other heparin-binding growth factors 
[391]. Consequently, NRP1 may play a role in the maintenance of stemness. 
Plexin B1 (PLXNB1) is part of the plexin family, which are transmembrane receptors 
of semaphorins. More precisely, PLXNB1 is the receptor for semaphorin 4D 
(SEMA4D) [392]. Like NRP1, studies demonstrated the role of PLXNB1 in cell 
guidance [393] in the neural system [394, 395], and in the vascular system [396, 
397].  
Two different groups showed the expression patterns of plexin family members 
during mouse embryogenesis, either specifically in the nervous systems [395] or in 
the whole embryo [398]. They both concluded in non-redundant and distinct 
patterns. However, another research group generated a mutant mouse with a loss 
of PLXNB1 expression that was viable and fertile, suggesting redundant roles in the 
plexin family [399]. 
Plexin B1, C1 and D1 were present in the hESC transcriptome, but only PLXNB1 was 
part of the specific sub-set only expressed by hESCs and was also part of the 
common/specific interface (Table 7). However, none of the semaphorin family 
members were found in this transcriptome (section 2.2). PLXNB1 has already been 
found expressed in tissues lacking SEMA4D, suggesting that this plexin could also 
have a SEMA4D-independent role [399]. Moreover, PLXNB1 is able to stimulate 
PI3K-Akt pathway [397], which is known to promote hESC self-renewal [178]. 
Serpin peptidase inhibitor clade E member 1 (SERPINE1), also known as 
plasminogen activator inhibitor-1 (PAI-1), is part of the serine protease inhibitor 
(serpin) superfamily and is a heparan sulfate binding protein [400]. This 
extracellular protein is an inhibitor of tissue- and urokinase-type plasminogen 
activators (tPA or PLAT, and uPA or PLAUR respectively), and hence it is an inhibitor 
of fibrinolysis [401]. It also plays a role in cell adhesion [402, 403], cell migration 
[404, 405] and angiogenesis [406, 407], and serves as prognostic marker in breast 
cancer [408, 409].  
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Several serpin members have been found to be commonly expressed by hESC and 
their early differentiated cells (SERPIN-B1, B4, B9, E1, E2 and F1), as well as PLAT, 
PLAU and its receptor PLAUR (section 2.2). However, SERPINE1 was the only one 
with hub and bottleneck properties. It was also at the extracellular/transcriptional 
interface (Table 7). Studies showed that SERPINE1 is expressed by human MSCs 
[410] and by hESCs [411]. Even if SERPINE1 knockout mice were viable and did not 
show any obvious phenotypes [412], as well as the close related SERPINE2 knockout 
[413], or SERPINE1 and SERPINE2 double knockout [413], this protein might still play 
a role is hESC stemness. Indeed, it has been shown that SERPINE1 is part of the TGF-
β pathway [414, 415], which is known to inhibit hESC differentiation [321-324]. 
Moreover, SERPINE1 binds to vitronectin [416], an extracellular matrix molecule 
involved in hESC in vitro self-renewal [302, 417].  
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Abstract 
Background. Human embryonic stem cells (hESCs) are pluripotent cells able to self-
renew or differentiate into a wide range of cell types. However, although the key 
intrinsic factors required for maintaining hESC stemness are well-defined, much less 
is known about the extrinsic mechanisms.  
Methods and results. We have recently undertaken a network-based meta-analysis 
approach to identify hESC putative stemness proteins (Mournetas V. et al, PeerJ 
2014). In this study, we have tested the role of four of these putative factors, CER1, 
NRP1, PLXNB1 and SERPINE1, together with the key stemness regulator OCT4, using 
a stable shRNA lentiviral-mediated knockdown approach. Systematic gene 
expression measurement of these four factors by RT-qPCR showed that they were 
modulating each other’s expression. Our results suggest that losing the expression 
of any one these factors has a limited effect on self-renewal, as shown by little or no 
effect on the expression levels of pluripotency markers. However, their expression 
is regulated by OCT4 and they appear to have a role in triggering the differentiation 
of hESCs to specific lineages.   
Conclusion. The microenvironment in the stem cell niche plays a crucial role in 
determining hESC fate. The four membrane/extracellular proteins studied here 
have clear links to the transcriptional network of hESCs that determine self-renewal 
and differentiation. Moreover, their effects on transcription can be extended to the 
level of their respective mRNAs, indicating that, at least these four extrinsic factors 
dynamically regulate hESC stemness.  
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Introduction 
Human embryonic stem cells (hESCs) are pluripotent cells derived from the inner 
cell mass of the blastocyst [1] that have the potential to self-renew or differentiate 
into the three embryonic germ layers (ectoderm, endoderm and mesoderm) [2]. 
These cells represent a powerful tool for understanding human embryonic 
development [2] and have enormous potential to treat various human diseases [2-
4]. However, the mechanisms that regulate hESC self-renewal are still not fully 
understood, which is hindering the development of the necessary scale-up 
procedures that would be required to produce sufficient numbers of hESCs for 
clinical use. This problem is highlighted by a recent report showing that only ~3% of 
karyotypically normal hESCs are able to generate colonies following sub-culture [5]. 
To address this problem, it is necessary to discern the molecular determinants 
required for both hESC self-renewal and differentiation to specific lineages. 
Octamer-binding protein 4 (OCT4) [6], sex determining region Y-box 2 (SOX2) [7] 
and NANOG [8, 9] constitute the core transcriptional network responsible for the 
regulation of pluripotency [10-14]. Even if these three transcription factors are 
clearly the gatekeepers of pluripotency [15, 16], different type of cells express them 
independently [17-21]. Thus, hESC stemness must depend on other factors. The 
development of xeno-free culture conditions that require the addition of 
extracellular molecules, such as heparan sulfate [22], fibroblast growth factor (FGF)-
2 [23, 24] and activin A [25], demonstrates the importance of the cell 
microenvironment in maintaining pluripotency [26, 27].  
Our previous in silico study identified the following novel putative stemness 
proteins that potentially have a role in the maintenance of hESC self-renewal: 
cerberus 1 (CER1), neuropilin 1 (NRP1), plexin B1 (PLXNB1) and serpin peptidase 
inhibitor clade E member 1 (SERPINE1).  
CER1 (also known as DAND4) encodes a cytokine that is a BMP/Nodal/WNT 
antagonist involved in head formation in vertebrates [28-30]. It is known that BMP 
signalling plays a complex role in hESC fate (review [31]). For instance, to maintain 
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hESC self-renewal, activin A and FGF2 repress BMP signalling [25,32], whereas 
BMP4 induces differentiation to trophoblast [33] and to mesoderm [34]. Moreover, 
Nodal and WNT are also known to play a role in the maintenance of hESC stemness 
[35-37]. Therefore, CER1 which is involved in the regulation of these three signalling 
pathways might also be involved in regulating hESC fate. 
NRP1 (also known as CD304) is a co-receptor/pure agonist for vascular endothelial 
growth factor (VEGF) [38, 39] and a receptor for semaphorin III [40], while PLXNB1 
is a semaphorin 4D receptor [41]. NRP1 and PLXNB1 are both involved in cell 
guidance in the neural [42-44] and vascular [45-48] systems during embryogenesis, 
and NRP1 plays a role in the differentiation of endothelial and neuronal cells from 
hESCs [49]. Neither NRP1 nor PLXNB1 have previously been shown to play a role in 
maintaining hESC stemness, but NRP1 is known to regulate the activity of the key 
hESC growth factor FGF2 [50], and PLXNB1 is able to stimulate the PI3K-Akt 
pathway [48], which is known to promote hESC self-renewal [51]. 
SERPINE1 (also known as plasminogen activator inhibitor-1, PAI-1) is an extracellular 
protein that inhibits fibrinolysis [52]. It is involved in cell adhesion [53, 54], cell 
migration [55, 56] and angiogenesis [57, 58], and serves as a prognostic marker in 
breast cancer [59, 60]. It has been shown that SERPINE1 is part of the TGF-β 
pathway [61, 62], which inhibits hESC differentiation [35, 37, 63, 64]. SERPINE1 also 
binds to vitronectin [65], an extracellular matrix molecule that supports hESC self-
renewal [66, 67]. 
The aim of this study was to investigate the role of these candidate stemness 
factors in hESC self-renewal, previously identified through an in silico study, by 
stably knocking down their expression using shRNA lentiviral particles. How this 
affected the expression levels of pluripotency genes, the other candidate stemness 
factors and various lineage markers revealed that these candidates have a limited 
effect on markers of hESC self-renewal, whereas they are clearly involved in 
regulating hESC differentiation to specific lineages.  
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Materials and methods 
Human ESC culture 
The HuES7 line (Harvard University, hES Cell Facility/Melton Laboratory, MA, USA) 
was cultured in a serum-free and feeder cell-free preparation developed in our 
laboratory [68] composed of DMEM:F12 (Lonza BE12-719F, Cambridge UK) 
supplemented with 2mM L-glutamine (Sigma-Aldrich G7513, Dorset UK), 0.1% (w/v) 
bovine serum albumin (Sigma-Aldrich A1470-25G, Dorset UK), 1X non-essential 
amino acids (Invitrogen 11140-035, Paisley UK), 0.1 mM β-mercaptoethanol 
(Invitrogen 31350-010, Paisley UK), 1X N-2 (Invitrogen 17502-048, Paisley UK) and 
1X B-27 serum-free supplements (Invitrogen 17504-044, Paisley UK), 40 ng/mL FGF2 
(prepared in house, [69]), 10 ng/mL activin A (R&D Systems 338-AC-050, Abingdon 
UK) and 4 ng/mL NT4 (Peprotech 450-04, London UK). Culture dishes were coated 
with 100 μL/cm2 fibronectin (EMD Millipore FC010-10MG, Watford UK) at 25 μg/mL 
for 1 h at 37°C. Cells were incubated at 37°C in a humidified incubator with 5% (v/v) 
CO2. Culture medium was changed every two days. Cells were passaged every three 
to five days by trypsinisation (50 μL of 0.5X trypsin/cm2, Sigma-Aldrich T4174, 
Dorset UK). 
shRNA knockdown  
Short-hairpin RNA (shRNA) lentiviral particles were produced by human embryonic 
kidney (HEK)-293TN cells (Cambridge Bioscience LV900A-1, Cambridge UK) after co-
transfection of the transfer vector [70, 71] (Sigma-Aldrich Mission shRNA SHCLNG, 
Dorset UK, Table1 and Table S1 for BLAST analysis) with the packaging vector 
psPAX2 (Addgene plasmid 12260, Middlesex UK) and envelope vector pM2D.G 
(Addgene plasmid 12259, Middlesex UK). A detailed protocol can be found section 
3.2. At day 0, hESCs were seeded at 2,600 cells/cm² and incubated at 37°C in a 
humidified incubator with 5% (v/v) CO2 for 6 h. Lentiviral particles were added to 
the cell medium at a concentration of 36 pg viral RNA/cell. At day 1, cell medium 
was changed and cells were incubated for two more days. At day 3, cells were 
passaged and puromycin (Gibco A11138-03, Paisley UK) was added to the medium 
at a concentration of 0.5 μg/mL for selection. At day 5, cells were either fixed for 
Chapter 4 – In vitro study: extracellular protein knockdowns and hESC fate 
107 
 
immunofluorescence, or lysed for protein or RNA extraction. Table 1 recapitulates 
the number of biological replicates per shRNAs and per target mRNA. 
Gene expression analysis 
Viral RNA extraction, cDNA synthesis and real-time qPCR – Cell lyses were 
performed by using TriZOL reagent (Life Technologies 15596026, Paisley UK). RNA 
was then purified by chloroform extraction (1:5 of TriZOL volume, 10 min incubation 
at room temperature, 15 min centrifugation at 12,000 g and 4°C) and isopropanol 
precipitation (1:2 of TriZOL volume added to the aqueous phase, 10 min incubation 
at room temperature, 15 min centrifugation at 12,000 g and 4°C). Pellets were 
washed with 75% ethanol (1:1 of TriZOL volume, 15 min centrifugation at 12,000 g 
and 4°C) and dissolved in 25 to 100 µL of distilled nuclease-free water before 
storage at -80°C. RNA concentration and purity were measured using Nanodrop 
2000 (Thermo Scientific, Hemel Hempstead UK, Table S2). RNA (1 µg) was treated 
with 1 unit of RQ1 DNase (Promega M198A, Southampton UK) for 30 min (the 
reaction was stopped by adding 1 µL of RQ stop buffer (Promega M199A, 
Southampton UK) followed by an incubation for 15 min at 60°C) before performing 
the reverse transcription by adding 200 ng of DNase-treated RNA with 200 units of 
SuperScript III enzyme (Invitrogen 18080-044, Paisley UK) in the presence of 200 ng 
of random hexamers (Qiagen 79236, Manchester UK) and 10 mM of dNTPs 
(Invitrogen 10297, Paisley UK). The cDNA was synthesised in three steps (25°C for 
5 min, 50°C for 60 min and 70°C for 15 min) and stored at -80°C.  
PCR primers were designed with NCBI primer-BLAST online tool [72] to amplify all 
variant transcripts of each target gene (Table 2) with the following parameters: PCR 
product size between 60 and 150 base pairs, melting temperature (Tm) at 60.0°C ± 
1.0°C with a maximum Tm difference of 1.0°C, and primers spanning an exon-exon 
junction or being separated by at least one intron whether possible. Primers were 
synthesised by Sigma-Aldrich (Dorset UK). 
Real-time qPCR was performed on a Bio-Rad CFX Connect Real-time system. 
Amplification mixtures contained 5 μL of 1/10 diluted cDNA, 10 µL of 2X SYBR Green 
JumpStart Taq ReadyMix (Sigma-Aldrich S4438, Dorset UK), 3 µL of water and 1 µL 
of each primer at 10 µM (final concentration of 200 nM per reaction). The initial 
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denaturation step was performed for 3 min at 95°C, followed by 50 cycles of two-
step PCR (denaturation at 95°C for 10 s, annealing and elongation at 60°C for 30 s). 
Following completion of the qPCR reaction, melting point analysis was undertaken 
(0.5°C temperature increase every 5 s, from 65°C to 95°C).  
For relative quantification, each sample was run in triplicate. If the Cycle threshold 
(Ct) standard error of the mean (SEM) was > 0.25, the outlier Ct was removed from 
the analysis, or the sample was rerun. ‘No reverse transcription’ and ‘no template’ 
controls were performed to confirm absence of contamination. Each qPCR plate 
contained a calibrator (two wells with the same cDNA in each plate) to mitigate 
plate-to-plate variability in the analysis. Raw qPCR data were extracted and 
analysed with Bio-Rad CFX Manager 3.1 software. The cDNA relative quantification 
was calculated against the expression of three housekeeping genes HPRT1, MAPK1 
and UBC (Table 2) and compared to the expression in untransduced control hESCs 
using the ∆∆Ct method [73]. Housekeeping gene stability was determined by the 
software and validated if the coefficient of variance < 0.5 and the M-value (GeNorm 
stability) < 1 [74]. Statistical analysis was performed using IBM SPSS Statistics 21 
software. Data for each individual shRNA and for each individual experiment are in 
Fig. S1.  To mitigate ‘off-target’ effects of each shRNA sequence [75], the data from 
different shRNAs against the same target were pooled together for statistical 
analysis. The EOMES data are represented twice, since it is both a trophectoderm 
and mesoderm marker. 
Protein analysis 
Immunofluorescence – Cells were cultured in glass bottom cell culture dishes 
(Greiner Bio-one 627861, Stonehouse UK) coated with 100 μL fibronectin at 25 
μg/mL (EMD Millipore FC010-10MG, Watford UK) for 4 h at room temperature.  Cell 
fixation was performed with 4% (w/v) paraformaldehyde (Thermo Scientific 28908, 
Hemel Hempstead UK) in PBS for 10 min at 4°C. Cells were then washed three times 
with PBS (Sigma-Aldrich D8537, Dorset UK) before incubation with 5% goat/5% (v/v) 
chick sera in PBS, and 0.1% (v/v) Triton-X100 (BDH 30632, Lutterworth UK) for 1 h at 
room temperature. After PBS washes, cells were incubated with primary antibodies 
(1:500 mouse monoclonal OCT4, Santa Cruz Biotechnology sc-5279 and 1:500 rabbit 
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polyclonal GATA6, Santa Cruz Biotechnology sc-9055, Heidelberg Germany; 1:650 
rabbit polyclonal NANOG, Abcam ab21624 and 1:500 rabbit polyclonal CER1, Abcam 
ab103122, Cambridge UK) overnight at 4°C in a humidified chamber. Cells were 
then washed and incubated with secondary antibody solution (1:1,000 dilution; 
Alexa Fluor 594 goat anti mouse, Invitrogen A21145; Alexa Fluor 488 chicken anti 
rabbit, Invitrogen A21441, Paisley UK) at room temperature for 2 h in a humidified 
chamber protected from light to prevent photobleaching. Primary and secondary 
antibodies were diluted in 0.5% goat/0.5% (v/v) chick and 0.1% (v/v) Triton-X100 
(BDH 30632, Lutterworth UK). After PBS washes, nuclei were staining with 4',6-
diamidino-2-phenylindole (DAPI) solution (Invitrogen D1306, Paisley UK) at 1:50,000 
in PBS for 10 min at room temperature in a chamber protected from light. A last PBS 
wash was done before application of the fluorescence mounting medium (Dako 
S3023, Ely UK).  
Western blotting – Cells were washed with 2 mL PBS before adding 7 μL/cm2 of lysis 
buffer. The lysis buffer composition was: 50 mM Tris-HCl pH 7.5 (Sigma-Aldrich 
T2319, Dorset UK), 1mM ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich 
E9884, Dorset UK), 1 mM ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-
tetraacetic acid (EGTA, Sigma-Aldrich 34596 FLUKA, Dorset UK), 1 mM sodium 
orthovanadate (Sigma-Aldrich 450243, Dorset UK), 1% (v/v) Triton-X100 (BDH 
30632, Lutterworth UK), 5 mM sodium pyrophosphate (Sigma-Aldrich 221368, 
Dorset UK), 10 mM sodium β-glycerophosphate (Sigma-Aldrich G6501, Dorset UK), 
1% (v/v) protease inhibitor cocktail (Sigma-Aldrich P8340, Dorset UK) and 1% (v/v) 
phosphatase inhibitor cocktail (Sigma-Aldrich P0044, Dorset UK). 
A cell scraper was used to detach cells from the dish. Cell lysate was then collected 
into 1.5 mL tubes and rotated for 60 min at 4°C. After a 15 min centrifugation at 
14,000 g, protein concentration was measured using Pierce™ BCA protein assay kit 
(Thermo Scientific, Hemel Hempstead UK) on the supernatant. Cell lysate 
supernatant was kept at -20°C for long storage. 
Protein samples were mixed with 6 μL 4X NuPAGE® LDS sample buffer (Life 
Technologies NP0008, Paisley UK), 2.4 μL 10X NuPAGE® reducing agent (Life 
Technologies NP0004, Paisley UK) and deionised water up to 24 μL, and heated for 
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10 min at 70°C. Samples (24 μL/well) and OdysseyTM protein molecular weight 
marker (3 μL/well, LI-COR 928-4000, Cambridge UK) were then run on NuPAGE® 
Novex® 4-12% (w/v) Bis-Tris protein gels (Life Technologies npo336box, Paisley UK) 
in 1X MES SDS running buffer (Life Technologies NP0002, Paisley UK) for 35 min at 
200 V constant. Proteins were either transferred on PVDF membranes for Western 
blotting or gels were stained for subsequent protein quantification. Gel staining was 
done using Instant Blue solution (Expedeon ISB1L, Cambridge UK) for 1 h following 
by 3x1 h washes in deionised water. Stained gels were kept overnight in deionised 
water at 4°C. Proteins were transferred on PVDF membranes (activated for 30 s in 
100% methanol), in 1X NuPAGE® transfer buffer (Life Technologies NP0002, Paisley 
UK), 0.1% (v/v) NuPAGE® antioxidant (Life Technologies NP0006, Paisley UK), 10% 
methanol (Sigma-Aldrich 322415, Dorset UK) for 1 h at 30 V constant. Membranes 
were blocked using OdysseyTM blocking solution (LI-COR P/N 927, Cambridge UK) for 
1 h at room temperature with gentle shaking.  
Membranes were incubated with primary antibody (1:500 dilution; mouse 
monoclonal OCT4, Santa Cruz Biotechnology sc-5279, Heidelberg Germany) 
overnight at 4°C. After triple rinsing in 1X PBS-0.1% (v/v) TWEEN® 20 (Sigma-Aldrich 
P2287, Dorset UK), membranes were incubated in the secondary antibody solution 
(1:50,000 dilution, IRDye 680RD goat anti mouse, LI-COR 926-68170, Cambridge UK) 
at room temperature for 1 h and protected from the light to prevent 
photobleaching. Primary and secondary antibodies were diluted in 1X PBS-0.2% 
(v/v) TWEEN® 20 (Sigma-Aldrich P2287, Dorset UK). Membranes were finally rinsed 
in 1X PBS and imaged using LI-COR ODYSSEY Sa instrument after complete drying. 
Relative quantification was performed by measuring the intensity of all the 
polypeptides in the gels stained with the Instant Blue solution, with Image Studio 
4.0 software, and using this as a reference as described [76]. Statistical analysis was 
performed using IBM SPSS Statistics 21 software. Similarly to qPCR relative 
quantification, data from different shRNAs against the same target were also 
pooled together for statistical analysis.   
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Results 
Knockdown controls and efficiencies 
A shRNA control, targeting no mRNA, served as a negative control to mitigate the 
possibility of any side effects related to the use of lentiviral particles (Fig. 1A). The 
knockdown of OCT4, the well-studied key regulator of hESC fate, served as a 
positive control of the shRNA lentiviral system and resulted in a rapid differentiation 
of hESCs (Fig. 1B). 
Each candidate mRNA was targeted by at least two different shRNAs (Table 3 and 
Fig. 1B-F) and their analyses were combined to decrease ‘off-target’ effects specific 
to each shRNA sequence. All knockdowns were confirmed at the mRNA level by RT-
qPCR (Fig. 2A), and at the protein level for OCT4 (by and Western blotting, Fig. 2B; 
and immunofluorescence, Fig. 2C) and CER1 (by immunofluorescence, Fig. 2D). 
Knockdown of NRP1, PLXNB1 and SERPINE1 could not be confirmed at the protein 
level due to the lack of specificity of commercial antibodies in our hands. At the 
mRNA level, the most efficient knockdown was PLXNB1 (84% ± 6%), followed by 
OCT4 (78% ± 10%), CER1 (73% ± 12%), SERPINE1 (66% ± 9%) and NRP1 (59% ± 7%). 
Morphological changes 
Cells transduced with the shRNA control displayed a similar morphology to 
untransduced hESCs, forming compact single-layered colonies containing cells with 
the typical characteristics of hESCs (e.g. high nuclear:cytoplasmic ratio, prominent 
nucleoli). No noticeable difference in cell number between the shRNA control and 
untransduced cells suggested that the transduction process did not affect the 
proliferation rate (Fig. 1A). shRNAs against OCT4 on the other hand triggered a rapid 
loss of colonies and a marked reduction in cell number. Furthermore, the remaining 
cells appeared more spread and had a reduced nuclear:cytoplasmic ratio, 
suggesting that they had differentiated (Fig. 1B). Cells with CER1 knockdown 
exhibited smaller colonies and more single cells, often appearing with an elongated 
shape compare to control cells (Fig. 1C). NRP1 and PLXNB1 knockdown also 
exhibited smaller colonies (Fig. 1D,E). Cell colonies were even smaller and sparse 
with SERPINE1 knockdown (Fig. 1F).  
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Thus, shRNA targeting either OCT4, CER1, NRP1, PLXNB1 or SERPINE1 had clear 
effects on the morphology of hESCs.  The relationship between these morphological 
changes and the expression of pluripotency and embryonic germ layer markers, as 
well as the expression of the mRNA encoding these five proteins was examined. In 
this way the functional significance of CER1, NRP1, PLXNB1 and SERPINE1, together 
with OCT4, would be identified. 
 Knockdown of individual candidates identifies regulatory hierarchies  
The relative mRNA expression of OCT4, CER1, NRP1, PLXNB1 and SERPINE1 were 
systematically measured by RT-qPCR (Fig. 3 and S1). Follistatin (FST) was similarly 
measured, because it has been previously identified as potentially involved in hESC 
self-renewal by our previous in silico study (section 2.2) and is known to induce 
hESC differentiation [77].  
OCT4, CER1 and SERPINE1 knockdowns significantly downregulated PLXNB1 
expression (Fig. 3B, C and F, and Fig. S1C, D and G), whereas PLXNB1 knockdown 
significantly decreased the expression of OCT4, but not that of CER1 or of SERPINE1 
(Fig. 3E and S1F) suggesting that CER1 was upstream of PLXNB1. CER1 knockdown 
also had a small negative effect on SERPINE1 and OCT4 expression (Fig. 3C and S1D) 
that probably helped to promote the downregulation of PLXNB1 (Fig. 4A). OCT4, 
CER1 and PLXNB1 knockdowns upregulated the expression of FST and NRP1 (Fig. 3B, 
C and E and Fig. S1C, D and F), while SERPINE1 knockdown only significantly 
increased that of FST (Fig. 3F, S1D and 4A). Finally, OCT4 knockdown tended to 
upregulate SERPINE1 (Fig. 3B and S1C), while NPR1 knockdown decreased sightly, 
but significantly, OCT4 without any effects on the expression of the other measured 
genes (Fig. 3D and S1F).  
Taken together, these results showed that the expression of NRP1 and FST were 
likely downstream and controlled by OCT4 and CER1 through the regulation of 
PLXNB1. SERPINE1 seemed also to modulate FST, but not NRP1, through PLXNB1. 
Interestingly, OCT4 expression was mainly linked to NRP1 and PLXNB1, and only 
sightly to CER1 (Fig. 4A).  
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Effects of shRNA-mediated knockdown on hESC self-renewal and differentiation 
To identify the effect of the knockdown of selected mRNAs on hESC stemness, the 
expression pattern of mRNA encoding pluripotency markers (OCT4, SOX2 and 
NANOG), as well as markers of endoderm (AFP, GATA6 and SOX17), ectoderm 
(CHRD, NOG and OTX2), mesoderm (EOMES, MSX1, OSR1, SNAI2, T and TBX6) and 
trophecterm (EOMES and CDX2) were systematically measured by RT-qPCR (Fig. 3 
and S1). 
OCT4 – OCT4 knockdown upregulated the three endoderm markers (Fig. 3B and 
S1C) and the upregulation of GATA6 was at both mRNA (Fig. 3B and S1C) and 
protein levels (Fig. 5). OCT4 knockdown also highly increased the three ectoderm 
markers, but had heterogenous effects on mesoderm markers (Fig. 3B and S1C). 
Both trophectoderm markers CDX2 and EOMES were significantly decreased by 
OCT4 knockdown (Fig. 3B and S1C). 
CER1 – CER1 knockdown had heterogeneous effects on endoderm markers: it non-
significantly upregulated AFP, downregulated GATA6 (at the mRNA, Fig. 3C and S1D 
and protein levels Fig. 5) and did not affect SOX17 (Fig. 3C and S1D). It also had 
heterogenous effects on mesoderm markers (Fig. 3 C and S1D). Ectoderm markers 
tended to be increased by shCER1, similarly to shOCT4, but with a smaller effect 
(Fig. 3C and S1D). CDX2, a trophectoderm marker was not affected by shCER1, while 
EOMES, another trophectoderm marker, but also a mesoderm marker, was 
significantly downregulated (Fig. 3C and S1D). OCT4 and NANOG were slighlty 
decreased by CER1 knockdown, whereas SOX2 was not (Fig. 3C and S1D). 
NRP1 – NRP1 knockdown triggered the downregulation of the three endoderm 
markers (Fig. 3D and S1E). This knockdown had heterogeneous effect on ectoderm 
markers: CHRD was signficantly increased, NOG was downregulated while the 
expression of OTX2 did not change (Fig. 3D and S1E). NRP1 knockdown had also a 
heterogenous effect on mesoderm markers: it significantly upregulated T and TBX6, 
downregulated MSX1 and OSR1, but had no effect on EOMES and SNAI2 (Fig. 3D 
and S1E). For trophectoderm, shNRP1 negatively affected CDX2, but not EOMES 
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(Fig. 3D and S1E). NRP1 knockdown also slighlty downregulated OCT4, but not 
NANOG and SOX2 (Fig. 3D and S1E). 
PLXNB1 – Except shOCT4, PLXNB1 knockdown was the only condition that 
moderately but significantly downregulated the three pluripotency markers OCT4, 
SOX2 and NANOG (Fig. 3B and E, and Fig. S1C and F).  It also significantly decreased 
both trophectoderm markers CDX2 and EOMES (Fig. 3E and S1F). PLXNB1 
knockdown triggered the upregulation of most of the mesoderm markers, except 
EOMES which is also a trophectoderm marker (Fig. 3E and S1F), while it had 
heterogeneous effects on endoderm markers: it upregulated SOX17, sigthly 
downregulated GATA6 and did not affect AFP (Fig. 3E and S1F). For ectoderm, only 
CHRD was signficantly increased by shPLXNB1, whereas NOG and OTX2 were not 
affected (Fig. 3E and S1F). 
SERPINE1 – SERPINE1 knockdown upregulated most of the mesoderm markers, 
except EOMES, which is also a trophectoderm marker and was downregulated, 
similarly to CDX2 (Fig. 3F and S1G). Ectoderm markers were not affected by 
shSERPINE1 (Fig. 3F and S1G) and endoderm markers were differently regulated: 
AFP was upregulated, SOX17 was downregulated and GATA6 was not affected (Fig. 
3F and S1G). Similarly to shNRP1, shSERPINE1 also slighlty downregulated OCT4, but 
not NANOG and SOX2 (Fig. 3F and S1G). 
Fig. 4B recapitulates homogeneous effects, revealed at the mRNA level, of each 
studied putative protein on differentation markers. OCT4 knockdown blocked 
pluripotency and trophectoderm markers, whereas it promoted ectoderm and 
endoderm markers. CER1 knockdown enhanced ectoderm markers and NRP1 
knockdown retained endoderm markers. Both PLXNB1 and SERPINE1 knockdown 
blocked trophectoderm markers and promoted mesoderm markers. Finally, PLXNB1 
knockdown decreased pluripotency markers. 
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Discussion 
In this study, we have investigated the role of putative stemness factors in hESC 
self-renewal and lineage differentation and have also investigated whether the 
expression of any of these factors regulates and/or is regulated by OCT4. As soon as 
5 days after transduction (including only two days of antibiotic selection), gene 
expression changes were detected in pluripotency and differentiation markers.  
To summarise, OCT4 and NRP1 knockdowns had opposite, but homogeneous 
effects on endoderm markers. Thus OCT4 seems to inhibit endoderm specification, 
while NRP1 tends to promote it. The fact that OCT4 affected NRP1 expression 
suggests that NRP1 is downstream of OCT4 in the endoderm specification pathway. 
Knockdown of  OCT4 and  CER1, though to a lesser extent,  triggered a 
homogeneous positive effect on ectoderm markers. This suggests that OCT4 and 
CER1 tend to block ectoderm. CER1 affected OCT4 expression, whereas the contrary 
was not found, suggesting that CER1 was upstream OCT4 in the regulation of 
ectoderm commitment. 
PLXNB1 and SERPINE1 knockdowns were involved in the upregulation of most of 
the mesoderm markers except EOMES, which is also a trophectoderm marker. 
Consequently, PLXNB1 and SERPINE1 are likely to have an inhibitory effect on 
mesoderm differentation. SERPINE1  knockdown downregulated PLXNB1, whereas 
PLXNB1 knockdown did not affect SERPINE1 expression. Therefore, SERPINE1 is 
probably upstream PLXNB1 in the mesoderm regulation. 
Finally, both trophectoderm markers, CDX2 and EOMES were significantly 
decreased by PLXNB1, SERPINE1 and OCT4 knockdown. Therefore, trophectoderm 
differentiation seems to be promoted by OCT4, together with PLXNB1 and 
SERPINE1. Moreover, OCT4 affects both PLXNB1 and SERPINE1, which suggests it 
lies upstream of them in the commitment to trophectoderm.  
There are conflicting reports in the literature regarding the role of OCT4 in the 
specification of the embryonic germ layers. Our results showed that OCT4 
knockdown inhibited endoderm and ectoderm differentiation, and enhanced 
trophectoderm differentiation. Endoderm induction by OCT4 knowdown appears to 
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be a consensus [6, 78, 79]. Some studies showed trophectoderm differentation by 
OCT4 knockdown [79] that is probably linked to the culture conditions [6] and 
especially to the presence of BMP4 [80], which is not added in our culture medium. 
Other research groups showed the induction of mesoderm by OCT4 knockdown [78, 
80]. Overexpression of OCT4 has also led to conflicting results by triggering 
endoderm differentiation in some studies [78] and self-renewal or mesoderm 
differentiation in others [80]. Taken together, these studies demonstrated a clear 
yet complex involvement of OCT4 in hESC fate decisions, which is also likely 
dependent on OCT4 expression levels, cell culture conditions and probably timing. 
Our data showed that CER1 was expressed by hESCs, both at the mRNA and protein 
levels, and CER1 knockdown appeared to induce ectodermal differentiation. It has 
already been shown that CER1 overexpression did not induce hESC differentiation 
[77]. CER1 expression is also promoted during neuro-ectodermal differentiation [81] 
and in early endodermal hESC-derived cells [29], where it can serve as a marker for 
definitive endoderm differentiation [82]. These results highlight different roles of 
CER1 in the endoderm and ectoderm lineages. Further investigations would be 
needed to uncover the pathway through which CER1 acts. It is already known that it 
is an antagonist of BMP, Nodal and WNT, three signalling pathways involved in hESC 
fate [25, 32-37]. 
NRP1 was found to be expressed by hESCs, as previously shown [49], and its 
knockdown appears to inhibit endoderm differentiation. Further experiments would 
be needed to elucidate how NRP1 can push hESCs towards endoderm. There are at 
least two paths through which NPR1 could act: it is a co-receptor/pure agonist of 
VEGF [38, 39], signalling known to induce endothelial differentiation [83] and 
involved in the hematopoietic differentiation of hESCs [84]; and it modulates FGF2 
activity [50] which is a key hESC growth factor [24].  
Our qPCR results demonstrated that PLXNB1 was expressed by hESCs and its 
knockdown modestly, but significantly downregulated NANOG, OCT4 and SOX2, the 
gatekeepers of pluripotency. It also blocked trophectoderm and pushed hESCs to 
express mesoderm markers. Interestingly, PLXNB1 knockdown downregulated 
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SOX2, a transcription factor involved in preventing mesoderm differentiation [80]. 
SOX2 also triggers trophectoderm differentiation, either by its overexpression [85] 
or knockdown [7, 85]. Previous studies investigating the expression patterns of 
plexin family members during mouse embryogenesis [44, 86], concluded that these 
have non-redundant and distinct patterns, whereas another group generated a 
mutant mouse with a loss of PLXNB1 expression that was viable and fertile, 
suggesting redundant roles in the plexin family [87]. However, the role of plexin 
family members in hESC fate has not been investigated yet. One way PLXNB1 could 
help to regulate hESC stemness is through the stimulation of the PI3K-Akt pathway 
[48] which is known to play a role in hESC self-renewal [51]. 
SERPINE1 was expressed by hESCs as previously shown [88]. In our study, SERPINE1 
knockdown had similar effects as PLXNB1 knockdown on mesoderm induction and 
trophectoderm blocking. However, it did not affect the pluripotency markers, 
although it downregulated PLXNB1. Even if SERPINE1 knockout mice were viable 
and did not exhibit any obvious phenotypes [89], our results suggest that this 
extracellular protein plays a role in hESC fate decision. Its effect could be related to 
its role in regulating TGF-β signalling [61, 62], which inhibits hESC differentiation 
[35, 37, 63, 64], or to its binding to vitronectin [65], an extracellular molecule used 
to promote hESC self-renewal [66, 67]. 
FST is an activin inhibitor capable of inducing hESC differentiation [77]. Interestingly, 
its gene expression was upregulated by CER1, PLXNB1, SERPINE1 and OCT4 
knockdowns suggesting that these four proteins may prevent hESC differentiation in 
part by controlling FST level. 
In conclusion, the knockdown of CER1, PLXNB1, SERPINE1 and NRP1 identifies a 
complex relationship between their expression, pluripotency markers and 
embryonic germ layer markers. CER1, NRP1, PLXNB1, SERPINE1, together with 
OCT4, appear to balance hESC commitment into different lineages. The data also 
illustrate that these membrane/extracellular proteins are likely to regulate some 
aspects of hESC fate decisions, as there is an interplay between the cell 
transcription machinery and proteins of the extracellular environment.   
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Tables 
 
 
shRNA reference 
shOCT4 shCER1 shNRP1 shPLXNB1 shSERPINE1 
shControl 
-79 -81 -59 -78 -23 -24 -26 -27 -34 -35 -36 -69 -70 -72 
 N (total) 2 6 3 3 1 1 2 3 3 4 4 3 2 1 9 
N
 (
p
er
 t
ar
ge
t)
 
CDX2 3 5 2 7 6 6 
EOMES 3 5 6 6 6 8 
CHRD 2 5 6 10 6 9 
NOG 3 5 5 10 6 8 
OTX2 3 5 6 8 5 7 
EOMES 3 5 6 6 6 8 
MSX1 7 6 6 11 6 6 
OSR1 3 5 6 11 6 8 
SNAI2 4 4 6 10 6 7 
T 2 5 6 10 6 8 
TBX6 2 4 5 10 6 7 
AFP 8 6 6 11 6 6 
GATA6 8 6 6 9 6 9 
SOX17 6 6 6 11 5 9 
OCT4 6 5 6 10 6 9 
NANOG 6 6 6 11 6 8 
SOX2 4 5 6 10 6 7 
CDH8 6 6 6 10 6 7 
CER1 8 6 6 11 6 8 
NRP1 7 6 6 11 6 8 
PLXNB1 8 6 6 11 6 9 
SERPINE1 7 6 6 10 6 9 
ACTN4 2 6 6 11 6 9 
FST 2 6 6 11 6 8 
Table 1 | Biological replicates 
Number of biological replicates N per knockdown and per target mRNA.  
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Target 
acronym 
Target official name Variants Primer sequences (5'->3') Tm 
Product 
length 
Exon 
junction 
Intron 
HPRT1 
hypoxanthine 
phosphoribosyltrans
ferase 1 
1 
F GCAGCCCTGGCGTCGTGATTAG 60.2 
143 X   
R TCGAGCAAGACGTTCAGTCCTGTCC 60.5 
MAPK1 
mitogen-activated 
protein kinase 1 
(ERK2) 
2 (1)* 
F TCGCCGAAGCACCATTCAAGTTCG 60.3 
150   X 
R AGCACGTCCAGTCCTCTGAGCC 60.2 
UBC ubiquitin C 1 
F TGCGGAGGGATCTCCGTGGG 60 
140 X   
R GCATTGTCAAGTGACGATCACAGCG 59.2 
CER1 
cerberus 1, cysteine 
knot superfamily, 
homolog (Xenopus 
laevis) 
1 
F TCAGGGGGTCATCTTGCCCATCA 59.4 
144   X 
R ACAGACCCGCATTTCCCAAAGCA 59.3 
NRP1 neuropilin 1 5 
F GGATGACAGCAAACGCAAGG 60.1 
83   X 
R AGAGAGCTGGAAAAGTCCGC 60 
PLXNB1 plexin B1 2 
F GGCCCTGCATGAACTCTACA 59.8 
115   X 
R AATCTGCTGGAGCCGATAGC 60 
SERPINE1 
serpin peptidase 
inhibitor, clade E, 
member 1 
2 
F GGCACGGTGGCCTCCTCATC 59.5 
118 X X 
R GGACTGTTCCTGTGGGGTTGTGC 59.9 
FST Follistatin 2 
F GCTGCTGCTGCTCTGCCAGTT 60.2 
70   X 
R CGCTTGACGGAGCCAGCAGTT 60 
NANOG Nanog homeobox 1 
F TCCAACATCCTGAACCTCAGC 60 
125 X X 
R GAGGCCTTCTGCGTCACA 59.7 
POU5F1 
(OCT4) 
POU class 5 
homeobox 1 
3** 
F ATGTGGTCCGAGTGTGGTTC 60 
67     
R TGTGCATAGTCGCTGCTTGA 60 
SOX2 
SRY (sex determining 
region Y)-box 2 
1 
F TCAGGAGTTGTCAAGGCAGAG 59.7 
60     
R GGCAGCAAACTACTTTCCCC 59.1 
AFP alpha-fetoprotein 1 
F CCAGGAACAGGAAGTCTGCT 59.3 
101 X X 
R TTGTCTTCTCTTCCCCTGAAGTAA 59.1 
GATA6 
GATA binding 
protein 6 
1 
F GCTGTTTGTTTAGGGCTCGG 59.5 
68     
R CTTACTGCTCTGCCGGAAAAC 59.5 
SOX17 
SRY (sex determining 
region Y)-box 17 
1 
F AGGGCGAGTCCCGTATCC 60.5 
129 X   
R ACGACTTGCCCAGCATCTTG 61 
MSX1 msh homeobox 1 1 
F TAACCCTCACACTGCTCCAG 59 
87     
R CTCTTCCAGCCACTTTTTGGC 60 
OSR1 
odd-skipped related 
1 (Drosophila) 
1 
F CAGGACCTCTGCGGAACAAG 60.7 
68   X 
R AGGTTTTGCTGCCCATTTCG 59.7 
EOMES eomesodermin 4 
F TCAAATTCCACCGCCACCAA 60.5 
100   X 
R GCAGTGGGATTGAGTCCGTT 60.3 
SNAI2 
snail homolog 2 
(Drosophila) 
1 
F TTCCAGACCCTGGTTGCTTC 59.9 
61     
R AGAAAAAGGCTTCTCCCCCG 60 
T 
T, brachyury 
homolog (mouse) 
2 
F CCCGTCTCCTTCAGCAAAGT 60 
67     
R AGTTCAGCATGATCTGGCCC 60.1 
TBX6 T-box 6 1 
F GAACCGGGAGCTATGGAAGG 59.9 
132   X 
R AGAAACAAGTAGCGGGCCTC 60 
CHRD chordin 1 
F GTGAGCGGGATGACTGTTCA 60 
111     
R GATCAGTTCTGGTCTCTGGGG 59.5 
NOG noggin 1 
F TCGCCCTGGAGTAATTTCGG 59.8 
67     
R CAACTCCTCTCCCGGGTCTA 60 
OTX2 
orthodenticle 
homeobox 2 
5 
F CTTCATGCGAGAGGAGGTGG 60.2 
97   X 
R CTGTTGTTGGCGGCACTTAG 59.8 
CDX2 
caudal type 
homeobox 2 
1 
F CTACAGTCGCTACATCACCATCC 60.6 
119   X 
R TGTTGATTTTCCTCTCCTTTGCTCT 60.7 
* Primers recognise only variant 1 
** Primers recognise also variant 1B 
Table 2 | PCR primer references and sequences 
Description of key elements to identify the primers used in this work: the acronym and official gene 
symbol of the target mRNAs, the number of targeted transcripts, the primer sequences (F: forward; 
R: reverse) and their melting temperatures (Tm), and the PCR product length. It is specified whether 
primers span an exon junction or if they are separated by at least one intron. 
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Gene 
target 
Acronym used TRC Number Clone ID shRNA sequence 
Control 
shControl     
CCGGCAACAAGATGAAGAGCACCAACTCGAG 
(SHC002) TTGGTGCTCTTCATCTTGTTGTTTTT 
CDH8 
shCDH8-23 TRCN0000054223 NM_001796.2-1784s1c1 
CCGGGCCAAGTCATTCAAACTGTTACTCGAG 
TAACAGTTTGAATGACTTGGCTTTTTG 
shCDH8-24 TRCN0000054224 NM_001796.2-343s1c1 
CCGGCCGATGAATCAGTCTCAAGTTCTCGAG 
AACTTGAGACTGATTCATCGGTTTTTG 
shCDH8-27 TRCN0000054227 NM_001796.2-565s1c1 
CCGGGCTGGGACCATATTTCAAATACTCGAG 
TATTTGAAATATGGTCCCAGCTTTTTG 
CER1 
shCER1-59 TRCN0000156559 NM_005454.1-461s1c1 
CCGGGCCATGAAGTACATTGGGAGACTCGAG 
TCTCCCAATGTACTTCATGGCTTTTTTG 
shCER1-78 TRCN0000155478 NM_005454.1-564s1c1 
CCGGGAAATGCGGGTCTGTTCATTTCTCGAG 
AAATGAACAGACCCGCATTTCTTTTTTG 
NRP1 
shNRP1-23 TRCN0000063523 NM_003873.2-255s1c1 
CCGGGCAACGATAAATGTGGCGATACTCGAG 
TATCGCCACATTTATCGTTGCTTTTTG 
shNRP1-24 TRCN0000063524 NM_003873.2-369s1c1 
CCGGCGGACCCATACCAGAGAATTACTCGAG 
TAATTCTCTGGTATGGGTCCGTTTTTG 
shNRP1-26 TRCN0000063526 NM_003873.2-1702s1c1 
CCGGCCGAGAGAACAAGGTGTTCATCTCGAG 
ATGAACACCTTGTTCTCTCGGTTTTTG 
shNRP1-27 TRCN0000063527 NM_003873.2-694s1c1 
CCGGCAGCCTTGAATGCACTTATATCTCGAG 
ATATAAGTGCATTCAAGGCTGTTTTTG 
PLXNB1 
shPLXNB1-34 TRCN0000061534 NM_002673.3-5003s1c1 
CCGGGCTTGAGTATTTCACTGACATCTCGAG 
ATGTCAGTGAAATACTCAAGCTTTTTG 
shPLXNB1-35 TRCN0000061535 NM_002673.3-6152s1c1 
CCGGCCCGATCAACAAACTTCTGTACTCGAG 
TACAGAAGTTTGTTGATCGGGTTTTTG 
shPLXNB1-36 TRCN0000061536 NM_002673.3-132s1c1 
CCGGCCAACTGCATTCACTCCCAATCTCGAG 
ATTGGGAGTGAATGCAGTTGGTTTTTG 
SERPINE1 
shSERPINE1-69 TRCN0000052269 NM_000602.1-792s1c1 
CCGGCGATGGCCATTACTACGACATCTCGAG 
ATGTCGTAGTAATGGCCATCGTTTTTG 
shSERPINE1-70 TRCN0000052270 NM_000602.1-372s1c1 
CCGGGCATCTGTACAAGGAGCTCATCTCGAG 
ATGAGCTCCTTGTACAGATGCTTTTTG 
shSERPINE1-72 TRCN0000052272 NM_000602.1-546s1c1 
CCGGCATCATCAATGACTGGGTGAACTCGAG 
TTCACCCAGTCATTGATGATGTTTTTG 
POU5F1 
(OCT4) 
shOCT4-79 TRCN0000004879 NM_002701.1-998s1c1 
CCGGTCATTCACTAAGGAAGGAATTCTCGAG 
AATTCCTTCCTTAGTGAATGATTTTT 
shOCT4-81 TRCN0000004881 NM_002701.1-797s1c1 
CCGGCCCTCACTTCACTGCACTGTACTCGAG 
TACAGTGCAGTGAAGTGAGGGTTTTT 
Table 3 | shRNA plasmid references and sequences 
Description of key elements to identify the shRNA plasmids used in this work: the official gene 
symbol, the RNA Consortium (TRC) plasmid number, clone ID and detailed shRNA nucleotide 
sequence (nucleotides coloured in orange represent the beginning and the end of the insert, 
nucleotides coloured in green in the middle represent the loop sequence within the shRNA). 
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Table S1 | shRNA BLAST 
All the shRNA sequences were tested for sequence complementarity against the human genomic 
plus transcript databases. Only results with e-value<0.05 are displayed. 
 
 
 
 
 
 
 
 
 
 
 
Sample 
RNA 
concentration 
(ng/µL) 
260/280 260/230 
 
Sample 
RNA 
concentration 
(ng/µL) 
260/280 260/230 
CONTROL 
422.3 1.88 2.09  
shCER1-59 
731.05 1.92 2.03 
1009.2 1.98 1.96  569.45 1.93 1.865 
823.4 1.905 2.145  375.6 1.9 1.455 
857.35 1.96 1.96  
shCER1-78 
574.15 1.915 1.97 
963.75 1.94 1.94  467.15 1.875 2.035 
2111.95 1.975 2.015  551.75 1.945 0.9 
920.4 1.975 1.915  shNRP1-23 744.6 1.92 1.72 
566.65 1.93 2.11  
shNRP1-26 
647.1 1.91 2.12 
711.5 1.91 1.88  800.55 1.91 2 
shControl 
848.6 1.92 2.05  
shNRP1-27 
279.8 1.89 1.66 
1645.5 1.96 2.08  719.25 1.92 1.42 
790.7 1.885 2.13  949.65 1.915 1.845 
616.15 1.935 2.185  
shPLXNB1-34 
1282 1.955 1.97 
753.45 1.94 1.7  1033 1.94 2.07 
551.7 1.955 2.11  800.6 1.96 1.575 
676.8 1.925 1.71  
shPLXNB1-35 
830.2 1.93 1.96 
379.55 1.92 1.475  689.8 1.92 1.77 
680.8 1.895 1.925  1051.8 1.95 1.885 
shOCT4-79 
159.85 1.675 0.32  315.6 1.925 1.095 
85.05 1.685 0.155  
shPLXNB1-36 
595.55 1.92 1.91 
shOCT4-81 
186.9 1.84 1.89  884.15 1.92 1.695 
1674.9 1.96 2.06  807.2 1.93 2.09 
197.65 1.79 2.185  300.7 1.92 0.55 
413.1 1.905 2.09  
shSERPINE1-
69 
417.1 1.76 1.88 
70.6 1.645 0.285  285.3 1.885 1.455 
85.75 1.81 1.65  319.55 1.875 2.07 
shCDH8-23 
611.95 1.92 2.06  shSERPINE1-
70 
748.85 1.92 1.435 
339.4 1.89 1.75  598.6 1.915 2.07 
shCDH8-24 
1655 1.95 1.88  shSERPINE1-
72 
691.15 1.875 1.765 
761.45 1.92 2.11  1249.45 1.975 1.93 
613.75 1.94 1.9      
623.55 1.925 1.92      
shCDH8-27 692.4 1.91 1.97      
Table S2 | RNA concentration and purity 
RNA concentration and absorbance ratios (260/230 nm and 260/280 nm).  
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Figures 
 
Figure 1, Part 1 
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Figure 1, Part 2 
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Figure 1, Part 3 
Figure 1 | Transduced hESCs in culture 
Pictures were taken at day 5 after transduction including two days of selection: (A) non-transduced 
(control) cells and shRNA Control cells; (B) OCT4 knockdowns; (C) CER1 knockdowns; (D) NRP1 
knockdowns; (E) PLXNB1 knockdowns; (F) SERPINE1 knockdowns. 
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Figure 2 | Knockdown efficiencies 
Knockdowns of each specific shRNA (with a number) and their combination (without a number)  
were confirmed (A) at the mRNA level by RT-qPCR for all the tested shRNAs (relative gene 
expression, ∆∆Ct normalisation done against untransduced hESCs; the dash line indicates the level of 
expression in untransduced hESCs) and at the protein level for OCT4 (B) by Western blotting (relative 
gene expression, normalisation done against untransduced hESCs; mean±SEM; One sample t-test, 
*p-value<0.05, **p-value<0.01, ***p-value<0.001, N.S.: not significant, no star means n<3) and by 
(C) immunofluorescence, and for CER1 (D) by immunofluorescence. 
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Figure 3, Part 1 
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Figure 3, Part 2 
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Figure 3 | Gene expression profiles 
Relative gene expressions of CER1, NRP1, PLXNB1 and SERPINE1 in blue, pluripotency markers 
(OCT4, SOX2 and NANOG) in green, trophectoderm markers (CDX2 and EOMES) in purple, ectoderm 
markers (CHRD, NOG and OTX2) in red, endoderm markers (AFP, GATA6 and SOX17) in yellow and 
mesoderm markers (EOMES, MSX1, OSR1, SNAI2, T and TBX6) in orange in (A) shControl hESCs, (B) 
shCER1 hESCs, (C) shOCT4 hESCs, (D) shNRP1 hESCs, (E) shPLXNB1 hESCs and (F) shSERPINE1 hESCs. 
A dash line indicates the level of expression in untransduced hESCs (∆∆Ct normalisation done against 
untransduced hESCs; mean±SEM; One sample t-test,*p-value<0.05, **p-value<0.01, ***p-
value<0.001, if not stated: not significant). 
 
 
 
 
 
Figure 4 | Interconnectivity and regulation, our model 
(A) Deductions of gene expression relationships between OCT4, CER1, NRP1, PLXNB1, SERPINE1 and 
FST. (B) Deductions of the role of OCT4, CER1, NRP1, PLXNB1 and PLXNB1 in hESC fate. 
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Figure 5 | GATA6 protein expression 
Protein expression profile of GATA6 in untransduced hESCs (control in green), shControl hESCs 
(blue), shOCT4 (orange) and shCER1 (grey).  
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4.3. Additional material and methods 
4.3.1. Freezing/defrosting 
After trypsin dissociation, the cell pellet was resuspended in 500 µL of cell freezing 
medium (Sigma-Aldrich C6164, Dorset UK). The cell suspension was put into a 
cryovial and placed in a freezing chamber containing isopropanol at -80°C overnight. 
Then, the vial was transferred to a liquid nitrogen tank for long-term storage. 
For defrosting, the cell suspension was transferred to a conical 15 mL tube 
containing 9 mL of 10% (v/v) foetal bovine serum (FBS, GIBCO 10270-106, Paisley 
UK) in DMEM:F12 (Lonza BE12-719F, Cambridge UK) and centrifuged for 5 min at 
250 g. The pellet was resuspended in 500 µL of hESC culture medium and 
transferred to a 6 cm fibronectin-coated dish containing 4 mL of culture medium at 
37°C, 5% (v/v) CO2. 
4.3.2. hESC differentiation 
Cell differentiation was induced by culturing hESCs in DMEM:F12 (Lonza BE12-719F, 
Cambridge UK) supplemented by 10% (v/v) FBS (GIBCO 10270-106, Paisley UK). This 
culture medium was either added after cell dissociation or on attached cells. 
4.3.3. Additional information on the samples, shRNAs and primers 
Table 8 gives the list of shRNA sequences and table 9 gives the list of qPCR primers, 
together with their calculated amplification efficiencies (E). A range of different 
cDNA concentrations were run in duplicate, from no dilution to 1/1,000 dilution (8 
points tested). To determine qPCR amplification efficiencies (E), standard curves 
were constructed. Cycle threshold (Ct) values of the standard dilutions were plotted 
against the logarithm of cDNA dilution. Linear regression curves (Ct  =  [𝑠𝑙𝑜𝑝𝑒]  ×
 [𝑙𝑛(𝑁)] + b) were fitted to establish E =  10
−1
slope − 1. A slope of -3.32 is equivalent 
to an amplification efficiency E of 1 (or 100%).  
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Gene 
target 
Acronym 
used 
TRC Number Clone ID shRNA sequence 
Control 
shControl     
CCGGCAACAAGATGAAGAGCACCAACTCGAG 
(SHC002) TTGGTGCTCTTCATCTTGTTGTTTTT 
CDH8 
shCDH8-23 TRCN0000054223 
NM_001796.2-
1784s1c1 
CCGGGCCAAGTCATTCAAACTGTTACTCGAG 
TAACAGTTTGAATGACTTGGCTTTTTG 
shCDH8-24 TRCN0000054224 
NM_001796.2-
343s1c1 
CCGGCCGATGAATCAGTCTCAAGTTCTCGAG 
AACTTGAGACTGATTCATCGGTTTTTG 
shCDH8-27 TRCN0000054227 
NM_001796.2-
565s1c1 
CCGGGCTGGGACCATATTTCAAATACTCGAG 
TATTTGAAATATGGTCCCAGCTTTTTG 
CER1 
shCER1-59 TRCN0000156559 
NM_005454.1-
461s1c1 
CCGGGCCATGAAGTACATTGGGAGACTCGAG 
TCTCCCAATGTACTTCATGGCTTTTTTG 
shCER1-78 TRCN0000155478 
NM_005454.1-
564s1c1 
CCGGGAAATGCGGGTCTGTTCATTTCTCGAG 
AAATGAACAGACCCGCATTTCTTTTTTG 
NRP1 
shNRP1-23 TRCN0000063523 
NM_003873.2-
255s1c1 
CCGGGCAACGATAAATGTGGCGATACTCGAG 
TATCGCCACATTTATCGTTGCTTTTTG 
shNRP1-24 TRCN0000063524 
NM_003873.2-
369s1c1 
CCGGCGGACCCATACCAGAGAATTACTCGAG 
TAATTCTCTGGTATGGGTCCGTTTTTG 
shNRP1-26 TRCN0000063526 
NM_003873.2-
1702s1c1 
CCGGCCGAGAGAACAAGGTGTTCATCTCGAG 
ATGAACACCTTGTTCTCTCGGTTTTTG 
shNRP1-27 TRCN0000063527 
NM_003873.2-
694s1c1 
CCGGCAGCCTTGAATGCACTTATATCTCGAG 
ATATAAGTGCATTCAAGGCTGTTTTTG 
PLXNB1 
shPLXNB1-34 TRCN0000061534 
NM_002673.3-
5003s1c1 
CCGGGCTTGAGTATTTCACTGACATCTCGAG 
ATGTCAGTGAAATACTCAAGCTTTTTG 
shPLXNB1-35 TRCN0000061535 
NM_002673.3-
6152s1c1 
CCGGCCCGATCAACAAACTTCTGTACTCGAG 
TACAGAAGTTTGTTGATCGGGTTTTTG 
shPLXNB1-36 TRCN0000061536 
NM_002673.3-
132s1c1 
CCGGCCAACTGCATTCACTCCCAATCTCGAG 
ATTGGGAGTGAATGCAGTTGGTTTTTG 
SERPINE1 
shSERPINE1-69 TRCN0000052269 
NM_000602.1-
792s1c1 
CCGGCGATGGCCATTACTACGACATCTCGAG 
ATGTCGTAGTAATGGCCATCGTTTTTG 
shSERPINE1-70 TRCN0000052270 
NM_000602.1-
372s1c1 
CCGGGCATCTGTACAAGGAGCTCATCTCGAG 
ATGAGCTCCTTGTACAGATGCTTTTTG 
shSERPINE1-72 TRCN0000052272 
NM_000602.1-
546s1c1 
CCGGCATCATCAATGACTGGGTGAACTCGAG 
TTCACCCAGTCATTGATGATGTTTTTG 
POU5F1 
(OCT4) 
shOCT4-79 TRCN0000004879 
NM_002701.1-
998s1c1 
CCGGTCATTCACTAAGGAAGGAATTCTCGAG 
AATTCCTTCCTTAGTGAATGATTTTT 
shOCT4-81 TRCN0000004881 
NM_002701.1-
797s1c1 
CCGGCCCTCACTTCACTGCACTGTACTCGAG 
TACAGTGCAGTGAAGTGAGGGTTTTT 
Table 8 | shRNA plasmid references and sequences 
Description of key elements to identify the shRNA plasmids used in this work: the official gene 
symbol, the RNA Consortium (TRC) plasmid number, clone ID and detailed shRNA nucleotide 
sequence (nucleotides coloured in orange represent the beginning and the end of the insert, 
nucleotides coloured in green represent the loop sequence within the shRNA). 
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 Target 
acronym 
Target 
official name 
Variants 
Primer sequences  
(5'->3') 
Tm 
Product 
length 
Exon 
junction 
Intron 
qPCR efficiency 
 % R
2
 
H
K
G
 
HPRT1 
hypoxanthine 
phosphoribos
yltransferase 
1 
1 
F 
GCAGCCCTGGCGT
CGTGATTAG 
60.2 
143 X   103 1.00 
R 
TCGAGCAAGACGT
TCAGTCCTGTCC 
60.5 
MAPK1 
mitogen-
activated 
protein 
kinase 1 
(ERK2) 
2 (1)* 
F 
TCGCCGAAGCACC
ATTCAAGTTCG 
60.3 
150   X 114 1.00 
R 
AGCACGTCCAGTC
CTCTGAGCC 
60.2 
UBC ubiquitin C 1 
F 
TGCGGAGGGATCT
CCGTGGG 
60 
140 X   107 0.99 
R 
GCATTGTCAAGTG
ACGATCACAGCG 
59.2 
C
an
d
id
at
e
s 
CDH8 
cadherin 8, 
type 2 
1 
F 
CAGGCCCAGGATG
GCATTAT 
59.9 
83   X 113 0.99 
R 
GCTGCCTCTACCTT
TAGCGT 
59.8 
CER1 
cerberus 1, 
cysteine knot 
superfamily, 
homolog 
(Xenopus 
laevis) 
1 
F 
TCAGGGGGTCATC
TTGCCCATCA 
59.4 
144   X 130 1.00 
R 
ACAGACCCGCATT
TCCCAAAGCA 
59.3 
NRP1 neuropilin 1 5 
F 
GGATGACAGCAAA
CGCAAGG 
60.1 
83   X 111 0.98 
R 
AGAGAGCTGGAA
AAGTCCGC 
60 
PLXNB1 plexin B1 2 
F 
GGCCCTGCATGAA
CTCTACA 
59.8 
115   X 136 1.00 
R 
AATCTGCTGGAGC
CGATAGC 
60 
SERPINE1 
serpin 
peptidase 
inhibitor, 
clade E, 
member 1 
2 
F 
GGCACGGTGGCCT
CCTCATC 
59.5 
118 X X 110 1.00 
R 
GGACTGTTCCTGT
GGGGTTGTGC 
59.9 
ACTN4 
actinin, alpha 
4 
1 
F 
AGCAAGCAGCAGT
CCAACGAGC 
60.2 
101 X   111 1.00 
R 
ATGCGCCCGATCT
CCTCCATCTT 
59.9 
FST Follistatin 2 
F 
GCTGCTGCTGCTC
TGCCAGTT 
60.2 
70   X 98 1.00 
R 
CGCTTGACGGAGC
CAGCAGTT 
60 
P
lu
ri
p
o
te
n
cy
 
NANOG 
Nanog 
homeobox 
1 
F 
TCCAACATCCTGA
ACCTCAGC 
60 
125 X X 113 0.99 
R 
GAGGCCTTCTGCG
TCACA 
59.7 
POU5F1 
(OCT4) 
POU class 5 
homeobox 1 
3** 
F 
ATGTGGTCCGAGT
GTGGTTC 
60 
67     105 1.00 
R 
TGTGCATAGTCGC
TGCTTGA 
60 
SOX2 
SRY (sex 
determining 
region Y)-box 
2 
1 
F 
TCAGGAGTTGTCA
AGGCAGAG 
59.7 
60     104 1.00 
R 
GGCAGCAAACTAC
TTTCCCC 
59.1 
Ec
to
d
e
rm
 
AFP 
alpha-
fetoprotein 
1 
F 
CCAGGAACAGGA
AGTCTGCT 
59.3 
101 X X 113 0.93 
R 
TTGTCTTCTCTTCC
CCTGAAGTAA 
59.1 
GATA6 
GATA binding 
protein 6 
1 
F 
GCTGTTTGTTTAG
GGCTCGG 
59.5 
68     94 1.00 
R 
CTTACTGCTCTGCC
GGAAAAC 
59.5 
SOX17 
SRY (sex 
determining 
region Y)-box 
17 
1 
F 
AGGGCGAGTCCCG
TATCC 
60.5 
129 X   102 0.97 
R 
ACGACTTGCCCAG
CATCTTG 
61 
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 Target 
acronym 
Target official 
name 
Variants 
Primer sequences  
(5'->3') 
Tm 
Product 
length 
Exon 
junction 
Intro
n 
qPCR efficiency 
 % R
2
 
M
e
so
d
e
rm
 
MSX1 msh homeobox 1 1 
F 
TAACCCTCACACT
GCTCCAG 
59 
87     105 1.00 
R 
CTCTTCCAGCCAC
TTTTTGGC 
60 
OSR1 
odd-skipped 
related 1 
(Drosophila) 
1 
F 
CAGGACCTCTGCG
GAACAAG 
60.7 
68   X 120 0.99 
R 
AGGTTTTGCTGCC
CATTTCG 
59.7 
EOMES eomesodermin 4 
F 
TCAAATTCCACCG
CCACCAA 
60.5 
100   X 132 1.00 
R 
GCAGTGGGATTG
AGTCCGTT 
60.3 
SNAI2 
snail homolog 2 
(Drosophila) 
1 
F 
TTCCAGACCCTGG
TTGCTTC 
59.9 
61     120 1.00 
R 
AGAAAAAGGCTTC
TCCCCCG 
60 
T 
T, brachyury 
homolog (mouse) 
2 
F 
CCCGTCTCCTTCA
GCAAAGT 
60 
67     100 0.99 
R 
AGTTCAGCATGAT
CTGGCCC 
60.1 
TBX6 T-box 6 1 
F 
GAACCGGGAGCT
ATGGAAGG 
59.9 
132   X N. D. 
R 
AGAAACAAGTAG
CGGGCCTC 
60 
En
d
o
d
e
rm
 
CHRD chordin 1 
F 
GTGAGCGGGATG
ACTGTTCA 
60 
111     103 0.98 
R 
GATCAGTTCTGGT
CTCTGGGG 
59.5 
NOG noggin 1 
F 
TCGCCCTGGAGTA
ATTTCGG 
59.8 
67     108 0.99 
R 
CAACTCCTCTCCC
GGGTCTA 
60 
OTX2 
orthodenticle 
homeobox 2 
5 
F 
CTTCATGCGAGAG
GAGGTGG 
60.2 
97   X 106 0.99 
R 
CTGTTGTTGGCGG
CACTTAG 
59.8 
Tr
o
p
h
e
ct
o
d
e
rm
 
CDX2 
caudal type 
homeobox 2 
1 
F 
CTACAGTCGCTAC
ATCACCATCC 
60.6 
119   X 108 0.96 
R 
TGTTGATTTTCCTC
TCCTTTGCTCT 
60.7 
 * Primers recognise only variant 1         
 **Primers recognise also  variant 1B         
Table 9 | PCR primer references and sequences 
Description of key elements to identify the primers used in this work: the acronym and official gene 
symbol of the target mRNAs, the number of targeted transcripts, the primer sequences (F: forward; 
R: reverse) and their melting temperatures (Tm) and the PCR product length . It is specified whether 
primers are spanning an exon junction or if they are separated by at least one intron. The 
amplification efficiency is given in % with the corresponding R
2
 (N.D.: not determined). 
Table 10 gives the RNA concentration and purity of each sample and table 11 gives 
the number of biological replicates of each culture condition. 
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Sample 
Time - Lentiviral 
concentration 
RNA concentration (ng/µL) 260/280 260/230 
CONTROL 4D 
801.2 1.93 2.05 
827 1.94 0.77 
695.5 1.58 1.06 
386.3 1.91 1.36 
647.7 1.05 0.95 
489.3 1.89 1.3 
10% FBS 4D 
279.5 1.9 1.97 
173.6 1.9 1.5 
234.4 1.91 2.03 
314.7 1.93 1.74 
779.2 1.94 2.07 
277.3 1.83 2.08 
CONTROL 5D 
422.3 1.88 2.09 
1009.2 1.98 1.96 
589.5 1.825 0.73 
823.4 1.905 2.145 
857.35 1.96 1.96 
963.75 1.94 1.94 
2111.95 1.975 2.015 
920.4 1.975 1.915 
566.65 1.93 2.11 
711.5 1.91 1.88 
10% FBS 5D 
438.5 1.93 1.14 
1238.3 1.965 1.4 
567.6 1.945 2 
550.35 1.95 1.3 
983.1 1.965 1.98 
975.9 1.94 2.055 
712.95 1.95 1.93 
shControl 
5D - C1 
766.4 1.9 2.08 
1721.7 1.96 2.05 
2363.35 1.945 1.71 
637.2 1.915 2.02 
551.4 1.915 2.165 
197.85 1.875 1.295 
5D - C2 
848.6 1.92 2.05 
1645.5 1.96 2.08 
790.7 1.885 2.13 
616.15 1.935 2.185 
753.45 1.94 1.7 
551.7 1.955 2.11 
676.8 1.925 1.71 
379.55 1.92 1.475 
680.8 1.895 1.925 
shOCT4-79 5D - C2 
159.85 1.675 0.32 
85.05 1.685 0.155 
shOCT4-81 
5D - C1 
290.1 1.84 2.05 
1765.9 1.95 2.04 
1223.3 1.93 1.93 
417.35 1.87 1.985 
605.95 1.95 2.085 
10.2 1.96 0.06 
5D - C2 
186.9 1.84 1.89 
1674.9 1.96 2.06 
197.65 1.79 2.185 
413.1 1.905 2.09 
70.6 1.645 0.285 
85.75 1.81 1.65 
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Sample 
Time - Lentiviral 
concentration 
RNA concentration (ng/µL) 260/280 260/230 
shCDH8-23 
5D - C1 685.85 1.925 2.095 
5D - C2 
611.95 1.92 2.06 
339.4 1.89 1.75 
shCDH8-24 
5D - C1 
1513.2 1.94 1.95 
2852.25 1.985 1.985 
887.05 1.935 1.735 
532.65 1.935 1.845 
5D - C2 
1655 1.95 1.88 
761.45 1.92 2.11 
613.75 1.94 1.9 
623.55 1.925 1.92 
shCDH8-27 
5D - C1 736.6 1.92 2.1 
5D - C2 692.4 1.91 1.97 
shCER1-59 
5D - C1 
2262.1 1.96 1.775 
600.65 1.91 1.985 
699.55 1.925 1.825 
5D - C2 
731.05 1.92 2.03 
569.45 1.93 1.865 
375.6 1.9 1.455 
shCER1-78 
5D - C1 640.6 1.94 1.91 
5D - C2 
574.15 1.915 1.97 
467.15 1.875 2.035 
551.75 1.945 0.9 
shNRP1-23 5D - C2 744.6 1.92 1.72 
shNRP1-24 5D - C2 949.35 1.92 1.84 
shNRP1-26 
5D - C1 727.8 1.91 2.13 
5D - C2 
647.1 1.91 2.12 
800.55 1.91 2 
shNRP1-27 
5D - C1 
816.3 1.91 1.77 
2760.7 2 1.84 
967.55 1.92 2.11 
5D - C2 
279.8 1.89 1.66 
719.25 1.92 1.42 
949.65 1.915 1.845 
shPLXNB1-34 
5D - C1 292.25 1.85 0.795 
5D - C2 
1282 1.955 1.97 
1033 1.94 2.07 
800.6 1.96 1.575 
shPLXNB1-35 
5D - C1 789.5 1.92 2.07 
5D - C1 125.6 1.71 0.36 
5D - C2 
830.2 1.93 1.96 
689.8 1.92 1.77 
1051.8 1.95 1.885 
315.6 1.925 1.095 
shPLXNB1-36 
5D - C1 
4227.5 1.99 1.64 
821.35 1.93 1.96 
640.55 1.91 1.785 
5D - C2 
595.55 1.92 1.91 
884.15 1.92 1.695 
807.2 1.93 2.09 
300.7 1.92 0.55 
shSERPINE1-69 5D - C2 
417.1 1.76 1.88 
285.3 1.885 1.455 
319.55 1.875 2.07 
shSERPINE1-70 5D - C2 
748.85 1.92 1.435 
598.6 1.915 2.07 
shSERPINE1-72 5D - C2 
691.15 1.875 1.765 
1249.45 1.975 1.93 
Table 10 | RNA concentration and purity 
RNA concentration and absorbance ratios (260/230 nm and 260/280 nm): 4D = 4 days of culture; 5D 
= 5 days of culture; C1 = concentration 1 of lentiviral shRNA (18 pg viral RNA/cell); C2 = 
concentration 2 of lentiviral shRNA (36 pg viral RNA/cell). 
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Table 11 | Biological replicates  
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4.4. Additional in vitro results 
4.4.1. shRNA lentiviral concentration and knockdown, a correlation 
Two different shRNA lentiviral concentrations were tested on hESCs against CER1, 
NRP1, PLXNB1 and OCT4: C1 (18 pg viral RNA/cell) and C2 (36 pg viral RNA/cell). The 
highest concentration triggered higher knockdowns with the shRNAs shCER1-59 
(Figure 16A), shNRP1-26, shNRP1-27 (Figure 16B) and shOCT4-81 (Figure 16D), but 
not with shPLXNB1-35 and shPLXNB1-36 (Figure 16C). 
 
Figure 16 | Effect of shRNA lentiviral concentration on knockdown efficiency, part 1 
Relative gene expression results measuring the knockdown efficiency of (A) CER1, (B) NRP1, (C) 
PLXNB1 and (D) OCT4 with two different shRNA concentrations C1 (18 pg viral RNA/cell) and C2 (36 
pg viral RNA/cell, ∆∆Ct normalisation done against untransduced hESCs; mean±SEM; One sample t-
test, *p-value<0.05, **p-value<0.01, ***p-value<0.001, N.S.: not significant, no star means n<3). 
It should be noted that the quantification of shRNA is in terms of viral RNA amount. 
For different shRNAs, equal amounts may not be equal concentrations of the 
respective lentiviral particles. This may contribute to differences in knockdown 
efficiency between shRNAs targetting the same mRNA (Figure 17).  
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Figure 17 | Effect of shRNA lentiviral concentration on knockdown efficiency, part 2 
Relative gene expression results measuring the knockdown efficiency of different shRNAs targeting: 
(A) CER1, (B) NRP1, (C) PLXNB1, (D) SERPINE1 and (E) OCT4 (∆∆Ct normalisation done against 
untransduced hESCs; mean±SEM). Absolute quantification of the shRNA lentiviral titre of (F) NRP1, 
(G) PLXNB1, (H) SERPINE1 and (I) OCT4 shRNAs (molecule/ng of viral RNA). Correlation between the 
amount of shRNA lentiviral particles (molecule/ng of viral RNA) and the knockdown efficiency (%) of 
(J) NRP1 and (K) PLXNB1. 
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4.4.2. Timing, an important parameter 
Preliminary work using hESCs and differentiated hESCs in 10% FBS was performed 
to validate gene expression of the candidates and of the markers of pluripotency, 
mesoderm and endoderm, as well as investigate how those markers change in 
differentiation culture conditions (Figure 18A-E). The first set of experiments was 
performed on day 4 (4D) after induction of differentation, while the second set was 
performed on day 5 (5D). A difference in cell culture conditions also existed 
between these two sets: for the 4D set, FBS was added to cells which were still in 
suspension after passage, while for the 5D set FBS was added to attached cells one 
day after passage. 
 
Figure 18 | Expression of pluripotency markers, candidate genes and lineage markers in 
differentiating hESCs 
Relative gene expression results of differentiated hESCs cultured in 10% FBS for 4 days (4D in light 
red) or 5 days (5D in dark red) compared to undifferentiated hESCs (Control hESCs in green): (A) 
pluripotency markers, (B) the candidates, (C) trophectoderm marker, (D) endoderm markers and (E) 
mesoderm markers. (F) Relative gene expression of CDH8, NRP1 and SERPINE1 at 4 and 5 days in 
each individual experiment (∆∆Ct normalisation done against untransduced hESCs; mean±SEM; One 
sample t-test, *p-value<0.05, **p-value<0.01, ***p-value<0.001, if not stated: not significant). 
Some targets, such as NANOG, OCT4, CER1 or GATA6 (a marker of extra-embryonic 
and definitive endoderm) were similarly downregulated at the mRNA level for 4D 
and 5D (Figure 18A, B and D), and at the protein level for 5D (Figure 19). However, 
significant differences in the mRNA level were noticed for CDH8, NRP1 and 
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SERPINE1. CDH8 was upregulated at 4D but downregulated at 5D, similarly to NRP1, 
whereas SERPINE1 was upregulated at 4D but at 5D, levels were the same as in 
undifferentiated ESCs (Figure 18B). While there are indeed statistical differences in 
some instances between these values, the range of individual experimental 
measurements show that only some of the experiments actually contribute to the 
difference between the means (Figure 18F). These gene expression differences may  
be due to time rather than cell culture conditions (Figure 20B shows hESCs 
differentiated in 10% FBS at 5D). 
4.4.3. The CDH8 case  
Additionally to CDH8, CER1, PLXNB1 and SERPINE1, gene expression of follistatin 
(FST), another candidate identified in the in silico study (section 2.2), was 
systematically measured together with pluripotency and differentitation markers 
(Table 9). 
To knockdown CDH8 three different shRNAs were tested. Figure 20C shows shCDH8 
transduced hESCs in culture. Unfortunately, none of them actually reduced CDH8 
mRNA levels (Figure 21). Interestingly, the opposite effect was observed: shCDH8 
upregulated its target mRNA expression (Figure 21B). A dose-effect of the shRNA 
lentiviral concentration was noticed with the use of shCDH8-27 (Figure 21A), 
suggesting that the amount of shRNA lentiviruses utilised was perhaps too high. 
Morphologically, cells formed smaller colonies and exhibited an elongated shape, 
espcially with shCDH8-24 which upregulated CDH8 to the greatest extent (Figure 
20C).  
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Figure 19 | Immunofluorescence of differentiated hESCs in 10% FBS 
Protein expression in hESCs (control cells in green), shControl-transduced hESCs (in blue) and in 
differentiated hESCs in 10% FBS for 5 days (in red): (A) pluripotency markers OCT4 and NANOG, (B) 
OCT4 and CER1 and (C) endoderm marker GATA6. 
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Figure 20, Part 1 
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Figure 20, Part 2 
Figure 20 | Transduced or differentiated hESCs in culture 
Pictures were taken at day 5 after transduction, including two days of selection: (A) non-transduced 
hESCs and shControl hESCs, (B) hESCs differentiated in 10% FBS and (C) shCDH8 transduced hESCs. 
CDH8 was upregulated by CER1 and OCT4 knockdowns (Figure 21C). Overexpression 
of CDH8 increased the expression of the tested ectoderm markers CHRD, NOG and 
OTX2 (Figure 22F), like CER1 and OCT4 knockdowns (section 4.2). It also had 
heterogenous effects on both mesoderm (Figure 22D) and endoderm markers 
(Figure 22E), whereas it did not affect CDX2, the trophectoderm marker (Figure 
22C). Interestingly, CDH8 upregulation led to an increase in CER1 and NRP1 
expression (Figure 22A and 23), as well as NANOG and SOX2 (Figure 22B).  
To summarise the expression of the candidates identified by the in silico analysis 
(section 2.2), these data and the ones presented in the manuscript (section 4.2) 
show that CDH8 regulates CER1 and NRP1 expression, while CDH8 expression is 
regulated by CER1 and OCT4 (Figure 23). 
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Figure 21 | CDH8 relative gene expression 
Relative CDH8 gene expression results: CDH8 knockdown efficiencies (A) with different shRNA 
lentiviral concentration C1 (18 pg viral RNA/cell) and C2 (36 pg viral RNA/cell) and (B) with different 
shRNAs against CDH8; (C) CDH8 expression in all the other tested conditions (∆∆Ct normalisation 
done against untransduced hESCs; mean±SEM; the dash line indicates the level of expression in 
untransduced hESCs). 
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Figure 22 | Relative gene expression in CDH8 knockdown conditions 
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Figure 23 | CDH8 gene expression relationships 
Deductions of gene expression relationships between OCT4, CER1, NRP1 and CDH8. 
4.4.4. A hESC fate model 
Figure 24 presents a model for the hESC fate commitment that fits the results 
presented in sections 4.2 and 4.4.3. PLXNB1 promotes OCT4 expression that 
maintains pluripotency markers SOX2 and NANOG. PLXNB1 has also opposite roles 
in mesoderm and trophectoderm differentation: its expression, stimulated by 
SERPINE1, helps to prevent mesoderm specification, whereas it promotes 
trophectoderm together with OCT4. However, this induction is balanced by the 
downregulation of SERPINE1 through OCT4. Finally, OCT4 prevents endoderm 
commitment in part by downregulating NRP1. Data in section 4.4.3 and those 
presented in the manuscript (section 4.2) suggest that CER1 prevents ectoderm 
commitment via CDH8 downregulation and OCT4 upregulation.  
 
Figure 24 | Human ESC differentiation control, a model 
The diagram summarises that qPCR results suggest on the roles of OCT4, CDH8, CER1, NRP1, PLXNB1 
and SERPINE1 in hESC fate. 
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4.5. Discussion 
Further investigations would be required to confirm the above model. Several 
technical points, as well as complementary experiments that would be necessary 
are discussed below. 
4.5.1. Signal specificity and relative quantification  
Quantification of Western blot and qPCR experiments is dependent of many 
parameters that need to be evaluated. For both techniques, I calculated a relative 
quantification, which involves the use of reliable references and the determination 
of the linear range of quantification. In qPCR, commonly used housekeeping genes 
like GAPDH or β-actin are not always suitable [418, 419]. It has been reported that 
the choice of stable housekeeping genes is dependent on experimental settings, 
e.g. cell type [419, 420]. Several mathematical approaches have been developed to 
assess housekeeping gene stability [421-424], but they do not always indicate the 
same set of reliable references [420]. Increasing the number of housekeeping genes 
helps to prevent biased quantification by mitigating the inherent gene expression 
fluctuation. It is also important to look at the range of cDNA concentrations that 
enable linear and comparable amplification efficiencies of all housekeeping genes 
and targets, to avoid biases due to inhibition or primer dimer amplification (section 
3.2). In Western blotting, the usual relative quanfication technique often utilises 
actin or tubulin as a protein reference. However, it has been demonstrated that the 
linear range of quantification was greater when total protein, measured by Instant 
Blue solution staining of a gel lane was used for normalisation, rather than specific 
reference proteins [425]. 
Signal specificity in qPCR can be assessed by the contruction of a dissociation curve. 
This curve informs about the presence of unique or multiple products, and helps to 
determine the range of suitable cDNA concentrations by assessing the absence of 
primer dimers (section 3.2). In immunofluorescence and Western blotting, peptide 
competition assays can be perfomed to assess the specificity of primary antibody 
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bindings while the secondary antibody specific bindings can be tested by simply 
omitting primary antibody. 
4.5.2. Knockdown efficiency and side-effects 
Knockdown results showed that efficiency is in part linked to shRNA lentiviral 
concentration: higher concentration usually triggered higher knockdown. However, 
there were clear instances where knockdown effeciency did not correlated with the 
shRNA lentiviral concentration (section 4.4.1 on shPLXNB1). Therefore, other factors 
that impact on knockdown efficiency are likely to be linked to the shRNA sequence 
itself, such as the local structure of the targeted mRNA region [426]. That is why it is 
important to determine the best concentration to achieve the higest knockdown 
without saturating the RNAi machinery (section 3.3.2). 
To diminish ‘off-target’ effects as much as possible (section 3.3.2), shRNA sequences 
were chosen for their minimum homology to non-target mRNAs and at least two 
different shRNAs were utilised per target mRNA. Another approach to verify the 
specific effect of the shRNAs is to rescue the target mRNA expression by introducing 
a cDNA sequence resistant to the RNAi [427]. 
Knockdown efficacy can be assessed more widely at the protein level. As some of 
our candidates are secreted proteins, Western blotting should also be perfomed on 
cell medium. Such experiments must be done after decay of the pre-existing pool of 
proteins to see effects of the knockdown.  
4.5.3. What is next? 
The analyses in this study were all performed on the 5th day following transduction, 
which included two days of antibiotic selection. As a stable RNAi approach has been 
used, further investigations could be undertaken at later time points to validate the 
hESC fate. However, long-term knockdown efficacy would have to be verified 
regularly as the lentiviral vetors could potentially become silenced over time 
(section 3.3.2). 
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A complementary approach of knockin could be performed to overexpress the 
candidates and study if this impacts hESC fate, either by blocking or inducing their 
differentiation like OCT4 [128, 135]. Also, a combination of shRNAs targetting 
different candidates could be transduced at the time. For instance, according to the 
qPCR data, PLXNB1 and SERPINE1 are often involved in the same differentation 
lineages. Knockdown of both could bring novel clues on their role in the 
maintenance of hESC stemness. We could also consider downregulating one and 
upregulating the other. 
The CDH8 case could also be taken further. It would be interesting to understand 
how increasing shCDH8 concentration led to CDH8 upregulation instead of 
downregulation. The data suggest that it is not an ‘off-target’ effect, as it had been 
obsverved with different shCDH8 sequences. It could reflect a mechanism of auto-
regulation. This hypothesis could be tested by using siRNA for transient knockdown 
in hESCs and other cell lines. Moreover, overexpression of this protein led to an 
increase of NANOG and ectoderm markers. Different studies reported a link 
between NANOG expression and ectoderm differentation in hESCs: in one study, 
NANOG knockdown induced ectoderm commitment while its overexpression did 
not really affect hESC self-renewal [135]; in another study, NANOG was upregulated 
in early ectoderm differentation [428]. In our case, a knockin approach could 
confirm the upregulation of ectoderm markers together with NANOG, and it might 
give a novel clue on how NANOG is involved in ectoderm regulation. A successful 
CDH8 knockdown would then be complementary, but might not be achievable. 
Other investigations could lead to the identification of pathways through which 
these candidates control hESC fate. The use of high throughput experiments, either 
at the mRNA level or at the protein level, would define the number of possible 
pathways. Moreover, single-cell level analyses could also be performed, as it is clear 
that all hESCs do not express some proteins at the same level, such as GATA6 or 
CER1 as shown by immunofluorescence (section 4.2). This expression heterogenity 
is an intrinsic feature of hESCs which is currently understudied (section 5.1). 
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The microenvironment is clearly important in the maintenance of the hESC 
stemness, but had hitherto been neglected in the sense that there was no global 
perspective. In section 2 the results of an in silico meta-analysis of transcriptomic 
data were presented. It enabled the construction of a putative hESC protein-protein 
interaction network used to identify the likely key extracellular proteins playing a 
role in hESC fate. This study highlighted important issues. Transcriptomic data are 
the most comprehensive, in terms of sensitivity and coverage. However, there are 
important drawbacks (sections 2.2 and 2.4), which include: 
i) the lack of standardisation across experiments,  
ii) the correlation with protein expression,  
iii) the identification of mRNA variants and protein isoforms,  
iv) the lack of information on post-translational modifications and 
subcellular location of proteins.  
Moreover, the protein-protein interaction data are heavily skewed towards well-
studied proteins and the coverage in databases is still relatively low (section 2.2). In 
addition, documented interactions actually occur in a specific cell type and are only 
hypothetised in others. Finally, the interaction data are mainly restricted to proteins 
and there is an elephant in the room: the interactions with secondary gene 
products such as lipids and polysaccharides are central to their function in many 
important signalling proteins [429]. 
The function of five extracellular proteins in the maintenance of stemness identified 
through the in silico analyses was then tested experimentally in hESCs (section 4). 
This work provided a first line validation of the in silico approach and highlighted 
some important challenges. Thus, complex co-modulation of the expression of 
CER1, NRP1, PLXNB1, SERPINE1 and a recognised marker of stemness, OCT4 was 
discovered. These data also strongly suggested that these membrane/extracellular 
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proteins were balancing hESC fate decision in a complicated way (section 4.2 and 
especially the discussion part). Thus, it shows that uncovering wider links between 
the extracellular environment and the transcriptional network is important to the 
understanding of hESC fate. This in turn will pave the way to improving their culture 
conditions necessary to maintain their self-renewal and trigger their differentiation.  
However, the effects of these proteins on hESC fate are mild compare to proteins 
like OCT4, which is a key transcription factor for hESC pluripotency. That was to be 
expected, as biological networks are intrinsicly organised to be scale-free [136, 
217], meaning that there are hubs like OCT4 (which are vulnerable nodes and can 
disturb the entire system if they are targeted), but also there is redundancy to make 
the system more robust against random disturbances such as mutations [227].  
Both top-down and bottom-up approaches highlighted that stemness is a complex 
cell state governed by multiple chemical and most likely mechanical cues. 
Therefore, a far more sophisticated analysis is required to understand better the 
cell state called stemness. This could include developing an approach integrating 
different ‘omic’ data at different time points or going down to the analysis at the 
single-cell level. How this challenge may be addressed is discussed in the following 
sections. 
5.1. From cell population to single-cell analysis and beyond 
Discovering how hESC fate is regulated is a very challenging question that 
necessitates taking into account cell heterogeneity and cell complexity in terms of 
molecule interaction and regulation, inside and outside the cell over time. 
ESC heterogeneity is present at three different levels. Firstly, differences between 
mouse and human ESC can reflect species and/or time of derivation specificities [27, 
28, 303, 430-433]. Secondly, all the hESC lines have similar, but not identical 
expression patterns [434] that might be due to genetic variations. Thirdly, hESCs are 
also heterogeneous within the same culture at the single-cell level, an intrinsic 
feature that illustrates their multi-stable state allowing rapid and different cell fate 
commitment [237, 435, 436]. Thus, high-throughput analyses on hESCs such as 
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those that yielded the transcriptomic data used in section 2 suffer from averaging 
across a heterogenous population. One solution to avoid such averaging and to 
understand the importance, if any, of ESC heterogeneity in relation to their fate 
would be to perform high-throughput measurements on single cells.  
5.1.1. Going towards high-throughput single living-cell experiments 
Achieving successful high-throughput experiments at the cell population level 
demands a lot of effort and remains challenging (these techniques are described in 
section 2.1.2). An even more difficult task is now emerging: high-throughput 
experiments at the single-cell level. All the ‘omics’ techniques are getting there with 
the development of lab-on-chip devices for example. 
The first step in each of these techniques is the isolation of a single cell. Several 
approaches exist and are reviewed here [437]. Among them, two allow high-
throughput experiments: fluorescence-activated cell sorting (FACS) [438] and 
microfluidics. In the latter, cells are compartmentalised in nanolitre reaction 
chambers on microfluidic devices, allowing single-cell isolation, environment control 
and downstream experiments [438-441]. 
Genomics – As most of the bacteria diversity cannot be currently cultured, single-
cell sequencing is the unique tool allowing their deep study that could lead to major 
discoveries in the theory of natural selection [442, 443]. In human genetics, these 
techniques could help developing the haploid genotype or haplotype studies [444] 
and, therefore, identify maternal and paternal alleles to understand better some 
genetic variations that lead to diseases. For instance, it is important to determine 
high variability haplotypes of the human leukocyte antigen (HLA) for preventing 
graft rejection in the context of bone marrow transplants [445]. Single-cell 
sequencing also helps to understand cell lineage relationship [446-448]. 
Additionally, it has the potential of uncovering recombination events that create 
new genomes in the gametes [449, 450], as well as measuring mutation event rates 
[451] and valuating somatic variation [451-454].  
Transcriptomics – Single-cell transcriptomics opens the study of rare cell types, such 
as tumour cells in a patient blood stream [455], adult stem cells [456] or embryo 
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cells [457, 458]. It also enables the profiling of transcriptional fluctuation and the 
development of stochastic analyses, and, therefore, uncovering the importance of 
transcriptonal noise in cellular processes such as cell differentation [459, 460]. 
Single-cell transcriptomics has been successfully applied at a low-throughput scale 
using together microfluidics and RT-qPCR [98, 438, 441, 456, 457]. It is now scaling-
up to a high-throughput scale [440, 458]. 
However, despites advances in direct RNA sequencing [461], RNA still has to be 
converted into cDNA before being sequenced, which introduces inherent biases due 
to RNA loss and cDNA amplification. Moreover, amplification of small number of 
RNAs, which is impacted by the Monte Carlo phenomenon, becomes problematic in 
the single-cell transcriptomics field. Basically, this effect reflects the fact that low-
abundance transcripts have different probabilities of being processed and, 
therefore, exhibit significantly high variations in their detection and quantification 
[462]. Different single-cell RNA-sequencing methods have already been established 
(like single-cell tagged reverse transcription STRT [463], Quartz-seq [464], Smart-seq 
[465, 466] and CEL-seq [467]) but they all have in common a detection limit of 5 to 
10 RNAs and quantification biases [468].  
Proteomics – Single-cell protein analysis techniques are developing at a relatively 
low-throughput scale, giving information about protein identification and 
quantification (by antibody sandwich assay on microarray [469], mass cytometry 
[470, 471] and Western blotting [472]), localisation (by immunfluorescence or 
fluorescent-protein tagging [473]), post-translational modifications (by flow 
cytometry [474]) and interactions (by co-immunoprecipitation [475] or with a 
single-cell barcode chip [476]). High-throughput mass spectrtometry analyses are 
slowly emerging too, both in terms of number of analysed proteins [477, 478] and 
number of analysed single cells [479]. 
Single-cell proteomics is a very challenging area of research because the gigantic 
complexity of the cell proteome has to be studied with a relatively small amount of 
proteins that each cell contains. In addition, high-throughput analyses depend on 
mass spectrometry. The sensitivity of this technique (~attomole) means that only 
higher abundance proteins can be analysed. While the sensitivity is being increased 
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regularly, because it is pure analytical chemistry, the absence of a possible 
amplification step means that it is unlikely to rival the analysis of nucleic acids.  
Metabolomics, glycomics and lipidomics – These three ‘omic’ fields are also slowly 
going down to the single-cell level [480-483], but the lack of amplification means 
that they have the same sensitivity drawbacks as proteomics. 
Single living-cells – Current high-throughput techniques usually require working on 
dead cells and, therefore, generate only snapshots of information. With the 
development of living-cell arrays (reviewed here [484]), single living-cells are 
starting to be studied at both mRNA and protein levels, giving a spatial and 
dynamical view of cellular processes. Moreover, these experiments can be 
considered high-throughput in terms of number of analysed cells. Different systems 
allow high-throughput single living-cell isolation [485, 486], growth [485] and 
imaging [487], and different methods have been developed to measure gene 
expression in single living-cells. One of them is through fluorescent reporter with a 
microfluidic device [488]. Another enables mRNA visualisation directly on living 
tissues [165]. 
Single-cell analysis and lab-on-chip devices are powerful tools for personalised 
medicine: 
 in genomics, with the possible determination of HLA haplotypes to diminish 
the risk of graft rejection in bone marrow transplant [445]; 
 in transcriptomics, with the analysis of tumour cells circulating in the patient 
blood stream and the identification of biomarkers [466]; 
 in proteomics, with the examination of patient T cell population that could 
predict the immune response to drug therapy [489]. 
However, the success of these developing techniques are dependent on their 
sensitivity: being able to measure precisely and accuratly a small number of 
molecules, while dealing with off-target and contaminant detection or 
amplification, sample preparation bias and error rates. Another challenge is the 
analysis of the generated data where stochastic events are predominant.  
To control hESC fate in vitro, the processes through which these cells commit into 
different lineages have to be understood at the system level with the integration of 
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different ‘omic’ data over time. The single-cell level will uncover the importance of 
the hESC multi-stable state in their fate decision where the microenvironment role 
cannot be neglected. 
5.1.2. How to deal with big data? 
With the emergence of high-troughput techniques, the decrease of sequencing 
costs and, therefore, the exponentially growing volume of generated data, 
researchers have to face new issues: how to handle, store, move and process these 
big data? The article written by Vivien Marx in 2013 [490] gives some figures to 
understand what ‘big data’ means: 
 a single sequenced human genome is around 140 gigabytes  
(1 gigabyte is 109 bytes); 
 the Beijing Genomics Institute (BGI, Shenzen China), one of the largest 
producers of genomic data, has 157 genome sequencers generating 6 
terabytes of genomic data per day  
(1 terabyte is 1,000 gigabytes or 1012 bytes); 
 the European Bioinformatics Institute (EBI, Hinxton UK), one of the largest 
biological data repositories, currently hosts 20 petabytes of data  
(1 petabyte is 1,000 terabytes or 1015 bytes). 
In-house data storage, software and harware maintenance have to be financed. 
Moreover, downloading (moving) data is time-consuming. Cloud computing is a 
solution that can overcome these issues [491]. Data, software and/or hardware are 
situated in off-site centres from where users can access on demand. In Europe, 
Helix Nevula [u] and elixir [v] have been recently built and offer the possibility to 
easily share and process huge amounts of data which are usually spread across 
laboratories. The current state of cloud computing has been reviewed in genomics 
[492, 493] and proteomics [494]. However, safety issues are linked to the utilisation 
of these clouds: valuable data could potentially be stolen or could be destroyed if 
the data centre is damaged.  
Bioinformatic clouds also open a new field of biological research: dry biology. Data 
are analysed and interpreted under prior knowledge and with specific hypotheses. 
Consequently, generated data are under-used. Sharing them enables meta-analyses 
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(section 2), as well as the application of different pipelines or alogrithms to extract 
novel information and novel interpretation without spending more money in wet 
experiments. Of course, as dicussed in section 2.4.2, to achieve this goal effectively, 
data formats have to be standardised. 
Finally, the avaibility of such enormous amounts of data provides a platform for the 
development of personalised medicine, with data privacy as a concern [495, 496]. 
5.2. Improving cell culture: how to monitor and drive cell fate? 
Human ESCs and iPSCs have a substantial potential in regenerative medicine. For a 
use in cell therapies, it is crucial to be able to safely differentiate these cells at a 
large scale. Therefore, cell culture techniques have to to be improved 1) to better 
mimic the natural microenvironment and 2) to increase the cell culture capacity. 
This goal is at the interfaces of biology, medical sciences and engineering fields. 
5.2.1. Importance of the microenvironment in hESC fate 
The entire field of tissue engineering is tightly linked to biomimetic approaches 
[497, 498], especially to direct stem cell fate [499, 500]. Currently, the majority of 
hESCs are cultured in 2D under atmospherical level of O2 (21% v/v) whereas their 
natural niche is 3D under physiological levels of O2 (between 2% and 5% v/v). 
Oxygen level is known to play a role in embryonic development (reviewed here  
[501]). Studies showed that culturing hESCs at 2% O2 (v/v) induces significant 
transcriptional changes [181] and tends to prevent their differentiation and/or 
enhance their self-renewal [502-504]. 
The extracellular matrix is another important parameter. Not only molecules [505, 
506] (presented section 4.1), but also mechanical cues, such as substrate stiffness, 
affect hESC fate [507]. Moreover, extracellular environment can be controlled to 
either maintain hESC self-renewal [505] or commit their differentiation [508]. 
Finally, tissues are 3D structures. Some research groups have developed 3D 
microwells to culture hESCs where their self-renewal and pluripotency are retained 
[509, 510]. However, 3D culture could affect hESC growth and metabolism [511], 
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and is mainly used to form embryoid bodies (described section 4.1.1.2) for 
triggering their differentiation [512]. 
The fusion of 3D culture and microfluidics has enabled the nascent development of 
organs-on-chips (reviewed here [513]), where living cells are cultured in tiny 
chambers with tightly regulated microenvironment to recreate tissue-tissue 
interfaces and mimic organ microarchitecture (a protocol of fabrication is available 
here [514]). These devices provide novel platforms for drug screening and in vitro 
disease models [515] that could partially replace animal use. 
5.2.2. Scaling-up 
Fundamental research on the mechanisms underlying hESC commitment, and 
especially the role of the microenvironment in these processes is already helping 
the development of better culture conditions. 
Several research groups have developed the culture of hESCs [516-523] or hiPSCs 
[520, 521, 523, 524] and their differentiation [517, 525-527] in suspension in 
bioreactors, which is the first step for their clinical utilisation. However, a major 
issue for large-scale culture of hESCs remains its cost, due to the need of ‘pure’ 
growth factors. Efficiency and reproducibility have also to carefully be considered 
[528, 529]. 
As an extension of the conventional 3D culture and with the development of large-
scale culture, 3D printing has recently emerged as another type of tissue 
engineering. This consists of three steps: pre-processing (development of the bio-
ink and scaffold), processing (the actual tissue/organ printing) and post-processing 
(tissue/organ maturation). Basically, cells constitute the ink of the robotic bio-
printer that will drop cells layer by layer, leading to a 3D structure. Some of the key 
challenges are: 
 i) having a harmless process to deliver highly viable cells; 
ii) controlling the drop volume of cells; 
iii) getting the right structure, including the vascularisation of the tissue.  
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This approach is only at its first stages [530-532], but it has aroused considerable 
infatuation, judging by the number of reviews, opinion publications [533-538] and 
press articles [w,z] already written on the subject. 
Long-term and non-invasive cell tracking is another aspect that has to be considered 
to evaluate safety and efficacy in the utilisation of stem cells in therapies. Different 
labelling strategies have been established, such as contrast agents [539], 
fluorescent dyes [540], magnetic nanoparticles [541], quantum dots [542] and 
reporter genes [543]. Each technique has advantages and drawbacks (reviewed 
here [544]). For instance, nanoparticle signal is diluted over time with cell division 
and reporter gene implies genetic modification. Another concern is the need of high 
sensitivity and high spatial resolution imaging in vivo. 
Large-scale culture of hESCs and their differentations have to be driven, monitored, 
safe, robust and cost-effective to be used in regenerative medicine. Interdisciplinary 
efforts are required to achieve this goal.  
The plasticity of pluripotent cells make them unique and hugely attractive in both 
fundamental research and regenerative medecine. Over the past fifteen years, 
massive efforts have been made to characterise hESCs and hiPSCs by the 
development of large-scale experiments and computational models, especially to 
understand the transcriptional network underlying their pluripotency. However, the 
importance of the hESC extracellular environment in the regulation of their 
stemness cannot be underestimated with respect to successfully maintaining their 
self-renewal and/or commiting their differentation to specific cell lineages.  
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Figure 25 | The hESC future 
(A) Experiments are scaling-down to the single-cell level enabling the study of hESC heterogeneity 
while the number of analysed molecules is scaling-up. (B) hESC culture is becoming 3D to better 
mimic the natural environment and trigger differentiation. 3D printing is also emerging to sculpt 
organs for regenerative medicine while, in the meantime, large volume of homogeneously 
differentiated hESCs are produced. 
 
This thesis demonstrates that multidisciplinary approaches can bring novel 
hypotheses on how hESC stemness is governed. It also highlights the need of a 
wider view on cell function, as the one-molecule-at-a-time approach gives clues on 
processes, but cannot elucide the entire mechanism. To this end, high-throughput 
techniques are covering a part of the lack (Figure 25A). However, dynamics of 
pluripotency and differentiation processes, as well as the importance of hESC single 
cell heterogeneity remain currently understudied. This gap should be slowly filled 
by the appareance of novel techniques that permit the study of single living-cells 
(Figure 25A), which should characterise better both the extracellular environment 
and the transcriptional network responsible for hESC fate decision. However, all this 
fundamental work is already helping to culture hESC in 3D and at a large scale for 
self-renewal and differentiation purposes (Figure 25B), bringing the dream of 
regenerative medicine closer. 
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